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ABSTRACT 
 
Diabetes mellitus (DM) is one of the most established systemic conditions, with 
increasing epidemiological importance. It is known to cause numerous complications 
and severe damage among a variety of tissues and organs, including bone. Accordingly, 
type 1 diabetes mellitus (T1D) has been associated decreased skeletal mass, higher risk 
of fractures and delayed healing. Despite the numerous studies on diabetes and its 
influence on bone, the molecular events affecting both osteoblasts and progenitor cells, 
within the diabetic milieu, are still not fully understood. 
In this context, a detailed study was carried out in order to assess the functionality 
of diabetic-derived bone marrow-derived mesenchymal stem cells – i.e., osteoblastic 
precursor cells – regarding proliferation, functional activity, osteogenic priming, and 
relevant signalling pathways modulating these processes. Data showed that the diabetic 
environment affected both mesenchymal stem cells signalling and functionality, in a 
long-lasting way, contributing to a decreased osteogenic priming and increased 
adipogenic activation, which may converges to the verified bone alterations and 
weakening. 
Given the verified hindrances in diabetes, a novel therapeutic strategy for the 
enhancement of osteogenic activation was developed, based on the delivery of 
minocycline and doxycycline, two semi-synthetic derivatives of tetracycline, known to 
enhance cell proliferation and the functional activity of osteoblasts.  Initially, the 
osteogenic enhancement of bone marrow-derived mesenchymal stem cells and 
osteoblasts, developed under diabetic-induced conditions, was validated in vitro, in 
xii 
 
established cell culture models, and ex vivo, in a model of calvarial bone regeneration. 
Assayed regimens of low dosage tetracyclines, were able to normalize the impaired 
osteogenic commitment of osteoblastic precursor populations, enhancing the metabolic 
equilibrium, as assessed within the in vitro system. Furthermore, tetracycline 
administration were found to increase tissue healing and tissue mineralization in 
simulated diabetic conditions, as assayed ex vivo. 
Subsequently, and envisaging the development of a translational therapeutic 
application with reliable effectiveness within the clinical scenario, a PMMA cement-
based minocycline delivery system was developed and assayed for biocompatibility. 
Developed system was subcutaneously implanted in experimental animals, either in 
control or diabetic conditions. The controlled release of minocycline was able to 
enhance several inflammation-related factors, suggesting an enhanced tissue healing 
and biomaterial integration which may further be applied as a local therapy for bone 
regeneration. 
Overall, a novel therapeutic approach – the application of a low dosage regimen 
of tetracyclines – for the management of the verified hindrances in the osteogenic 
activation within the diabetic milieu was assayed and validated within in vitro, ex vivo 
and in vivo models, exhibiting an improved biological outcome and a prospective clinical 
application.   
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RESUMO   
 
A diabetes mellitus é uma patologia sistémica, com elevada incidência, e cuja 
relevância epidemiológica tem vindo a aumentar. A longo prazo, a diabetes está 
associada a inúmeras complicações e lesões graves nos tecidos e órgãos, incluindo o 
osso. Em particular, a diabetes tipo 1 está associada à perda de conteúdo mineral ósseo, 
aumento do risco de fraturas e atraso nos processos de regeneração. Apesar de terem 
sido realizados diversos estudos para compreender os efeitos da diabetes no osso, não 
estão claros quais os mecanismos moleculares envolvidos na afetação, tanto dos 
osteoblastos como das suas células progenitoras. 
Neste sentido, foi realizado um estudo pormenorizado, focado na avaliação da 
funcionalidade das células estaminais mesenquimais provenientes da medula óssea – 
células percursoras dos osteoblastos – na condição diabética. Foram avaliados 
parâmetros como a proliferação, atividade funcional, expressão osteogénica e vias de 
sinalização relevantes, que modulam estres processos. Os resultados mostraram que a 
condição diabética afeta tanto vias de sinalização como a funcionalidade das células 
mesenquimais de forma duradoura, contribuindo para uma diminuída expressão 
osteogénica e aumento da expressão adipogénica, convergindo desta forma para 
alterações na estrutura óssea, e seu consequente enfraquecimento. 
Tendo por base a identificação das alterações vigentes na condição diabética, foi 
desenvolvida uma nova abordagem terapêutica para melhorar a ativação osteogénica, 
baseada na libertação de minociclina e doxiciclina, dois derivados semissintéticos da 
tetraciclina, que demonstraram um efeito indutor na proliferação celular e na atividade 
xiv 
 
funcional de osteoblastos. Inicialmente, foi realizada uma validação in vitro dos efeitos 
promotores da expressão osteogénica de células estaminais mesenquimais da medula 
óssea, bem como os efeitos da doxiciclina num modelo ex vivo da regeneração da óssea 
da calote. As baixas doses de tetraciclinas que foram estudadas permitiram a 
normalização do comprometimento com a linhagem osteogénica, melhorando assim o 
equilíbrio metabólico no osso diabético. 
Com o intuito de desenvolver uma aplicação terapêutica com uma efetividade 
clínica, foi desenvolvido um sistema de libertação controlada de minociclina, a partir de 
um cimento de polimetil metacrilato (PMMA). O sistema desenvolvido foi implantado 
subcutaneamente em animais controlo e animais diabéticos, para avaliação da sua 
biocompatibilidade. A libertação controlada de minociclina permitiu melhorar 
determinados fatores relacionados com a resposta inflamatória, sugerindo uma 
melhoria tanto nos processos de regeneração dos tecidos envolventes como na 
integração do biomaterial que, por sua vez, poderá ser posteriormente aplicado em 
terapias locais de regeneração óssea. 
No geral, foi estudada uma nova abordagem terapêutica, baseada na aplicação de 
baixas doses de tetraciclinas, tendo em vista a indução osteogénica, que se encontra 
alterada na condição diabética. Esta abordagem foi validade com estudos in vitro, in vivo 
e ex vivo, e revelou resultados biológicos favoráveis para futuras aplicações clinicas. 
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CHAPTER 1 – AIM AND STRUCTURE OF THE 
THESIS 
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1.1 – AIM AND STRUCTURE 
 
Of worldwide importance, diabetes mellitus represents one of most established 
systemic conditions with increasing epidemiological importance. It encompasses a 
group of metabolic disorders which are ultimately characterized by a hyperglycaemic 
state and consequent requirement for continuous medical care with multifactorial risk-
reduction strategies (1). Diabetic hyperglycaemia is strongly associated with long-term 
tissue and organs failure due to severe damaged and unbalanced carbohydrate 
metabolism. The most well-known complications related with diabetes comprise 
neuropathy, nephropathy, retinopathy and osteopenia, among others (2). 
In which concerns the bone tissue, uncontrolled hyperglycaemia was broadly 
described to affect the normal bone metabolism interfering with the natural bone 
renewal, as well as, increasing the risk of fractures due abnormal cellular function to 
produce new bone, impaired mineralization and consequent altered bone mineral 
density (3, 4). Despite the contradictory reports, regarding bone tissue affection in the 
different types of diabetic condition (5), it is stablished that type 1 diabetes, in particular, 
exerts severe effects in bone though a variety of mechanisms including impairment of 
osteoblastic recruitment, maturation and function to produce new bone; promoting a 
disorganized and defective deposition of collagen matrix; inhibiting the expression of 
growth factors, essential for bone mineralization to occur; among other which culminate 
in a weakened structure (6). 
Recently, several studies reported that, tetracycline’s semi-synthetic derivatives, 
i.e., minocycline and doxycycline, were able to modulate osteoblastic cells and 
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improving the bone regeneration process in a mechanism independent of the 
antibacterial activity (7, 8). Furthermore, these non-antibacterial properties of 
minocycline and doxycycline were demonstrated to exert a significant beneficial effects 
in pathological conditions involving abnormal immune and inflammatory response and 
unbalanced apoptotic behaviour (such as rheumatoid arthritis, periodontitis, rosacea, 
among others) (9, 10). Accordingly, these semisynthetic tetracyclines may represent 
promising candidates to support bone healing therapies in both cases of fractures in 
physiological or pathological conditions. 
The increased risk of fracture among diabetic patients, lead to an increased 
requirement for orthopaedic implants. However, diabetes systemic abnormalities 
include defective host response and impaired wound healing which greatly increases 
the risk of infection among the patients with the disease (11). 
In this context, this work aims to achieve a deeper insight on the effects of 
minocycline and doxycycline as osteogenic agents, promotors of bone regeneration and 
tissue healing, in the tissues and cells of a well-established animal model of diabetes – 
the streptozotocin-induced diabetic rat. 
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The thesis is organized into six chapters: 
 
Chapter 1 
General considerations about the aim and structural organization of the present 
PhD thesis. 
 
Chapter 2 
The second chapter is divided in three parts. The first part consists of an overview 
of bone tissue including composition, structure and metabolic activity; bone remodelling 
and bone healing processes. Following, in the second part, a review of diabetes mellitus 
is made focusing the systemic unbalances, classifications and diagnosis; with especial 
relevance, the effects of diabetes in bone tissue; and biomaterial implants to support 
bone healing in diabetic-mediated pathological conditions. In the third part, a revision 
of tetracycline derivatives, minocycline and doxycycline, is carried out. In addition to 
their role as antibiotics, their properties as modulatory agents of bone metabolism and 
regeneration in physiological and pathological conditions are reviewed. 
 
Chapter 3 
The third chapter describes a detailed characterization of bone marrow-derived 
mesenchymal stem cells, harvested from both healthy and streptozotocin-induced 
diabetic Wistar rats, and cultured in control and osteogenic-induced conditions. In this 
module, in vitro assays leading to the characterizations of cell proliferation, metabolic 
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activity, as well as the assessment of gene expression and significant signalling pathways 
activated within the osteogenic priming and functionality, were critically detailed. 
 
Chapter 4 
In chapter 4, the effect of doxycycline is assessed on both in vitro and ex vivo 
models of control and diabetic conditions. In the first part, the effect of a low dosage 
regimen of doxycycline was assayed in the previously described cell culture model of 
bone marrow-derived mesenchymal stem cells, harvested from control and diabetic-
induced Wistar rats. Culture functionality was critically detailed, regarding cell 
proliferation, metabolic activity, osteogenic priming and activation. In a second part, an 
ex vivo experiment was conducted with new-born rats’ calvaria to assess the effect of 
the low dosage regimen of doxycycline in the bone regeneration process, in both control 
and diabetic simulated conditions. 
 
Chapter 5 
In the chapter 5, a novel PMMA cement-based system for the controlled release 
of minocycline, aiming the development of a clinical relevant formulation for drug 
delivery in diabetic conditions, was characterized for solid state parameters and 
biocompatibility. The tissue response to the implanted minocycline-loaded constructs 
was detailed, in both control and diabetic animal models, by histological and 
histomorphometric analysis, at several time points following subcutaneous 
implantation. 
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Chapter 6 
In the last chapter, a general conclusion is presented, based on the data gathered 
from the experimental studies presented on chapter 3, 4 and 5. 
Prospective studies and future perspectives are further discussed.  
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CHAPTER 2 - BACKGROUND AND LITERATURE 
OVERVIEW 
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2.1 - BONE TISSUE 
 
The bone is a highly complex and hard form of connective tissue which may be 
both coped as a tissue or as organ system, making up most of the skeleton. It combines 
the endurance and toughness of a mineralized matrix composed essentially by proteins 
and hydroxyapatite crystals with a dynamic organic/inorganic matrix. As a component 
of the skeleton, bone tissue plays crucial functions in the human organism including 
protection, support, motion of the entire organism and metabolic homeostasis. Bone 
unique and individual properties such as a high flexibility and elasticity promote the 
protection of vital organs. Yet its stiffness also underwrites to the conservation of the 
structural support and mechanical action allowing for the precise and controlled 
muscular movement. The organic component ensembles a variety of bony cells which 
are continuously involved in metabolic modulation of pH regulation, mineral storage, 
homeostasis, bone remodelling and other functions, causing bone to be a biologically 
active and dynamic entity (12). The adult human skeleton possesses around of 213 
bones. 
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2.1.1 - MACROSTRUCTURE 
Macroscopically, bones of the skeletal system are white coloured and usually 
classified individually according to their shape in long, short, flat, sesamoid and irregular 
bones (figure 2.1a). Long bones are characterized for being longer than wider and this 
category includes the majority of the bones of limbs such as femurs, tibiae and humeri. 
They are specifically designed for rigidity, possessing some elasticity and great hardness, 
and attachment of muscles and ligaments. The majority of long bones present 
morphological similarities (figure 2.1b) as they are constituted by three common 
components: (1) the diaphysis (or shaft), the body of long bones being mainly made up 
of compact bone organized in a long tubular structure; (2) the epiphyses, the long bones’ 
ends in which the joints with adjacent bones are established, being predominantly 
composed by cancellous bone; (3) the epiphyseal plate (or growth plate), a hyaline 
cartilage plate located in the metaphysis in the long bone’s ends. Short bones are those 
bones that are almost as wider as longer and commonly exhibit a cuboidal shape. These 
bones include smaller bones and they are found only in the ankle and wrist (e.g. tarsus 
and carpus). Flat bones are usually associated with protection functions due to their 
morphology thinner and flatted which provides broad section for protection or muscular 
attachment (e.g. ribs, sternum and cranial bones). Sesamoid bones are usually found in 
locations where tendons intersect the ends of long bones, being responsible for 
protection of these tendons from an excessive mechanical load (e.g. patella and knee 
cap). Just like the vertebrae of the spine or the facial bones, the irregular bones are 
characterized by their peculiar morphology, which cannot be included in none of 
previous classifications (12). 
13 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 - (a) Different types of bone morphology: long, short, flat, sesamoid and 
irregular; (b) Adult long bone structure, adapted (13). 
 
 
Despite these different morphologies, all bones are macrostructurally identical in 
that densely packed or compact bone – that is more external and the principal 
responsible for bone strength, whilst the inner bone tissue is commonly composed by a 
tridimensional structure of trabecular bone with metabolic and homeostasis functions. 
Although both compact and trabecular bone are made up of the same kind of 
extracellular matrix (ECM) and cell types, they differ in which regards to their structure 
and functions (14). Thereby, compact bone is mostly associated with biomechanical and 
a b 
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protective functions, whereas the majority of metabolic functions are due to the 
trabecular bone (table 2.1), such that it is more responsive to disturbances in metabolic 
homeostasis (12). 
 
 
Table 2.1 - Differences between human cortical and cancellous bone. Adapted 
from (15). 
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Compact bone, also known as cortical or dense bone, is found on the outer layer 
of all individual bones surrounding the trabecular structure and exhibit an ivory-like 
compact shape. It represents approximately 80% of the total bone mass and it is mainly 
composed of bony mineral and ECM providing the adequate strength to perform its 
functions. Structurally, cortical bone is made up of a collection of cylindrical units named 
Harvesian systems, or osteons, which run parallel to the bone axis. The Harvesian system 
represents the cortical bone fundamental unit and it combines a central canal – through 
which blood vessels, lymphatic nodes, connective tissue and poorly myelinated fibers 
pass – with its surrounding concentric bony tissue lamellae and respective osteocytes 
(14). The lamellae constitute a more external surface of the cortical bone and they are 
interspersed by small voids known as lacunae, which are interconnected by smaller 
channels – canaliculi (16). The osteocytes are found within the lacunae and they are 
interconnected with one another and with the osteoblasts on the surface of the bone 
by extending cytoplasmatic processes into the canaliculi. This communication with 
external osteoblasts allows the process of osteocytic osteolysis, which comprises the 
transference of Ca2+ from the interior of the bone to the surface (17). Additionally to 
cell-to-cell interaction, canaliculi enable the nutritional support and oxygenation of the 
whole cellular constituents and also permit the removal of waste products resultant 
from metabolic activities. The gaps between the osteons are filled with a tissue similar 
to lamellar bone although with a less organized pattern. The interstitial lamellae 
separate each Harvesian system from its neighbouring structures by forming a strongly 
basophilic cement line constituted essentially by inorganic matrix content (16). The 
superficial layer of compact bone is mainly constituted by osteoblastic and osteoclastic 
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precursor cells which are continuously renewing the cortical bone by producing new 
osteoid (figure 2.2) (18, 19). 
Trabecular bone, synonymous to cancellous or medullar bone, constitutes about 
20% of the remaining total bone mass and it is located in the inner layer of individual 
bones. Structurally, cancellous bone presents a honeycombed shape and is considerably 
less dense and resistant than compact bone, being committed essentially to metabolic 
and mineral homeostatic functions. It has a higher surface area reaching about 67% of 
the total and its structure consists of an irregular network of calcified spicules extended 
from the cortex to the inner canal – trabeculae – made up of osteon fragments. The 
trabecular structure is classified as being rod-like or plate-like and the portion of each 
type depends on the magnitude and distribution of loading. Its thickness commonly 
ranges from 50 to 400 µm and it is formed by bone lamellae. Furthermore, trabeculae 
structural organization is not random, rather the structures run according to the 
mechanical stress guidance and they are continuously able to adapt to mechanical 
tension solicitations (20). Similarly to the cortical bone, the most external layer is mostly 
coated by osteoblasts and osteoclasts responsible for constant renewal of cancellous 
bone. The cavities between trabeculae are filled with hematopoietic marrow, in which 
the majority of metabolic supportive functions of bone occur (16). 
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2.1.2 - MICROSTRUCTURE 
Independently from being cortical or cancellous, the microscopical structure of 
bone can be categorized in two major forms: woven bone or lamellar bone. Woven 
bone, also designated as primary bone, is broadly found during the embryonic stages, 
as well as in newborns and it is later resorbed and replaced by lamellar bone (21). 
Primary bone may also be found in locations where fast bone formation takes place, like 
in growth plates and during processes of bone healing of fractures, closure of cranial 
sutures or in pathological conditions, such as in Paget’s disease. Comparing to lamellar 
bone tissue, woven possesses a higher metabolic rate which substantiates an enhanced 
turnover during the remodelling phase. Woven bone is also characterized by an 
anisotropic distribution of cells and collagen fibers, which explains its diffused and 
irregular display, as well as its biomechanical fragility (21). After woven bone is laid 
down, it can undergo remodelling processes to become lamellar. Lamellar bone, or 
secondary bone (figure 2.2), commonly appears firstly during the third foetal trimester 
and it is produced much more slowly, being characterized by a highly and ordered 
arrangement whereas the cells are broadly uniform in size, shape and orientation, 
supporting a more resilient biomechanical performance than woven bone (21). 
 
 
2.1.2.1 - EXTRACELLULAR MATRIX 
Regarding its composition, the mature bone tissue may be considered a composite 
material constituted by a tough organic matrix (approximately 35%), which is greatly 
18 
 
strengthened by inorganic minerals (60 to 70% bone weight) and cells. The remainder 
ECM is filled with a homogenous gelatinous medium, named ground substance, that is 
composed of extracellular fluids and proteoglycans (e.g., chondroitin sulfate and 
hyaluronic acid), which are thought to assist on the regulation of calcium salts 
deposition. The proportions of these components vary with age, location and metabolic 
status (20). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 - Microstructural organization of mature lamellar bone comprising 
areas of compact and cancellous bone (20). 
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2.1.2.2 - BONE COLLAGEN 
The overall extracellular structure of the bone acts as an interconnected network 
for cells, in close interaction. The organic part of this matrix is 90 to 95 per cent 
constituted by collagen fibers, which closely resemble those of many other connective 
tissues and it is predominately composed by collagen type I fibers, combined with a very 
small amount of collagen type V, which is thought to regulate fibrillogenesis (20). 
Nevertheless, the molecular structure of collagen is unique in which regards its 
organization, which displays internal covalent cross-linkages, and larger transverse 
spacing, within its fibrils (figure 2.3). The cross-links make it stronger and chemically 
more inert while the internal gaps enable deposition of minerals. The adequate and 
ordered deposition of collagen in sufficient amounts is required to accomplish the 
formation of optimal bone mass and mineral density during the skeletal development, 
since bone mineral crystals deposition is aligned with the long axis parallel to the 
collagen axis. As so, collagen contributes largely to the mechanical strength of bone as 
well as to the tensile strength, compressive resistance and elasticity, which enhances 
the resistance to fractures during mechanical loading (20). 
Collagen is produced by osteoblastic cells which synthesize tropocollagen, which 
is lately polymerized in the ECM and gradually increases its cross-links with maturation. 
Collagen fibres from the periosteum, also designated as extrinsic fibres, are 
incorporated in cortical bone and anchor the fibrocellular layer, at their surface. 
Terminal collagen fibres of tendons and ligaments are incorporated deep into the matrix 
of cortical bone. The fibres may be interrupted by new osteons during cortical bone 
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modelling and turnover or remodelling, and remain as islands of interstitial lamellae or 
trabeculae (20). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 - Scanning electron microscopy image of collagen fibers of human 
cancellous bone (20). 
 
 
2.1.2.3 - NON-COLLAGENOUS ORGANIC COMPONENTS 
Several non-collagenous proteins can also be found among the extracellular 
organic component attached to collagen fibers or surrounding bone crystals. They are 
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essentially secreted by osteocytes and osteoblastic cells and they include among the 
several, osteopontin (or bone sialoprotein-1, BSP-1) (OPN), bone sialoprotein-2 (BSP-2), 
osteocalcin (OC) and osteonectin. Despite their exact biological role is far from being 
completely fulfilled these components play important role in bone metabolic functions 
as well as in osteoblastic and osteoclastic cell function and interaction (16). 
Bone matrix also contains proteoglycans (e.g. decorin and biglycan, which seem to 
modulate cell activity, especially the collagen fibrillogenesis process), glycoproteins 
(e.g., fibronectin and vitronectin, with a distinctive role in cell signalling), many growth 
factors (e.g. transforming growth factor β (TGF-β), bone morphogenic protein (BMP), 
insulin-like growth factor (IGF-9 among other), proteases and proteases inhibitors (16, 
20). 
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2.1.3 - BONE MINERALS 
The inorganic constituents of the extracellular matrix play an important role, 
conferring strength, rigidity and allowing ion storing. This component is the main reason 
why the bone maybe recorded on radiographs since it needs to be at least 50% 
mineralized to be visible on radiographs produced by a standard X-ray unit. With the 
mineral removal with calcium chelators, such as ethylene diamine tetra-acetic acid 
(EDTA), the bone keeps its shape but becomes highly flexible (20). 
The crystalline salts deposited in the organic matrix are constituted essentially by 
calcium and phosphate. The substance which largely mades up these crystals is 
commonly referred as hydroxyapatite, although with an important carbonate content 
and a lower Ca/P ratio than the pure hydroxyapatite, Ca10(PO4)6(OH)2. Bone crystals are 
thin plates or leaf-like structures that possess a broad surface area despite the small 
size. These structures range in size up to 150 nm long, per 80 nm wide, per 5 nm thick; 
however most of them are broadly half this size (20). 
Ionic substituents, such as magnesium, strontium, carbonate, citrate, and fluoride 
are broadly present among the bone salts. It is thought they are conjugated with 
hydroxyapatite rather than organized separately. Additionally, these ions seem to 
modulate the biological response in the local microenvironment (16). 
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2.1.4 - BONE CELLS 
Bone tissue exhibits four main types of cells among its organic matrix including 
osteoclasts, osteoblasts, osteocytes and bone lining cells. Bony cells may be generally 
classified attending to their functional activity into bone forming and bone resorbing 
cells, or according to its differentiation or maturation state. 
The cell-to-cell and cell-to-matrix interactions are critical in order to maintain bone 
mass balanced and bone tissue homeostasis. For instance, osteoblasts are known to 
bind bone matrix through integrins which recognize RGD among other bone-specific 
protein sequences, such as osteopontin, collagen and bone sialoproteins. Moreover, 
osteoclasts interaction with bone matrix and osteoblastic-secreted factors are essential 
for the osteoclastic function and bone renewal to occur correctly (18).  
 
 
2.1.4.1 - OSTEOCLASTS 
Osteoclasts are the only cells known to be able of absorb or breakdown bone 
tissue. These large (ranging 40 µm and higher) and multi-nucleated cells (normally 3 to 
20 nuclei) are derived from circulating hematopoietic stem cells that differentiate along 
the monocyte/macrophage lineage (see figure 2.4a). Since their differentiation pathway 
is common to macrophages and dendritic cells, osteoclastic differentiation depends 
directly on precursor cell exposition to several specific factors such as the macrophage 
colony-stimulating factor (M-CSF) and the receptor activator of nuclear factor kappa-β 
ligand (RANKL), both secreted by osteoblastic cells (22). Both cytokines are crucial not 
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only for differentiation but are also required for proliferation, survival and 
differentiation of osteoclastic precursor cells (20). The M-CSF binds to its receptors in 
osteoclastic precursors, stimulating their proliferation and disrupting apoptosis, while 
RANKL binds to its ligand (RANK), triggering osteoclastogenesis (23, 24). Along with 
these two factors, osteoprotegerin (OPG) was found to bind RANK preventing RANK-to-
RANKL interaction, leading to inhibition of osteoclastogenesis (24). This three-way 
system works as a key regulator of bone resorption.  
 
 
 
 
 
 
 
Figure 2.4 - (a) Rat multinucleated osteoclast (OC) revealing some nucleus (N) and 
vacuoles (V) and the organization of a ruffle border (RB) next to bone surface (B) 
undergoing resorption, adapted from (18); (b) Histological analysis of human bone 
revealing multinucleated osteoclasts forming Howship’s lacunae (25). 
 
 
Osteoclastic cells are commonly found in areas undergoing bone resorption (figure 
2.4b) and reveal high mobility. These cells mediate the resorption process via the release 
a b 
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of powerful lysosomal enzymes and acids, which digest protein and mineral components 
of the bone matrix, respectively. The key family of proteinases involved in this 
degradation process of bony tissue are the cathepsins and matrix metalloproteinases 
(26). 
 
 
2.1.4.2 - OSTEOBLASTS 
Osteoblasts are derived from undifferentiated stem cells of mesenchymal origin, 
which can be found in bone marrow, endosteum, and periosteum, among other 
locations (see figure 2.5). These osteoblastic progenitor cells, also referred as 
“preosteoblasts”, can migrate from neighbouring tissues or through the vascular system 
to the target area. Commonly, osteoblasts comprise 4 to 6% of the total resident bone 
cells and are located in bone outer layers and in bone cavities undergoing bone 
remodelling events (i.e. trabeculae). These are the unique cells known to be able of 
promote new bone formation by deposition of extracellular matrix rich in collagenous 
and non-collagenous proteins, being further responsible for the subsequent 
mineralization process. Morphologically, mature and active osteoblasts are 
mononucleated cells with plump cuboidal-like shape, with a prominent Golgi apparatus 
and endoplasmic reticula, both related with their high secretory activity (18, 27). With 
the decreasing of the metabolic level, the osteoblasts shape becomes progressively 
flattened out with the decreasing of the metabolic index. 
The synthesis of new bone tissue takes place in two main steps. In the first step, 
osteoblastic cells secrete the most of bone remodelling modulators and bone matrix 
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molecules such as type 1 collagen, non-collagenous proteins (such as osteonectin, bone 
sialoprotein 2,  osteocalcin and osteopontin), proteoglycans (including decorin and 
biglycan) which promotes the matrix formation (16). The second step, focuses on the 
matrix mineralization and takes place into two phases namely, the vesicular (i) and the 
fibrillar phase (ii). In vesicular phase, numerous matrix vesicles (ranging from 30 to 200 
nm) are released into the newly formed bone matrix binding to the previously secreted 
components (28). These vesicles were described to contain a phosphatase, active at 
neutral pH, which has strong specificity and promote further hydrolyse of a variety of 
nucleotide and metabolite. Additionally, matrix vesicles were found to up 45Ca, even in 
the presence of low levels of Ca (29). Following, the fibrillary phase occurs with the 
rupture of the vesicles leading to the spreading of hydroxyapatite crystals on the 
surrounding matrix as the vesicles’ content contact with phosphate-containing 
substrates in the presence of ATP (29, 30). 
Osteoblasts cytoplasmic membrane is rich in alkaline phosphatase (ALP), an 
important enzyme for ECM mineralization. The increasing of ALP expression is intimately 
bounded with a shift to a more differentiated state of the osteoblastic cells and generally 
determines the occurrence of the mineralization process, at least within in vitro systems 
(31). Furthermore, ALP is responsible for the degradation of matrix vesicles leading to 
the release of phosphate and calcium ions, allowing the subsequent formation of 
hydroxyapatite crystals (18). 
Osteocalcin and osteonectin (ON) are both products of osteoblasts which play 
crucial roles in new bone mineralization. The first is a 6-kDa protein, synthetized at the 
locations undergoing bone remodelling and binds to hydroxyapatite, thus suggesting a 
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participation of OC in nucleation of the bone mineralization. The 35-kDa protein 
osteonectin also binds to hydroxyapatite and to collagen fibres, facilitating extracellular 
mineralization (17). 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 - Histological analysis of rat bone section stained with toluidine blue. 
The image reveals osteoblasts (Ob) and bone lining cells (BLC) present on bone surfaces 
and the osteocytes (Ot) trapped into the bone matrix along the bony trabecula (B). BV 
refers to blood vessels (18). 
 
Osteoblastic activity continues in living bone through life time span, allowing a 
continuous renewal of bony tissue. Once the remodelling cycle is finished, osteoblasts 
cease the production of bone matrix and become committed to one of three pathways: 
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(1) become embedded by new mineralized bone matrix and differentiate in osteocytes, 
(2) shift their shape turning into flattened lining cells covering the bone surface, or (3) 
become relatively inactive or undergo apoptosis (18, 32). 
 
 
2.1.4.3 - OSTEOCYTES 
Osteocytes comprise around 90 to 95% of bone cells in the adult skeleton. When 
osteoblasts become entrapped in the newly formed bone matrix (figure 2.5), a 
subpopulation differentiate into osteocytes which are more mature cells and mainly 
responsible for bone matrix maintenance (33). This differentiation process comprises 
also conspicuous morphological and ultrastructural changes including osteoblast size 
reduction, decreasing number of organelles such as rough endoplasmic reticulum and 
Golgi apparatus, and decreasing nucleus-to-cytoplasm ratio resulting in a diminished 
protein synthesis (34). Despite that fully-matured osteocytes are relatively inactive 
when compared to active osteoblasts downregulating the expression of osteoblastic 
markers such as OC, BSP-2, collagen type 1 and ALP, they still can produce several 
factors, essential for bone matrix support, including dentine matrix protein 1 and 
sclerostin (18, 35). Osteocytes may be found in bone lacunae of 1 to 2 µm wide, 
surrounded by collagen fibrils, which support cytoplasmic process responsible for the 
intercellular communication through cannaliculi channels and gap junctions (20). 
Additionally to cell-mediated exchanges of minerals, this network also act as 
mechanosensor, as it has the capacity to detect mechanical deformation within bone, 
thus modulating processes such as bone formation or bone resorption (36). The specific 
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mechanical stimuli to which bone cells respond in vivo may be connected with strain 
changes itself, as well as strain-generated changes to their fluid environment, which 
consequently affects the release of signalling molecules and growth factors, that seem 
to regulate cell proliferation and differentiation (37). 
 
 
2.1.4.4 - BONE LINING CELLS 
Bone lining cells derive from osteoblastic cells which cease the production of new 
bone matrix, becoming partially inactive. They exhibit an elongated shape (see figure 
2.5 and 2.6) with a flat nuclei and usually are located over bone surfaces where neither 
bone resorption nor bone formation occur (38). Due to their abridged metabolic activity, 
they possess fewer organelles than osteoblasts. 
Bone lining cells are compactly associated and connect each other via gap 
junctions and communicate with internal bone cells, such as osteocytes, by cytoplasmic 
extensions or thigh junctions made through surface canaliculi (39). Since the activation 
of bone remodelling process takes place at inactive bone surfaces, bone lining cells are 
thought to interfere in bone metabolism in two possible ways: (1) building a 
microenvironment suitable for bone resorption mediated by osteoclasts, as well as by 
producing OPG and the receptor activator of nuclear factor kappa-β ligand; and (2) 
regulating new bone matrix deposition and mineralization, enrolling osteoblast-like 
functions (39). 
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Also, bone lining cells showed to play an important role in the maintenance of the 
bone fluids and the fluxes of ions between the bone fluid and interstitial fluid 
compartments, interfering deeply into mineral homeostasis (20). 
 
 
 
 
 
 
 
 
Figure 2.6 - Bone lining cells (BLC) exhibiting flat shape with scarce cytoplasm, 
located on the osteoid (Otd) surface. B refers to calcified bone surface and N to the 
nucleus. Adapted from (18). 
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2.1.5 - BONE REMODELLING 
Bone remodelling is a natural process wherewith bone tissue renew itself 
throughout lifespan. Due to its cellular components and functions, bone has been 
described as a highly dynamic and metabolic active specialized connective tissue. These 
cellular components are the main responsible for this remarkable ability and highly 
regulated process of bone renewal in which older bone is continually being absorbed by 
osteoclastic cells while new bone is being continually deposited by osteoblastic cells. 
Thus, the bone renewal process is dependent upon the stringent interaction between 
osteoclasts and osteoblasts, which are further modulated by specific bio-molecular 
factors. Generally, with the exception of growing bones, each cycle of bone remodelling 
is balanced such the bone resorption rate and the new bone deposition rate are equal 
to each other, preserving the loss of bone mass. Usually, in the adult bone, this cycle 
lasts about 90 to 130 days (40). 
Bone remodelling process aims to preserve bone strength and mineral 
homeostasis, preventing skeleton weakening derived from the accumulation of fatigue 
and microdamage. Once under the specific environmental stimulus, bone remodelling 
occurs following four phases (see figure 2.7): osteoclast activation, old bone resorption, 
reversal phase, and new bone formation (41). 
In the earliest phase, several factors induce osteoblasts to produce molecules that 
will give rise to osteoclastic precursor cells differentiation and osteoclast activation. 
Among the factors involved in this activation stage vitamin D and parathyroid hormone 
(PTH) play a critical role.  Vitamin D is a known enhancer of calcium absorption in the 
intestinal tract and it is also an important agent, modulator of both bone resorption and 
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deposition. After being converted to 1,25-dihydroxycholecalciferol in liver and kidneys 
with PTH interference, vitamin D is able to modulate bone remodelling process. 
Accordingly, high doses of functional vitamin D increase bone resorption rate, 
nevertheless the reduction of vitamin D or its absence, interferes with PTH causing a 
sharp decrease of bone absorption and increased bone calcification (17). The cellular 
mechanisms behind these effects carried out by functional vitamin D are not completely 
cleared, although it is thought to be related with the ability of 1,25-
dihydroxycholecalciferol to increase calcium ions transport through cell membranes.  
The secretion of PTH is dependent on both ionized plasma calcium and vitamin D 
concentrations. The diminished blood calcium levels lead to an increased PTH 
production. This augmentation of PTH modulates osteoblasts and stromal cells inducing 
them to produce other important molecules for osteoclast activation: the macrophage 
colony-stimulating factor and the receptor activator of nuclear factor kappa-β ligand 
(17). As mentioned before, the M-CSF, also known as CSF-1, is an important factor for 
osteoclast development. Additionally, it was showed that cell-to-cell contacts between 
osteoblastic and osteoclastic cells were crucial for M-CSF signalling and osteoclast 
activation (18). With the increasing of PTH, osteoblasts initiate the expression of surface 
receptors RANKL, which are specific receptors for RANK, present in the membrane of 
osteoclast progenitor cells. Once this link occurs, osteoclastics progenitor cells are 
stimulated to differentiate in mature osteoclasts. RANKL together with M-CSF are able 
to differentiate osteoclasts and activate them for bone resorption, begging another 
bone remodelling cycle. 
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Once osteoclasts are activated, a resorption phase of limited duration (second 
phase) begins, in which osteoclasts give rise to bone resorption, following a two-step 
mechanism. Firstly, osteoclasts bind to bone matrix via integrin receptors and become 
polarized. Accordingly, four types of osteoclastic membrane domains can be observed: 
upon the contact with the bone matrix, the fibrillary actin cytoskeleton organizes into 
an actin ring promoting the formation of the sealing zone (i) - the bone resorption cavity. 
Then, osteoclast continues to rearrange its cell membrane forming a ruffled border (ii) 
that contacts with bone surface. The remaining domains of osteoclasts membrane are 
basolateral (iii) and functional secretory domain (iv) which are not in contact with the 
bone matrix (42, 43). Posteriorly to the establishment of ruffle border structure, two 
types of substances are produced and excreted to the microenvironment: proteases and 
acids. The acids secretion is mediated through an H+ pump at the ruffle border and aims 
to acidify the resorption lacuna and to enable dissolution of hydroxyapatite crystals (17, 
42). The proteases digest the majority of bone matrix proteins by hydrolysis. Another 
important hormone playing an important role in bone remodelling is calcitonin. It is 
produced by the thyroid gland in response to a certain rising of calcium level and its role 
include the inhibition of osteoclastic activity by inducing loss of ruffle borders and cells’ 
dislocation from the underlying bone (17). 
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Figure 2.7 - Schematic representation of the four stages of bone remodelling cycle 
(41). 
 
After the end of bone resorption, a reversal phase (third phase), representing the 
transition from bone resorption to bone formation, occurs. In this phase, several 
markers produced by osteoclasts and preosteoblasts are thought to induce osteoblastic 
maturation and activation. Then, osteoclasts leave the area undergoing remodelling and 
resorption cavities are filled with functional osteoblasts. The formation of new bone 
begins (fourth phase), with the synthesis of new collagenous matrix by osteoblasts, 
followed by the matrix mineralization (19). Once the new bone formation is completed, 
osteoblasts embedded in new matrix become osteocytes, and remaining functional 
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osteoblastic cells become flat lining cells or undergo apoptosis. Several matrix-derived 
markers were reported to be involved in bone turnover and homeostasis. Thus, 
osteoclast formation and activation is broadly regulated not only by RANKL and M-CSF 
but also by OPG, 1,25-dihydroxyvitamin D3, calcitonin and others (19). Factors such as 
growth hormone (GH) thyroxine, estrogens, androgens, glucocorticoids, as well as 
mechanical stress, have also influence in bone metabolism. These factors are 
particularly significant as they exert their effects on the bone by producing local growth 
factors. Further, bone metabolism is also directly mediated by several cytokines and 
growth factors, which are produced by bone cells, where other cells in the 
microenvironment act in an autocrine or paracrine way to regulate the proliferation and 
differentiation of bone cell precursors (44). 
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2.1.6 - BONE HEALING 
Bone tissue is characterized by an adequate capacity to regenerate itself upon the 
establishment of a lesion or small defects. This healing process aims to generate new 
bone tissue to stabilize the damaged bone parts with minimal alterations of bone 
anatomy and function. Ordinarily, bone healing occurs following four main stages (see 
Figure 2.8). Primarily, after an injury such as a fracture, the damaged bone zone 
undergoes an inflammatory phase (a) in which the necrotic tissue is cleaned; following, 
a repair phase (b) is initiated with the formation of a cartilage tissue – soft callus – 
replacing the lost bone. Simultaneously, osteoclasts continue the resorption of 
remaining bone debris and new blood vessel formation occurs. Also during this stage, 
new collagen fibers are produced by fibroblasts leading to the formation of a denser 
fibrous net, which will consolidate new bone tissue; in a third phase, the newly formed 
cartilage is replaced by trabecular bone (c) in a process similar to endochondral 
ossification; finally, fracture healing is completed by a remodelling phase (d) that may 
last for more than a year and in which the morphology is mended to ensure a perfect 
bone recover (45). 
This ability, however, is limited since it may prevent only low magnitude fractures 
or small defects. When bone defects or fractures exceed a critical size, additional 
therapeutic solutions are required in order to attain fully structural repair and normal 
functionality (46). Also, circumstances that impair the physiological tissue healing, such 
as local infections, may decrease the correct healing capability of the damaged bone. 
Several pathological conditions encompassing diabetes mellitus, osteoarthritis, 
osteopenia, osteoporosis, among other, are known to decrease cellular function and to 
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impair the formation of the bone mineralized matrix, leading to severe bone weakening 
and bone remodelling unbalancing (47). 
These situations represent major complications in therapeutic strategies for bone 
tissue healing and require alternative therapeutic solutions. 
 
 
 
 
 
 
 
Figure 2.8 - Schematic representation of the four stages of bone fracture repair 
(45). 
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2.2 - DIABETES MELLITUS 
 
Diabetes mellitus (DM) is not a single pathological entity but rather a group of 
metabolic disorders which are globally characterized by a chronic hyperglycaemia, as 
well as by impaired carbohydrate, fat and protein metabolism (48). These metabolic 
modifications arising from a persistent hyperglycaemic state seem to be caused by 
abnormal insulin production or decreased sensitive of the tissues to insulin, or most 
commonly, both (48). Accordingly, it may be difficult to identify which of mechanisms, 
if either alone, is the major cause of hyperglycaemia (49). 
The chronic hyperglycaemia or the lack of control of glucose concentration in the 
organism, together with the protracted depleted action of insulin on its target organs, is 
associated with long-term damage and consequent dysfunction, or even failure, of 
various organs, especially the eyes, kidneys, blood vessels and nerves (2). The most well-
known factors behind DM development include the genetic factors, pathologic 
triggering (i.e. viruses) and environmental factors, including increased sedentary life 
styles and poor eating habits (1, 50). 
Despite being a common metabolic disorder, DM triggering and developmental 
processes are not completely understood as they apparently range from immuno-
mediated events of autoimmune destruction of insulin-producer cells, to organ-specific 
dysfunctional uptake of functional insulin or abnormal resistance to insulin action (48, 
51). Following the establishment of the hyperglycaemic state, a few physiological 
changes occur leading to the emergence of several clinical symptoms, which are 
considered typical of the diabetic condition. The common symptoms associated to 
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diabetic patients include polyuria, polydipsia, weight loss, and blurred vision. In several 
cases, susceptibility to certain infections and delayed growth may also keep up with 
chronic hyperglycaemia (51). Acute, life-threatening consequences of uncontrolled 
diabetes are hyperglycaemia associated with ketoacidosis or the nonketotic 
hyperosmolar syndrome, which may progress to coma and, if not treated, death (51). 
Long-term exposure to hyperglycaemia and non-attenuated insulin production 
and uptake impairment result in severe damage of several organs leading to 
retinopathy, nephropathy, peripheral and autonomic neuropathy, which may further 
induce gastrointestinal, genitourinary, and cardiovascular symptoms. Diabetic patients 
also tend to develop hypertension, and abnormalities of lipoprotein metabolism (49). 
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2.2.1 - DIABETES CLASSIFICATION 
Typically, diabetes mellitus is classified into two broad categories: type 1 diabetes 
mellitus (T1D) and type 2 diabetes mellitus (T2D). Although, more recently literature 
describing glucose metabolic disorders uses a more complex classification considering 
four main groups: type 1 diabetes; type 2 diabetes; other forms of diabetes mellitus; and 
gestational diabetes mellitus (GDM) (1). Similarly to other autoimmune disorders, T1D 
involves chronic inflammatory infiltration and massive destruction of insulin-producing 
β-cells of the pancreatic islets of Langerhans, leading consequently to the absolute 
deficiency of insulin secretion (52). In contrast, T2D is characterized by the combination 
of abnormal resistance to insulin uptake and action, which promotes an inadequate 
compensatory insulin secretion. In this category, a degree of hyperglycaemia sufficient 
to cause pathologic and functional changes in various target tissues, but without clinical 
symptoms, may prevail for an extended period of time before clinical detection (51). 
Other variants of diabetes mellitus were found to arise from genetic abnormalities or 
specific pathological or clinical conditions, in which insulin action is negatively affected 
(see table 2.2). 
 
 
2.2.1.1 - TYPE 1 DIABETES 
Type 1 diabetes mellitus accounts for around 5-10% of diabetes-affected 
individuals and it is also known as insulin-dependent diabetes mellitus, or juvenile-onset 
diabetes, as its onset usually occurs during childhood (53). 
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Table 2.2 - Etiologic types and stages of glycemic disorders. Adapted from (51). 
 
 
 
 
 
 
 
 
T1D is known to be triggered by a cell-mediated autoimmune response in which T 
lymphocytes react against poorly defined β-cells leading to a progressively deficient 
insulin production. The destruction rate of insulin-producing cells is quite variable and 
substantially influenced by age, being rapid in some individuals (mainly infants and 
children), and slow in others (mainly adults) (51, 53). The HLA region of chromosome 
6p21 is known to play important role regarding the susceptibility to develop several 
human autoimmune diseases, including T1D (54). After decades of progress in T1D 
study, HLA class II is still considered the strongest contributor to the development of this 
type of diabetes. HLA linkage to the DQA and DQB genes was described as pivotal for 
T1D onset. Additionally, these genes together with the influence of DRB genes, may 
confer either a predisposed or protective phenotype against T1D (55). For example, 
individuals with DR3/4-DQ2/8 expression were reported to have a risk for develop 
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persistent anti-islet autoantibodies and 60% risk for diabetes onset at age 15 (56). A less 
prominent association was found between the HLA class I genes, such as HLA-A and HLA-
B, and T1D (55). Despite the autoimmunity seems to be the predominant mechanism of 
T1D, associated primary causes are not yet fully established. In fact, even before T1D 
clinical onset, autoantibodies reacting against β-cells are spotted suggesting a sequence 
of inciting events preceding hyperglycaemia. 
The most studied pathological agents contributing to T1D incidence comprises 
viral, bacterial and other infections. Enteroviruses, specifically coxsachievirus, were 
earlier described by Yoon et al. to be involved in β-cells infection, precipitating insulin-
dependent diabetic state (57). Further studies reported the presence of enteroviruses 
in recent onset patients (58). Among the discoveries of the intestinal bacterial 
composition, few information was achieved regarding T1D. The presence of 
Mycobacterium avium subspecies paratuberculosis (MAP) were described to be a major 
risk factor. Accordingly, clinical significant humoral responses to MAP antigens and 
whole cell lysates were detected in patients with juvenile-onset diabetes (59). 
Regarding the immune events taking place before the emergence of clinical 
symptoms, the most critical encompass the production of autoantibodies following the 
activation of self-reactive lymphocytes. The core-targeted antigens by the 
autoantibodies comprise the insulinoma-associated antigen-2 (I-A2 and ICA512), insulin 
(micro IAA), glutamic acid decarboxylase 65 (GAD65) and zinc transporter 8 (ZnT8) (53, 
60). Consequently, the insulin-producing β-cells are persistently targeted and destroyed 
in a continuous autoimmune process, which may take several years before the clinical 
symptoms arise. Following the pronounced reduction of insulin production, the clinical 
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symptoms emerge. While some patients may firstly develop ketoacidosis (particularly 
children and adolescents), others experience modest fasting hyperglycaemia which may 
rapidly evolve to severe hyperglycaemia accompanied (or not) by ketoacidosis 
associated with infection or other stresses (61). Yet, few other patients may retain a 
residual number of functional β-cells sufficient to prevent ketoacidosis for several years. 
Notwithstanding, some forms of T1D have no known etiology since these patients suffer 
a permanent insulinopenia and are likely to develop ketoacidosis, without evidence of 
autoimmunity (51). 
 
 
2.2.1.2 - TYPE 2 DIABETES 
Type 2 diabetes mellitus is also referred as non-insulin-dependent diabetes 
mellitus, or adult-onset diabetes, and represents around 90% of those patients affected 
by diabetes (62). 
T2D develops mainly due to genetic factors associated with sedentary life style 
which, together, lead to deficient insulin production, impaired insulin action or both, 
simultaneously. The specific etiology associated to this form of DM is not completely 
understood. However, in contrast with T1D, autoimmune destruction of pancreatic β-
cells does not seems to occur in these patients (51). Instead, in the majority of cases, 
insulin metabolism disorders are the result of prone lifestyle habits, lack of practice of 
physical exercise, and consequent obesity, which itself causes some degree of insulin 
resistance (51, 63). Additionally, T2D is rarely associated with ketoacidosis despite that 
this complication may occur temporarily, caused by associated infections (51). 
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Due to the gradual development of hyperglycaemia, which may not be severe 
enough to trigger any of the classic symptoms, T2D may remain underdiagnosed for 
many years. Commonly β-cell function is still sufficient to avoid the need for insulin 
administration. However, with time, the insulin secretion may get progressively 
decreased, becoming insufficient to compensate the insulin resistance, which may also 
accentuate (51). 
The abnormal insulin uptake and the resistance to insulin normal functionality may 
be improved with weight reduction, practice of physical exercise, and pharmacological 
treatment of hyperglycaemia nonetheless, it is rarely restored to normal (51, 64). The 
risk of T2D incidence is strongly associated with the ageing, obesity or history of obesity, 
and lack of physical activity; yet, it seems to show greater occurrence in individuals with 
hypertension and/or dyslipidaemia, and its frequency varies in different racial/ethnic 
subgroups (65). 
Although, type 2 diabetes onset is often associated with patients of middle age or 
later, recently, it was noticed an increase of T2D incidence in children and young people 
(66). 
 
 
2.2.1.3 - OTHER FORMS OF DIABETES MELLITUS 
Apart from the most common type 1 and type 2 diabetes mellitus, other forms of 
diabetes have been identified and classified independently according to their specific 
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etiology, into two main categories: (1) diabetes mellitus derived from genetic defects; 
and (2) diabetes mellitus associated with particular disorders or conditions. 
The variant forms of diabetes associated with genetic defects have its causes in 
identified genetic abnormalities which interfere with pancreatic β-cells or insulin action 
physiological mechanisms. A kind of genetic abnormalities includes defects in the insulin 
gene leading to a condition commonly referred as maturity onset diabetes of the young 
(MODY), or monogenic diabetes, which results in an impaired insulin production (51). 
These types of defects are generally hereditary and inherited in an autosomal dominant 
pattern (67). Another kind of genetic defects are associated with insulin action and 
usually related with insulin receptors, which may induce a variety of conditions ranging 
from hyperinsulinemia and moderate hyperglycaemia to severe diabetes (67). 
Other variants of DM may have their etiology connected with primary diseases or 
other conditions. For instance, severe diseases of the exocrine pancreas such as 
pancreatitis, infections, pancreatic carcinoma, traumas or pancreatectomy may lead to 
a significant loss in β-cell mass and subsequently to the establishment of a diabetic state 
(68). Attending to its origin, either accompanying a syndrome or a specific pathological 
condition, the types, of diabetes encompassing these group is conventionally labelled as 
secondary diabetes. This variant may also be triggered by several endocrinopathies, 
which are strongly associated with an increased level of hormones that antagonize 
insulin action. This is the case of Cushing’s syndrome, glucagonoma, acromegaly, 
pheochromocytoma in which the cortisol, glucagon, growth hormone and epinephrine, 
respectively, are secreted in excess (69). 
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Additionally to the previously mentioned causes of diabetes, several drugs (e.g. 
pyriminil and pentamidine) are known to interfere negatively in the production, uptake 
and normal function of insulin and thereby, may precipitate a diabetic-like state (69). 
 
 
2.2.1.4 - GESTATIONAL DIABETES 
Gestational diabetes mellitus (GDM) was known, for many years, as a group of 
disorders associated with glucose metabolism or any degree of glucose intolerance 
condition, with its onset or first recognition during pregnancy (51). This DM variant 
shares several symptoms with T1D and T2D. However, some patients may not be clearly 
classified as having one particular form of the two main types of the disease. Further, 
this definition applies independently on the need of insulin administration, or specific 
diet modification treatment, or even if the condition persists after pregnancy (51). This 
kind of DM may be detected in the second or third trimester of pregnancy through a 
screening for clinical risk factors and testing abnormal glucose tolerance, which is usually 
mild and asymptomatic (70). Pregnancy itself impairs the normal glucose metabolism 
thus a special attention is required regarding both diagnosis and control, especially since 
it was demonstrated that the risk of adverse maternal, foetal and neonatal outcomes, 
continuously increase as a function of maternal glucose at 24-28 weeks (71). 
Besides sharing symptoms, GDM etiology also shares common background of 
physiological and genetic abnormalities that characterized diabetes mellitus outside 
pregnancy. Commonly, glucose metabolism returns to normal after delivery; however, 
women developing GDM are more likely to develop diabetes posteriorly (72). 
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2.2.1.5 - NEONATAL DIABETES 
Neonatal diabetes (ND) represents another form of diabetes which should be 
highlighted, since it differs from the main types previously described. ND may be 
diagnosed in the first 6 months after birth and similarly to GDM, it may be temporary or 
permanent (51). 
Among the main causes leading to a temporary form of this neonatal disorder, the 
most common genetic defect is an abnormality on ZAC/HYAMI. On the order hand, 
defects on the gene encoding the Kir6.2 subunit of β-cell KATP channel represents the 
most common alteration responsible for a permanent ND (51). 
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2.2.2 - DIABETES DIAGNOSIS 
The diagnosis of diabetes mellitus aims not only to detect evidence of altered 
glucose metabolism, but also to understand the etiology, stage of development and 
degree of both glucose metabolism and associated complications. 
Diabetes may be diagnosed through three well-known clinical tests: (1) the fasting 
plasma glucose (FPG); (2) the 2-h plasma glucose value after 75g of oral glucose 
administration – the oral glucose tolerance test (OGTT); being both focused on plasma 
glucose criteria; and (3) the A1C-based test (1). 
The FPG must be conducted under fasting and since the plasma glucose levels may 
be affected by situations of severe stress such as infections, myocardial infarction, 
surgeries, among other, this information needs to be taken in account (73). The 
temporal relation of diet-to-blood sampling time is not considered in the casual FPG. 
The second test, the OGTT, is the most sensitive technique to provide solid information 
about the diabetic disorder by measuring the rate of glucose disposal after a particular 
and significant oral administration of glucose (73). 
The A1C Test has been recommended more recently by international 
organizations in order to diagnose diabetes with a threshold of ≥6.5%, which is referred 
as A1C (haemoglobin A1C). Further, this test was reported to be clinically useful since 
A1C parameter is broadly relevant reflecting chronic hyperglycaemia as well as it is a 
specific pointer of glycaemic control, used as guide for diabetes treatment (1). 
Additionally, in comparison with the remaining tests, A1C possess several advantages 
including greater convenience (since it does not require a specific diet condition nor 
fasting), evidence to suggest greater preanalytical stability, and less interference by 
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factors such as day-to-day unbalances due to additional stress or illness (74). 
Nevertheless, A1C alone is unable to allow for the diagnose of diabetes, being necessary 
a complementary evaluation with one of those previously mentioned tests. The main 
reason for this limitation lies in the fact of A1C results being conditioned by erythrocytes 
renewal in addition to plasma glucose levels (73). Furthermore, when compared with 
FGP or OGTT tests, A1C is significantly more expensive and the final correlation between 
A1C and glucose may be incomplete for several individuals (1, 74). 
The currently accepted criteria for the diagnosis of diabetes are showed on table 
2.3. 
 
 
Table 2.3 - Criteria for the diagnosis of diabetes mellitus. Adapted from (51). 
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2.2.3 - DIABETES AND BONE 
Diabetic osteopenia (DO) is among the variety of complications that may arise 
from diabetes mellitus development, which regard tissue and organ damage or function 
impairment. 
Indeed, diabetes mellitus is known to broadly affect bone metabolism leading to 
abnormal conditions such as mineral loss conducting to an osteopenic state, which 
worsens due to chronic hyperglycaemia and latterly, osteoporosis (3, 75-77). Following, 
DO is tightly associated with bone fractures which are considered the major causes of 
morbidity and premature mortality and thus the relation between diabetes and bone 
healing and metabolism has been extensively reviewed (3, 76, 78). 
Despite this focused studies, the processes involving the risk for osteoporosis 
development and low- and high-trauma fractures remains unclear since reports became 
contradictory at times, depending upon the type of diabetes, the metabolic control, the 
onset of the disease, the clinical trials or experimental animal models, the gender, and 
the time points selected for the evaluation, among other factors (3, 79, 80). 
For instance, type 1 diabetes was reported to have a greater tendency to cause 
bone mineral loss and consequently facture risk due to a fragile bone structure. On the 
contrary, type 2 diabetes was described as a multidimensional condition, therefore 
specific experimental models available to mimic this condition are far from the real 
representation of the disorder increasing the contradictory and poor accurate 
information. 
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2.2.3.1 - EFFECTS OF TYPE 1 DIABETES ON BONE 
Type 1 diabetes mellitus is strongly associated with severe bone tissue 
comorbidities, comprising the modest reduction of bone mineral density (BMD), 
decreased linear bone growth during puberty, and early development of osteopenia and 
later osteoporosis (6, 79, 81, 82). 
The overall research focused in T1D was consistent in that this diabetes type tends 
to be associated with a diminished bone mass (83). Accordingly, several data shown that 
about 20% of T1D patients, between ages 20-65, are osteoporotic and up to 40% are 
osteopenic (78, 84, 85). Further, clinical evaluation has demonstrated a substantially 
increased risk of hip fracture. This was supported by in vivo studies using rodent models, 
which reported an abnormal bone turnover process in which osteoblastic function is 
impaired, while osteoclastic activity seems to be enhanced (75, 77, 86). Additionally, an 
induction of apoptosis of bone lining cells was noticed which, together with impaired 
bone turnover, seems to lead to an unbalanced cycle with greater bone suppression 
than new bone formation (87). 
Systemic interferences may also elicit a response in bone tissue, namely diabetic-
mediated acidosis, leading to renal complications which, by themselves, lead to a 
decreasing blood and extracellular pH (88). Despite the verified pH alterations, this does 
not imply an increased osteoclast activity. In fact, several studies report increased bone 
destruction under hyperglycaemic conditions, despite the fact that there is a significant 
amount of evidence showing a normal or even decreased osteoclastic activity in 
experimental diabetes (75, 87). 
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In contrast with bone resorption, bone formation is considerably affected by T1D 
and this outcome derives from impaired function of osteoblastic cells which, in 
physiological conditions, would express receptors for insulin and insulin-like growth 
factor-1 (IGF-1), known growth factors able to stimulate the activity, maturation and 
proliferation of osteoblastic-lineage cells. Further, hyperglycaemia itself reduces 
osteoblast replication and function. Numerous reports regarding bone histology in 
studies involving animals showed diminished osteoblast, number together with a 
reduced osteoid volume and mineral apposition, moreover, lower levels of important 
bone formation-related factors in plasma such as OC, IGF-1 and ALP, were also reported 
in both spontaneously diabetic and chemical-induced diabetic rats (83, 89). 
More recently, a study conducted on diabetic mice showed a relation between 
T1D hyperglycaemia and the decreasing expression of osteoblastic master regulator 
runt-related transcription factor 2 (RUNX2), as well as of some of its target genes such 
as matrix metalloproteinase-9 (MMP-9) and OC. Given its importance at the regulation 
of osteoblastic differentiation, RUNX2 down-regulation points to an impaired 
osteoblastogenesis and consequent impaired new bone formation. In which regards OC 
and MMP-9 diminished secretion along with deficient expression of critical factors such 
as DMP-1, MMP-13 and others, these were found to affect mineral homeostasis and 
new bone tissue mineralization (90, 91). 
Several reports pointed to a negatively affected mineralization in diabetes, 
together with a lowered torsional strength, angular deformation and energy absorption, 
even with soft reductions in BMD. Despite this reduction in mineral density, this 
unbalanced process is accompanied by an increasing glomerular filtration rate (+70%) 
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and calcium output (+568%), as well as a reduced calcium reabsorption (92). These 
comes in line with histological and radiographic evaluations which showed significant 
decreased trabecular connectivity density of tibiae, combined with an increased 
trabeculae separation, even under diabetic conditions with insulin treatment (93). 
 
 
2.2.3.2 - EFFECTS OF TYPE 2 DIABETES ON BONE 
In contrast to type 1 diabetes, type 2 diabetes is known as a multidimensional 
condition reported to exert a variety of adverse and sometimes contradictory effects in 
bone metabolism and regeneration. 
While some studies reported a reduced bone density in T2D patients (94, 95), 
other approaches registered an increased bone mineral density (76, 96) or even no 
changes, as comparing with physiological conditions (97, 98). Despite this variability, 
T2D is broadly associated with BMD increase rather than an osteopenic condition. 
Additionally, studies regarding the fracture risk within T2D also point to divergent 
conclusions however the majority indubitably suggests a higher risk of fracture which is 
thought to be strongly associated with obesity, since complications occur mainly in the 
hips, ankles, proximal humeri and feet. Other works, such as the Rotterdam study, 
detected changes in the fracture risk, specifically in women (5). In this case, a decreased 
risk of fracture of wrist and forearm in older women affected by T2D was reported (99, 
100). These results may indicate a site-specific relation between type 2 diabetes and 
bone fracture as well as an age correlation.  
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Ultimately, the higher BMD and consequent increased fracture risk in type 2 
diabetes may be explained by the following causes. Firstly, T2D is associated with an 
increase of 50 to 60% risk of falling (3, 101, 102). Secondly, long-term hyperglycaemia 
leads to complications which are considered prevalent risk factors for falls, including 
retinopathy and peripheral neuropathy (3). At last, despite the increased BMD and 
larger bone volume, diabetes is associated with a poor bone quality and, which is not 
detected in cross-sectional BMD measurements (3). 
 
 
2.2.3.3 - ANIMAL MODELS OF DIABETES MELLITUS 
The aiming for a more accurate insight on diabetes mellitus requires complex 
studies, which enable both the assessment of isolated cell and tissues, as well as 
systemic modifications and impairments. This need for an improved knowledge about 
this ensemble of metabolic disorders has led to a continual enhancement of in vitro and 
in vivo models. The most frequent experimental animal models of diabetes embrace 
small animals such as rodents, as these models may share the common properties with 
the attained outcome of the human disease (103, 104). 
While some animal models may spontaneously develop diabetes, such as the non-
obese diabetic (NOD) rat, other models may be pharmacologically induced by specific 
compounds such as streptozotocin (STZ), alloxan, vacor, dithizone and others (104, 105). 
Alloxan and streptozotocin are the most prominent diabetogenic chemicals, as they are 
toxic glucose analogues, which preferentially accumulate in pancreatic β-cells, leading 
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to a massive destruction or malfunction of these cells consequently inducing a diabetic 
state (105, 106). 
Alloxan was firstly discovered by Whöler and Liebig in 1838 (107) as a derivative 
of pyrimidine and was used as a diabetic inducer by McLetchie (108). This compound 
was reported to exert two distinct pathological effects: (1) inhibition of glucose-induced 
insulin secretion by a specific inhibition of glucokinases; and (2) induce the formation of 
reactive oxygen species (ROS) leading to a selective necrosis of pancreatic β-cells and 
consequent insulin-dependent state. Biochemically, alloxan is known to have a short 
half-life and it also decomposes spontaneously into non-diabetogenic alloxanic acid, 
when in aqueous solutions. Thus, alloxan uptake through glucose transporter 2 (GLUT2) 
must be fast in order to achieve a representative model of type 1 diabetes. In other 
hand, higher concentrations of alloxan may inhibit a variety of functionally important 
enzymes and proteins, as well as the cellular functions leading to undesired metabolic 
changes beyond the diabetic state. 
Streptozotocin is a nitrosurea derived from Streptomyces achromogenes and was 
firstly introduced as a broad-spectrum antibiotic, and a drug for cancer treatment (106, 
109). However, years later, STZ was reported by Rakieten and co-workers to exert a 
diabetogenic effect additionally to its antimicrobial action (110). Similarly to alloxan, 
following absorption, STZ enters pancreatic β-cells through GLUT2 channels in plasma 
membrane and starts a cascade of biological responses that ultimately lead to 
hypoinsulinemia and hyperglycaemia, in animals (106). When injected, STZ alkylates 
DNA by transferring its methyl group to the 6th oxygen of the guanine base, damaging 
the molecule. Following, poly(ADP)-ribose polymerase is over-activated to offset the 
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STZ-caused DNA breaks, resulting in the depletion of NAD+, and subsequently ATP, 
within cells. Thus, the unbalances in these molecules’ metabolism may result in the 
inhibition of several cell functions, namely regarding insulin production (105, 106). 
In rodents, STZ-induced diabetes exhibits several hallmarks representative of the 
verified chronic complications commonly associated with human DM (103). 
Furthermore, the pathologies development may be controlled depending on the length 
of the study and the time for which the animals are hyperglycaemic (92, 109). 
After STZ administration, blood glucose follows a well described triphasic pattern 
of hyperglycaemia (105, 106). The first phase begins as early as 1 hour following STZ 
administration and lasts 2-4 hours, during which an inhibition of insulin production 
originates a hypoinsulinemia, leading to the hyperglycaemia development. This stage is 
associated with morphological changes in the pancreatic β-cells, such intracellular 
vacuolisation, swelling of the mitochondria and decrease in Golgi body area (105). 
Approximately 4 to 8 hours after STZ injection, hypoglycaemia sets in. This second phase 
commonly lasts several hours, is irreversible, and may be severe enough to cause 
convulsions and death, particularly following the depletion of glycogen stores in liver 
(105, 109). This state is mainly caused by an extreme release of insulin into circulation 
upon explosion of vesicles and bursting of the cell membranes (105). The last phase 
occurs 12-48 hours after STZ administration and it is characterized by degranulated and 
destroyed β-cells, which debris are posteriorly cleaned by non-activated macrophages. 
No β-cells remain intact, further demonstrating the specificity of this drug (105, 106).  
The streptozotocin-induced diabetes model has been extensively used and is 
highly reproducible, being particularly useful for building upon and data comparison. 
57 
 
2.2.4 - DIABETES AND BIOMATERIALS IMPLANTATION 
The increasing incidence of DM has lead to a higher occurrence of complications 
associated with hyperglycaemia and consequent severe damage to tissues and organs 
(111). Accordingly, as the number of diabetic patients increase, the requirement of 
specific therapies and/or the implantation of biomedical devices to support tissue 
healing, is increasing as well. The most common implants used by DM patients include 
orthopaedic implants and glucose sensors. In particular, the glucose sensors have been 
especially designed for use in diabetic patients (11). 
The acceptance and performance of an implant highly depends on fibrosis, 
infections and integration on the damaged tissues. Implant-associated infections 
represent a major cause of implant’s failure and rejection (112). A variety of factors may 
contribute to the occurrence of these infections, including factors related with the 
surgery asepsis, the quality of the host tissues (e.g. bone and soft tissues around the 
wound), and even the complexity of the operation (11, 112). Further, infections 
associated with biomaterial implantation are generally more difficult to overcome as 
they usually require longer period of antibiotic therapy and additional surgical 
procedures, including prostheses removal and wound cleanse (113, 114). 
Diabetes mellitus, along with other pathological disorders, such as rheumatoid 
arthritis, and immunocompromising diseases, for instance, are known to alter wound 
healing as well as an increase in the risk of infection (115, 116). Further, compared with 
the general population, a higher implant failure and rejection rate has been registered 
in diabetic patients even in those with adequate metabolic control (117). Despite a 
number of studies have focused the understanding the diabetes effects on healing 
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ability (118-121), only few have discussed the infection prevalence and the ability of 
diabetic patients to receive implants and modulate the associated infections (11). 
Furthermore, many causes were described to promote infection in DM, including 
defective immune response, enhanced adherence of several microorganisms to diabetic 
cells, and higher amount of medical interventions (116), among other. 
It is known that in physiological conditions, the presence of a foreign body, such 
as biomaterial, triggers an inflammatory reaction and eventual fibrotic encapsulation, 
which can severely reduce the device’s performance or resulting in biomaterial rejection 
(11). For example, regarding the glucose percutaneous implants, some work has been 
carried out in order to diminish the risk for infection (122). These devices have been 
coated, aiming not only to reduce bacterial adherence and eradication, but also to 
minimize foreign-body encapsulation, which is a cause of implant malfunction, since the 
lack of vascularization and the fibrotic dense barrier blocks the accurate glucose 
measurement (11). 
Regarding orthopaedic implants, several studies have addressed the effects of 
diabetes on the osseointegration. These works reported higher rate of implant failure 
among the cases in which the disease was poorly controlled (123). Further, as 
mentioned previously, diabetes affect bone remodelling and mineralization which 
contributes to diminished implant osseointegration. Additionally, reduced bone-implant 
contact area in diabetes was reported, even with similar bone formation and quality in 
both physiological and diabetic conditions (124, 125). 
In which regards the effect of insulin on implant osseointegration, studies are 
contradictory. Conformably, a study conducted in alloxan-induced diabetic rat, 
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demonstrated that insulin treatment restored bone formation around endosseous 
implants (126). The authors found that the ultra-structural characteristics of bone-
implant interface was similar in both healthy and diabetic-insulin-treated animals. These 
results are endorsed by other reports which strongly suggest that metabolic control is 
essential to achieve successful implant osseointegration (126-128). In contrast, Fiorelli 
et al. have shown that, despite that insulin treatment and normoglycaemia maintenance 
seem to enhance bone formation around the implant, it is not enough to equally the 
bone-implant contact attained in non-diabetic animals (129). 
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2.3 - TETRACYCLINES 
 
Tetracyclines (TCs) are a family of broad-spectrum anti-microbial agents that are 
widely used in human and veterinary medicine. The range of TCs anti-microbial activity 
includes aerobic and anaerobic Gram-positive (e.g. Staphylococcus spp., Streptococcus 
spp., Bacillus spp.) and Gram-negative bacteria (e.g. Haemophilus, Escherichia, 
Salmonella spp.), and other organisms such as Rickettsia, Plasmodium and Chlamydia 
spp., Mycoplasma pneumoniae, and some protozoa (such as amoebae) (10, 130). 
In early 1948, due to the failure of most used antibiotics to improve his condition, 
the young Toby Hockett was the first patient treated with “the yellow-colored 
compound” developed by the Lederle Laboratories, under the name of aureomycin, or 
chlortetracycline (131). This active principle was discovered in the early 1940’s by 
Duggar and co-workers, as a natural fermentation product of the soil bacterium 
Streptomyces aureofaciens and it drew special attention due to the inhibitory effects on 
growth of all strains, in an initial panel of bacteria (9, 131). Authors further found that 
the extract exerted a remarkable antibacterial activity, even against most lethal 
pathogens at that time (such as typhus and rickettsias) (131). For this reason, 
researchers labelled aureomycin as a “broad spectrum antibiotic”. Few years later, 
Alexander Finlay and colleagues at Pfizer gathered various soil samples from around the 
world and isolated a compound from Streptomyces rimosus, which was similar to 
aureomycin and named Terramycin, also known as oxytetracycline (132). Joint work of 
Lederle and Pfizer teams leaded to the understanding of both aureomycin and 
terramycin preliminary chemical structures (see figure 2.9). Following, the 
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understanding of chlortetracycline and oxytetracycline leaded to the preparation of 
tetracycline through the hydrolysis of chlortetracycline, which showed the same anti-
microbial potential of both chlor- and oxytetracycline, and an enhanced stability (133). 
Following these findings, several TCs’ derivatives were later developed and chemically 
modified in order to attain enhanced efficacy and output, within the management of 
infectious conditions. 
Apart from their generation, tetracyclines are commonly classified according to 
their origin into natural-derived products (e.g. tetracycline, chlortetracycline, 
demeclocycline) and semisynthetic compounds or chemically modified tetracyclines 
(e.g. minocycline and doxycycline) (134, 135); or according to their half-life into short-
acting (e.g. chlortetracycline, tetracycline and oxytetracycline) or long-acting (e.g. 
minocycline and doxycycline). 
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Figure 2.9 - Chemical structure of naphthacene ring system, first-generation 
antibiotics (chlortetracycline, oxytetracycline and tetracycline), and second generation-
antibiotics, followed by the year they were approved by the FDA; Adapted from (136). 
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2.3.1 - CHEMISTRY AND ANTI-MICROBIAL PROPERTIES 
Chemically, tetracyclines from the first generation share a common basics 
structure. This common chemical structure consists of a tetracyclic naphthacene 
carboxamide ring system (figure 2.10), with similar functional groups displaying minor 
differences (131, 137). Second generation, encompassing semisynthetic and chemical 
modified tetracyclines, share the same basis of naphthacene ring with an A-ring carbon 
1 (C1)- carbon 3 (C3) diketo substructure and an exocyclic C2 carbonyl or amine group. 
Additionally, an active tetracycline requires a C10-phenol group and a C11-C12 keto-
enol substructure in conjunction, with a 12a-OH group. The antibiotic function has been 
associated with the dimethylamine group bound to carbon 4 (C4), in ring A (137). The 
removal of dimethylamine group from C4 or its replacement may significantly diminish 
the antibacterial properties. 
 
 
 
 
 
 
 
Figure 2.10 – Chemical structure of tetracycline. Adapted from (131). 
 
64 
 
Both upper and lower peripheral regions are able to bind several functional groups 
and substituents, of which replacement may significantly affect TC’s function. For 
instance, chemical changes of the lower peripheral regions are strongly associated with 
sharp reduction of both antibiotic and non-antibiotic effects (135). In contrast, synthetic 
modifications of C7 and C9, of D ring, have been reported to enhance stability, half-life, 
as well as the non-antimicrobial activity (137). This was accomplished with some 
semisynthetic tetracyclines, including minocycline and doxycycline. 
The basis of TCs bacteriostatic action relies on their ability to interfere with the 
normal cellular function of bacteria. It is currently accepted that tetracyclines bind to 
the 30S subunit, more specifically the 16S particle, of bacterial ribosomes (131, 138). In 
this specific mechanism of action, the lower region of the A-ring was demonstrated to 
form an H-bond and bind with ribosomal magnesium and key RNA nucleotide bases 
(139). Consequently, TCs inhibit the binding of charged tRNA to its receptor on the 
mRNA-charged ribosome complex, ultimately blocking the protein synthesis processes 
(140). Tetracyclines were also reported to bind the 40S subunit of eukaryotic ribosomes 
however, their concentration within eukaryotic cells is not sufficient to disrupt protein 
synthesis (141). 
The inhibition of protein synthesis is considered the key mechanism of 
tetracyclines bacteriostatic effects however, other mechanisms have been associated 
with TCs activity. Tetracyclines were reported to affect cell growth through membrane-
mediated mechanisms, as in the case of Gram-negative bacteria (131). Accordingly, the 
most lipophilic tetracyclines were reported to exert an atypical bactericidal effect by 
65 
 
causing membrane perturbations, which interfere with multiple signalling pathways, 
leading to severe cellular dysfunction (142).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
2.3.2 - NON-ANTIBIOTIC PROPERTIES 
Around three decades ago, this class of antimicrobial agents was unexpectedly 
found to modulate cellular behaviour, as well as extracellular factors secretion or 
inactivation. Tetracyclines and some of semisynthetic derivatives are known to inhibit 
collagenases and other host-derived metalloproteinases (MMPs), in a mechanism 
independent of their antimicrobial activity, interfering with biological processes such as 
proteolysis, inflammation, angiogenesis and apoptosis (143). MMPs are responsible for 
crucial processes including connective tissue remodelling, wound healing, tumor 
invasion and metastasis. However, the overexpression of several MMPs due to 
pathological conditions may lead to a breakdown of collagen fibrils, consequently 
affecting the basement membrane (9).  
Regarding their non-angiogenic properties, TCs were found to disrupt the 
formation of new blood vessels. Accordingly, TCs and derivatives were described to 
inhibit the synthesis of MMP-8 and MMP-9 by endothelial cells subsequently affecting 
the migration of endothelial cells (144). Accordingly, tetracyclines were considered 
useful for therapies of a wide variety of conditions in which pathologically elevated 
MMP’s activity and concomitant extracellular matrix proteins degradation are the 
hallmark of the disease pathogenesis (145). The conditions which may represent 
suitable targets for TCs include periodontitis, corneal ulceration, 
osteopenia/osteoporosis, rheumatoid arthritis, cancer invasion and metastasis, 
abdominal aortic aneurysms, inflammatory skin diseases among other immune-
inflammatory conditions (145). Further, it is known that collagenases, as well as other 
MMPs, may be involved in the degradation of type I collagen matrix which is the major 
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constituent of bone organic matrix. This, together with the destruction of other 
components of connective tissue leads to impaired bone remodelling or regeneration. 
Early in vivo research has shown that tetracyclines were able to inhibit bone loss by 
inhibiting osteoclast-mediated bone resorption, but also by enhancing the osteoblastic 
differentiation and activity, upregulation of type I collagen expression and increased 
bone formation, essentially in conditions of significant bone loss (146, 147). 
Additionally, tetracyclines derivatives have been reported to inhibit caspase-1 
functions thus diminishing the apoptotic activity in pathological conditions which cause 
unbalanced programmed cell death (e.g. cancer and neurodegenerative disorders) (9). 
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2.3.3 - DOXYCYCLINE 
Further studies and synthetic modifications conducted by Lederle and Pfizer led to 
the development of second generation tetracyclines derivatives. Pfizer researchers 
opted for a disjunctive approach, modifying the C-ring of oxytetracycline in order to 
attain a compound with higher stability combined with preserved antimicrobial activity 
(148). Two years later, Doxycycline (C22H24N2O8, figure 2.9) was synthetized by Charlie 
Stephens as an analogue presenting relevant advantages in comparison with the original 
tetracyclines including, remarkable activity, chemical stability and pharmacological 
efficacy which was later approved by Food and Drug Administration (FDA) (149). 
Doxycycline became a long-acting second generation tetracycline-derivative most 
frequently prescribed to treat a wide variety of infectious agents including Gram-
positive pathogens (e.g. Staphylococcus aureus, and Streptococcus pneumoniae, Bacillus 
anthracis), Gram-negative pathogens (e.g. Pasteurella multocida, and Escherichia coli) 
and other such as Plasmodium falciparum and rickettsias (131, 150). 
In addition to its antibacterial potential, doxycycline was reported to possess non-
antibacterial properties, which mechanisms of action were broadly described to 
minimized host tissue breakdown by inhibiting matrix metalloproteinases specifically 
collagenases and gelatinases action (145). The compound revealed to be able to disrupt 
several matrix metalloproteinases, such as MMP-8 and MMP-9, preventing connective 
tissue degradation and enhancing the treatment of pathological conditions, in which 
MMPs play a central role, such as rheumatoid arthritis (151, 152), inflammatory skin 
disease rosacea (153, 154), cancer invasion and metastasis (155), corneal ulceration 
(156), periodontitis (157),  osteopenia and osteoporosis (8, 145, 158). 
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Doxycycline was reported to act as an osteogenic agent enhancing new bone 
formation and regeneration by improving type 1 collagen synthesis as well as other 
osteogenic factors (i.e. bone morphogenetic proteins) (159). The benefits of doxycycline 
in bone healing were assessed in several conditions. Following, recent work of Walter 
and co-workers (160) demonstrated the efficiency of doxycycline coating process on a 
titanium zirconium implant surface and its beneficial effects on osseointegration and 
bone regeneration. Authors’ in vitro studies with MC3T3-E1 cell lineage demonstrated 
enhanced bioactivity as well as good bioavailability of doxycycline coated surfaces. 
Additionally, the implantation of this doxycycline-coated alloy on rabbits showed 
positive effects on bone formation markers as well as enhanced bone regeneration 
when compared with the implant without doxycycline coating (160). Eglence 
demonstrated that low concentrations of doxycycline induce an osteoblastic 
differentiation similar to that obtained from cells exposure to bone morphogenic 
protein-2 (BMP-2). Doxycycline was also reported to modulate positively 
osteoprogenitor cells from human femoral cancellous bone (161). its efficacy was once 
more demonstrated in vivo with studies of periodontal implantation on dogs (162) and 
clinically in the repair of bilateral infrabony defects in humans (163). Additionally, 
regarding clinical application of MMPs inhibitors, doxycycline’s non-antibacterial 
properties have been reported to contribute to their effectiveness in situations as 
cation-quelation activity with consequent avidity for mineralized tissues, and MMPs 
inactivation, and long-term clinical safety (7, 164). 
Following, low-dose regimens of doxycycline (sub-antimicrobial doxycycline doses 
SDD) shown to be non-antimicrobial, safe and effective.  Further, these regimens were 
described to preserve doxycycline anti-apoptotic, anti-inflammatory and 
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immunomodulatory properties over the bone tissue while preventing complications 
associated with long-term high doses therapies (e.g. hyperpigmentation, increased 
photosensitivity, hypersensitivity, among other) (157, 165). Within this therapeutic 
regimen, doxycycline was reported to attain peak plasma levels of around 1 µg/mL, and 
to maintain mean plasma levels of around 0.5 µg/mL for several hours. Within these 
concentrations, doxycycline was able to stimulate the proliferation of osteoblastic-
induced bone marrow cells (7). Moreover, an extended clinical trial have demonstrated 
beneficial effects of SDD in postmenopausal women exhibiting both local (periodontitis) 
and systemic (osteopenia) bone loss (8, 158). These properties made a compelling case 
for SDD as an attractive option for the management of local, as well as systemic, 
osteoporosis or osteopenia conditions. 
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2.3.4 - MINOCYCLINE 
The studies focused on tetracyclines, conducted by Lederle scientists, aimed to 
produce new semisynthetic derivatives which the maintenance of the structure needed 
for antimicrobial activity, while the remaining functional groups would be removed or 
replaced to achieve unique non-antimicrobial properties (131). The modifications on C-
ring and D-ring functional groups led to the development of a novel compound with a 
characteristic D7-dimethylamino group (figure 2.9) which was later found to exhibit far 
greater antibacterial and pharmacological activity, in comparison with first generation 
tetracycline (10, 131). 
Minocycline (C23H27N3O7) was approved for clinical use by FDA, in 1971, and 
became one of the most used second-generation, semi-synthetic tetracycline till 
nowadays (10). It combines the tetracyclines efficacy against gram-positive and gram-
negative bacteria and it was also reported to exert a beneficial effect on treatment of 
acne vulgaris, rheumatoid arthritis and some sexually transmitted diseases (10, 166). 
Minocycline exhibits enhanced pharmacological properties when compared with first-
generation tetracyclines including faster and complete absorption (when administrated 
orally), longer half-life, excellent tissue penetration and bioavailability (167). 
Additionally, minocycline lipophilicity was studied in order to assess its relation with the 
pharmacological behaviour. The results showed that, due to its highly lipophilic 
properties, this molecule was able to cross the blood-brain membrane accumulating on 
the CNS (168). 
Similarly to first-generation tetracyclines and other semi-synthetic compounds, 
minocycline non-antimicrobial properties were also points of great interest. It was 
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considered the most effective tetracycline-derivative concerning neuroprotection and 
this potential was early reported in experimental models of ischaemia (169, 170), brain 
trauma (171) and neuropathic pain (172), as well as on the modulation of Parkinson’s 
(173), Alzheimer’s (174) and Huntington’s (175) diseases. Furthermore, minocycline was 
demonstrated to be a potential promotor of bone regeneration and remodelling. 
Accordingly, it was considered to be a suitable compound for periodontal disease 
treatment since it combines antimicrobial, anti-inflammatory and anti-apoptotic 
properties (10, 176). Additionally, it was found that long-term exposure to minocycline 
strongly stimulates osteoblastic progenitors to proliferate and differentiate in fully 
functional osteoblasts, subsequently promoting new bone formation and enhancing 
mineralization (7, 177). 
Minocycline benefits on bone physiology were further reported to improve 
osteopenic/osteoporotic conditions (178, 179). Following, studies performed on animal 
models of induced osteoporosis showed that minocycline was able to increase new bone 
formation and prevent trabecular bone loss (179). Also, it was reported to prevent bone 
mineral density decrease in pathological conditions at least thought three main 
mechanisms: (1) reduction of the bone resorption by modulating osteoclastic activity; 
and (2) promotion of the efficiency of bone-marrow derived progenitor cells enhancing 
osteoblastic differentiation and function (178); (3) inhibition of collagenases, leading to 
an improved bone regeneration and remodelling, through the increase of bone matrix 
osteoid and osteoblastic cells organization, favouring the formation of a more adequate 
collagen matrix (180). 
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CHAPTER 3 - THE OSTEOGENIC PRIMING OF 
MESENCHYMAL STEM CELLS IS IMPAIRED IN 
EXPERIMENTAL DIABETES 
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3.1 - INTRODUCTION 
 
Diabetes mellitus includes several metabolic disorders which are ultimately 
characterized by chronic hyperglycaemia arising from abnormalities in insulin 
production, action or both (48). Uncontrolled chronic hyperglycaemia leads to severe 
dysfunction and failure of various tissues and organs including bone (6, 53). Clinically 
this seems to result in diminished linear bone growth followed by early onset of 
osteopenia and latterly osteoporosis, and consequent increased risk of fragility fracture, 
and deficient bone healing (181). 
Type 1 diabetes is undoubtedly associated with a significant reduction of bone 
mineral density, broadly correlated with an increased risk of fragility fractures (76, 182). 
The most T1D patients have inadequate accrual peak of new bone mass essentially due 
to abnormalities on bone formation process (79). Indeed, in vivo and in vitro studies of 
DM effects on bone tissue reported consistent impaired osteoblastic maturation and 
function, rather than osteoclastic and bone resorption enhancement (80, 89). 
Current knowledge regarding cellular and molecular mechanisms of DM was 
provided by in vitro studies, in which osteogenic-induced precursor cells were cultured 
in diabetic conditions, such as hyperglycaemic medium (183-187). Despite these models 
yielded information on the effect of high glucose levels, they provided limited data since 
they fail to disclose the systemic-modulation of osteogenic precursor cells developing 
under a full diabetic environment. In an attempt to overcome this limitation, animal 
models of experimental diabetes became popular especially alloxan- and 
streptozotocin-induced diabetes. These new approaches allowed data gathering on 
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diabetic-derived precursors to respond to osteogenic stimuli (188-191). Accordingly, 
impaired cellular activity was reported specifically regarding the osteogenic 
responsiveness although the reasons leaning to this impairment still unclear. 
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3.2 - RESEARCH HYPOTHESIS AND OBJECTIVES 
 
Within the previously mentioned context, the present work aimed to characterize 
the priming capability and functionality of undifferentiated precursor cells developed 
within the diabetic environment. In order to achieve the main goal, bone marrow-
derived mesenchymal stem cells (MSCs), harvested from animals with experimental 
diabetes chemically induced with STZ, were grown in the absence of any given 
differentiation factor. Cultures were characterized for cell proliferation, 
viability/apoptosis, morphology, alkaline phosphatase activity, collagen synthesis and 
osteogenic and adipogenic gene expression profile, and compared to MSCs cultures 
harvested from sham animals. 
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3.3 - MATERIALS AND METHODS 
 
3.3.1 - ANIMALS 
The protocols involving animals were performed under the authorization of 
Direção Geral de Alimentação e Veterinária (DGAV) and comprised the standards for the 
protection of experimental animals, according to the Portuguese (Decree No. 113/2013) 
and European (Directive 2010/63) legislations. 
This study used 12 male Wistar rats (Charles River, Wilmington, MA), 7 to 8 weeks 
old, with a body weight of around 250-300 g. Animals were allowed to acclimatize for 1 
week before the beginning of the study and then, were housed in groups, in 
conventional type II cages, on a controlled environment of temperature and humidity, 
in a 12h light/dark cycle. The animals were clearly identified with indelible ink, and 
received dry food (4RF21 Mucedola, Settimo Milanese, Italy) and water ad libitum. 
Experimental diabetes was induced by an intraperitoneal injection of STZ, Sigma® 
(60 𝑚𝑔. 𝑘𝑔−1, dissolved freshly in 10 nM citrate buffer, pH 4.5, 𝑛 = 6) – STZ group. 
Control rats were injected with citrate buffer alone (𝑛 = 6) – CTRL group. 
Hyperglycaemia was confirmed by measuring tail vein blood glucose levels with a 
glucometer (Accu Check GO, Roche Diagnostics, Portugal) 72 hours after streptozotocin 
or buffer injection, and levels were expressed as milligrams per decilitre. Animals with 
blood glucose levels ≥ 300 𝑚𝑔. 𝑑𝑙−1 were considered to be diabetic. 
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Six weeks following both STZ and vehicle administration, animals were euthanized 
by exsanguination under general anaesthesia (intraperitoneal injection of pentobarbital 
sodium 35 𝑚𝑔. 𝑘𝑔−1). 
 
 
3.3.2 - DIABETIC BONE ALTERATIONS 
Proximal tibial specimens were scanned by microcomputed tomography (µCT). 
µCT was performed in a µCT 35 (Scanco Medical), with a voxel size of 12 µm, X-ray tube 
voltage of 70 kVp, current intensity of 114 mA, and integration time of 600 ms. 
Microstructural measures, included bone volume per total volume (BV/TV), connective 
density (CD), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular 
separation (Tb.Sp) The computation of these structural measures has been previously 
detailed (192). 
 
 
3.3.3 - ESTABLISHMENT OF BONE-MARROW CELL CULTURES 
Bone marrow-derived MSCs were isolated from Sham and STZ animals using a 
modification of Dobson (193) and Sekiya (194) methodologies, for bone marrow harvest 
and MSCs isolation. Accordingly, tibiae and femora were aseptically excised, cleaned of 
soft tissues and decontaminated in a solution of Rat Mesenchymal Stem Cell Growth 
Medium (Lonza), with the addition of 1000 UI.mL-1 penicillin and 1000 µg.mL-1 
streptomycin, for 30 minutes, plus 30 minutes. Following, long bones epiphyses were 
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cut off and diaphysis were flushed out with Rat Mesenchymal Stem Cell Growth 
Medium. 
Nucleated cells were isolated with a density gradient (Ficoll-Paque Premium®), re-
suspended in culture medium supplemented with 10% heat inactivated fetal bovine 
serum (FBS, Gicbo), penicillin-streptomycin (100 UI.mL-1 – 100 mg.mL-1, Gibco) and 
fungizone/amphotericin B (2.5 𝜇𝑔. 𝑚𝑙−1, Gibco), and plated onto conventional 6-well 
culture microplates and kept in a humidified atmosphere (5% CO2/air, 37°C).  
Culture medium was subsequently renewed every 2 days until around 75% 
confluence (approximately 15 days), when the cells were enzymatically released with 
trypsin 0.04%  in 0.25% ethylenediaminetetraacetic acid (EDTA) solution, and seeded at 
104 cells.cm-2 in culture microplates. 
Cultures were maintained in the previously described conditions for 12 days and 
assessed for proliferation/viability, morphology, functional activity and differentiation 
events. 
 
 
3.3.4 - OPTICAL MICROSCOPY 
Cell cultures were regularly monitored by phase contrast optical microscopy, for a 
qualitative assessment of cell morphology and proliferation. 
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3.3.5 - CELL PROLIFERATION AND METABOLIC ACTIVITY 
Cell proliferation was estimated by the total DNA content, using the Quant-iT™ 
PicogreenVR DNA assay (Life Technologies) according to the manufacturer’s 
instructions, following cell lysis with Triton X-100 0.1%. 
Metabolic activity was determined with MTT assay at days 1, 5, 8 and 12. The 
method consists of the reduction of the MTT salt [3-(4,5-di-methylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide, Sigma®] by the mitochondrial succinic dehydrogenase of 
proliferating cells, to a purple formazan product that accumulates in the cytoplasm. 
Cultures were incubated with MTT solution (0.5 mg.ml-1) at 37°C, in a humidified 
atmosphere of 95% air and 5% CO2 for 4 hours. Following, the medium was decanted 
and the formazan crystals were dissolved in DMSO, and the absorbance was measured 
at 550 nm (Synergy HT, Biotek). 
 
 
3.3.6 - CELL MORPHOLOGY 
Cell cultures morphology were evaluated by confocal laser scanning microscopy 
(CLSM) following staining of cytoskeleton and nucleus counterstaining. 
For CLSM assessment, the cultures were fixed in 3.7% paraformaldehyde (15 
minutes) and permeabilized with Triton 0.1%. Following, cell cultures were incubated 
with albumin (10 mg.ml-1), in order to reduce non-specific staining. Cell cytoskeleton 
filamentous actin (F-actin) was visualized by treating cells with Alexa Fluor 488®-
conjugated phalloidin (1:20 dilution in phosphate buffered saline (PBS), 20 minutes) and 
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propidium iodine (1 µg.ml-1, 10 minutes) for cell nuclei labelling. Labelled cultures were 
mounted in Vectashield® and examined with Leica SP2 AOBS (Leica Microsystems) 
microscopy. 
 
 
3.3.7 - ALKALINE PHOSPHATASE ACTIVITY AND TOTAL PROTEIN CONTENT 
Alkaline phosphatase (ALP) activity was determined in cell lysates, by the 
hydrolysis of p-nitrophenyl phosphate into a yellow coloured product, i.e., p-
nitrophenyl, which has a maximal absorbance at 405 nm, in an alkaline buffer solution. 
The rate of the reaction is directly proportional to the enzyme activity. 
Cell lysates were obtained by treatment of the cultures with 0.1% Triton in dH2O 
and then assayed by colorimetric determination of the product p-nitrophenol at 𝜆 =
405 nm, in an ELISA reader (Synergy HT, Biotek). The hydrolysis of p-nitrophenyl 
phosphate (pH 10.3) was carried out for 30 minutes at 37°C then the reaction was ceased 
by adding NaOH 5M. The ALP activity of each sample was normalized to its protein 
concentration (measured according to the Lowry method) and the results were 
expressed as nanomoles of p-nitrophenol produced per minute per µg of protein 
(nmol.min-1. µg-1). 
The total protein content was determined according to the Lowry method. In this 
method, the peptide bonds of proteins react with copper, under alkaline conditions, to 
produce the ionized form of copper (Cu+), which then reacts with the Folin reagent – a 
mixture of phosphotungstic acid and phosphomolybdic acid in phenol. The product 
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becomes reduced molybdenum/tungsten blue by the copper-catalyzed oxidation of 
aromatic amino acids. The reaction results in a strong blue colour, which depends 
partially on the tyrosine and tryptophan content, and may be detected colorimetrically, 
by absorbance, at 705 nm. The protocol for protein determination included the 
following solutions: 
 
A. 20 g Na2CO3 · L-1 0.1 N NaOH 
B. 0.1 g Na Tartrate + 0.05 g CuSO4.5 H2O + 10 ml dH2O + H2SO4 
C. 50 ml reagent A + 1 ml reagent B 
D. Phenol Reagent – 1 part Folin-Ciocalteau 2 N: 1 part dH2O 
 
Cultures were washed with PBS and incubated with 0.1% Triton in water (15 
minutes at room temperature). 200 µl of the cell lysates were treated with 1.5 ml of 
reagent C, vortexed and incubated for 10 minutes. Following, 150 µl of reagent D was 
added and the samples were vortexed and incubated in dark, for 1 hour, at room 
temperature. Finally, the absorbance was measured at 750 nm in 1 cm cuvettes, in a 
spectrophotometer (Jenway 6405). 
A series of dilutions of 0.5 𝑚𝑔. 𝑚𝑙−1 bovine serum albumin in 0.1% Triton were 
used as standard. Results were expressed as micrograms per square centimetres (µg.cm-
2). 
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3.3.8 - PROGRAMMED CELL DEATH 
Apoptotic activity was quantified by assessing caspase-3 activity with the 
EnzCheck® Caspase-3 Assay Kit #2 (Molecular Probes), according to manufacturer’s 
instructions. 
 
 
3.3.9 - COLLAGEN SYNTHESIS 
Assessment of the total collagen synthesis was conducted by in situ determination 
with Sirius red dye. 
Briefly, previously fixed cell cultures were incubated with 100 µL/well of 0.1% 
Sirius red F3BA solution (BDH, UK) in saturated picric acid for 1 hour, at room 
temperature, under mild shaking. Thereafter, the dye solution was removed by suction 
and the stained cell layers extensively washed with 0.01 N hydrochloric acid, to remove 
all non-bound dye. The cell morphology was photodocumented before dissolving the 
stain. Following, the stained material was dissolved in 200 µL of 0.1 N sodium hydroxide 
using a microplate shaker, for 30 minutes, at room temperature. The absorbance was 
measured at 500 nm on an ELISA reader (Synergy HT, Biotek) against 0.1 N sodium 
hydroxide blank. 
Results were presented as percentage of staining compared to control. 
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3.3.10 - GENE EXPRESSION 
 
Cell cultures of both control and STZ-induced groups were analysed by qPCR, at 
days 5 and 12, for the expression of housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), ALP, RUNX2, collagen type 1 alpha 1 (Col1α1), OPN, OC, OPG, 
insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2), peroxisome 
proliferator-activated receptor gamma (PPAR𝛾), and adipocyte protein 2 (AP2). 
Total RNA was extracted using the NucleoSpin® RNA II kit (Macherey-Nagel), 
according to the manufacturer’s instructions. Total RNA concentration and purity were 
assessed by UV spectrophotometry at 260 nm, and by calculating the A260 nm/ A280nm 
ratio, respectively. RNA was reverse transcribed to cDNA using the SuperScript III First-
Strand Synthesis (Invitrogen). cDNA was amplified by real-time quantitative PCR using 
the SYBR Green RT-PCR kit (Applied Biosystems, Foster City, CA) in a Bio-Rad iCycler 
Relative RNA levels were calculated using the iCycler software and normalized using 
GAPDH levels. The reaction was followed by melting curve analysis to verify specificity. 
The expression of each gene was evaluated using the 2−∆∆𝐶𝑇  method and dilution curves 
were used to test the PCR efficiency. 
Results were expressed as the percentage variation from control, corresponding 
to 100% at each time point. The primers used are listed on table 3.1. 
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Table 3.1 - Forward and reverse sequences of the primers used for the qPCR 
analysis. 
 
GENE FORWARD SEQUENCE REVERSE SEQUENCE 
GAPH AAATGGTGAAGGTCGGTGTG CCCATACCCACCATCACACC 
ALP GGCTCTGCCGTTGTTTC GGGTTGGGTTGAGGGACT 
RUNX2 ATCCAGCCACCTTCACTTACACC GGGACCATTGGGAACTGATAG 
COLLAGEN 1 Α1 TGGCAAGAACGGAGATGA AGCTGTTCCAGGCAATCC 
OSTEOPONTIN AAAAATGCTCACCATCACTGC AATTGCCACACTGACTTCCAC 
OSTEOCALCIN GCCCTGACTGCATTCTGCCTCT TCACCACCTTACTGCCCTCCTG 
OSTEOPROTEGERIN ATTGGCTGAGTGTTCTGGT CTGGTCTCTGTTTTGATGC 
IRS-1 TGTGCCAAGCAACAAGAAAG ACGGTTTCAGAGCAGAGGAA 
IRS-2 GAGCCTTCAGTAGCCACAGG CAGGCGTGGTTAGGGAGTAA 
PPAR𝜸 GCGGAGATCTCCAGTGATATC TCAGCGACTGGGACTTTTCT 
AP2 ATGTGTCATGAAAGGCGTGA AAACCACCAAATCCCATCA 
 
 
3.3.11 - OSTEOGENIC INDUCTION AND CULTURE CHARACTERIZATION 
Bone marrow mesenchymal stem cells were isolated from Sham and STZ animals, 
following the previously described methods. In order to assess the capability of 
osteogenic induction of these populations, first passage cells were grown in osteogenic 
inducing conditions for 12 days. To attain these conditions, alpha-modified minimum 
essential medium (αMEM) supplemented with 10% foetal bovine serum, penicillin-
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streptomycin (100 UI.mL-1 – 100 mg.mL-1, Gibco), fungizone amphotericine B (2.5 µg.mL-
1, Gibco), ascorbic acid (50 mg.mL-1, Sigma-Aldrich), beta-glycerophosphate (4 mmol.L-1, 
Sigma-Aldrich), and dexamethasone (10 nmol.L-1, Sigma-Aldrich), was used and changed 
every 2 days. 
Cell cultures were characterized at days 5 and 12 for the expression of osteogenic-
specific genes ALP, RUNX2, Col1α1, OPN, OC, OPG, as previously described, and 
normalized using GAPDH levels. Results were expressed as the percentage variation 
from control. 
 
 
The Alizarin Red histochemical assay was further conducted to address the 
mineralization of the ECM of the grown cultures, at day 12, through the identification of 
calcium deposits within the matrix. Briefly, fixed cultures were covered with 1% Alizarin 
Red S solution (0.028% in NH4OH, Sigma-Aldrich), pH 6.4, for 2 minutes, and were rinsed 
with distilled water and acid ethanol (ethanol, 0.01% HCl). Stained cultures were photo-
documented with an inverted microscope (Nikon TMS) and digital imaging system 
(Nikon DN 100). 
 
 
3.3.12 - ACTIVATION OF SPECIFIC SIGNALING PATHWAYS IN STZ-DERIVED CULTURES 
The activation of specific signalling pathways was evaluated in cultures growing in 
the presence of specific inhibitors. At day 8, established MSCs cultures were treated with 
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10 mM of the ERK inhibitor PD 98059 (Sigma-Aldrich), 10 mM of the WNT inhibitor ICG-
001 (R&D Systems), or 20 mM of the p38-inhibitor SB 203580 (Sigma-Aldrich), for at last 
6 hours of the culture. These were characterized for metabolic activity and gene 
expression analysis, as described above. The expression levels of ALP, RUNX2 and PPAR𝛾 
were assayed. Results were presented as percentage of variation from control. 
 
 
3.3.13 - STATISTICAL ANALYSIS 
Three independent experiments were performed with the cell cultures established 
from different animals. In biochemical assays, each point represents the mean ± 
standard error of six replicates. Statistical analysis was done by two-way analysis of 
variance (ANOVA) followed by Tukey range test post hoc analysis. P values ≤ 0.05% were 
considered significant. 
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3.4 - RESULTS 
 
3.4.1 - DIABETIC EXPERIMENTAL MODEL 
Diabetes mellitus was chemically induced by a single intraperitoneal injection of 
streptozotocin. Animals of control group revealed the normal course of body weight 
increase (6.41% ± 3.45), while animals of STZ group lost weight (37.57% ± 8.65), during 
the experimental period. At euthanasia, STZ group had a significantly higher glycaemia 
in comparison to control (≤ 125 𝑚𝑔. 𝑑𝑙−1). 
 
 
3.4.2 - DIABETIC BONE ALTERATIONS 
Bone structure of proximal tibia of both control and STZ groups were addressed 
by microcomputed tomography. The results of µCT evaluation showed a significant 
reduction of trabecular content in STZ animals (figure 3.1, right) in comparison with 
control (figure 3.1, left). Decreased trabecular interconnectivity was also verified at the 
bone’s proximal metaphysis, in diabetic bone. Additionally, morphometric indexes of 
the trabecular structure revealed a significant decrease in BV/TV and in trabecular 
thickness, combined with a tendency for connective density reduction. Despite the 
overall reduction of trabecular bone mass, no significant differences were found 
regarding trabeculae number and separation. Resulting measurements are shown in 
table of figure 3.1. 
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Figure 3.1 - Top: representative 2D microtomographic images of the proximal tibia 
methaphysis, in control and STZ animals (𝑛 = 6). Bottom: table of microstructural 
parameters of the trabecula structure of the proximal tibia. The addressed variables 
included BV/TV (bone volume per total volume), CD (connective density), Tb.N 
(trabecular number), Tb.Th (trabecular thickness), and Tb.Sp (trabecular separation). * - 
significantly different from control (𝑃 ≤ 0.05). 
 
 
3.4.3 - CELL PROLIFERATION AND METABOLIC ACTIVITY 
The figure 3.2 shows the results of cell proliferation assessment with DNA 
quantification assay, along the culture time points. Accordingly, STZ-derived cell cultures 
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presented reduced total DNA content values from day 5 onwards, in comparison with 
control cultures. At days 8 and 12, significant differences were achieved with a reduction 
in diabetic-derived cells proliferation, higher than 20%, when compared with control. 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 - Cell proliferation (DNA assay) of STZ-derived bone marrow 
mesenchymal stem cell cultures, established for 12 days. Percentage of variation from 
control at each time point. * - significantly different from control (𝑃 ≤ 0.05). 
 
The MTT assay was the method used to assess the metabolic activity of the 
cultures (figure 3.3). Cultures established from control animals presented an increasing 
of metabolic activity from the first day till around day 8, remaining stable afterwards, 
with a slight decrease of MTT values. Cultures established from diabetic animals 
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followed a similar growth pattern, with the MTT values increasing during the first week 
and diminishing softly subsequently. STZ-derived cultures showed higher MTT reduction 
values at early culture time points (days 1 and 5), comparing to control cultures, 
although without significant differences. At day 8 and 12, metabolic activity values 
attained for STZ were significantly lower than those achieved with control cultures. 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 - Cell viability/metabolic activity (MTT assay) of STZ-derived bone 
marrow mesenchymal stem cell cultures, established for 12 days. Percentage of 
variation from control at each time point. * - significantly different form control (𝑃 ≤
0.05). 
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3.4.4 - CELL MORPHOLOGY 
Cell colony morphology was addressed by confocal laser scanning microscopy 
(CLSM) and representative images are shown in figure 3.4. Control cultures, at day 3, 
presented a fibroblastic-like morphology, characteristic of osteoblastic cells in culture, 
with elongated cytoplasm, adequate nuclear organization, and a dense network of 
microfilaments and stress fibers. Strong labelling was often observed along cellular edge 
and within the extended cellular filopodia. Moreover, culture exhibited intense cell-to-
cell contacts establishment, typical of nodular growth pattern. Cells proliferated 
adequately and, at day 5, a large area of the culture plate surface was already covered 
by a cell monolayer. At day 8, an organized flattened sheet of continuous cell multilayers 
was observed, similarly to the organization achieved at day 12. 
The STZ-derived cultures showed a similar behaviour in this time course. However, 
at day 3, fewer stress fibers were visible on proliferating cells and the intense labelling 
at the cellular edge, broadly observed in control, was more rarely identified. 
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Figure 3.4 - Confocal laser scanning microscopy imaging of rat bone marrow-
derived mesenchymal stem cell cultures, established for 12 days, from control and STZ-
induced diabetic animals. Cytoskeleton was stained in green and nucleus counterstained 
in red. Scale bar corresponds to 200 µm. 
 
 
3.4.5 - ALKALINE PHOSPHATASE ACTIVITY 
The results regarding ALP activity were normalized by total protein content, 
determined by the Lowry method, and are shown in the figure 3.5 below. ALP activity 
showed a gradual increase with the culture time in both experimental conditions. 
Despite the similar pattern of increasing activity, STZ-derived cultures revealed a 
significantly higher ALP activity at days 8 and 12, as compared with the one attained 
within control cultures. 
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Figure 3.5 - Alkaline phosphatase activity (ALP per total protein content) of STZ-
derived bone marrow mesenchymal stem cell cultures established for 12 days. 
Percentage of variation from control at each time point. * - significantly different form 
control (𝑃 ≤ 0.05). 
 
 
3.4.6 - PROGRAMMED CELL DEATH 
Apoptosis was estimated by the determination of caspase-3 activity at 
experimental days 1, 5, 8 and 12 (figure 3.6 below). Concerning programmed cell death, 
in comparison to control cultures, STZ-derived cultures demonstrated significant higher 
caspase-3 activity at later culture time points. 
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Figure 3.6 - Apoptotic analysis (caspase-3 activity assay) of STZ-derived bone 
marrow mesenchymal cell cultures established for 12 days. Percentage of variation from 
control at each time point. * - significantly different form control (𝑃 ≤ 0.05). 
 
 
3.4.7 - COLLAGEN SYNTHESIS 
Total collagen synthesis was evaluated qualitatively (Sirius red dye histochemical 
staining) and then, following, quantified. Representative imaging of histochemical 
staining is presented on figure 3.7. Accordingly, in control cultures, an increasing staining 
intensity was verified throughout the culture time points. At earlier time points, control 
cultures exhibited a cluster-like organization. Until day 12, an increasing intensity of 
staining was observed, combined with a re-organization of the cultures into multilayers. 
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The same pattern of collagen synthesis was verified in STZ-derived cell cultures however, 
with no evidences of cluster organization, and with slighter less intense coloration, 
suggesting lower levels of collagen synthesis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 - Total collagen staining of STZ-derived bone marrow mesenchymal 
stem cell cultures established for 12 days, from control and STZ-induced diabetic animals 
(𝑛 = 6). The scale bar corresponds to 750 µm. 
 
 
The quantitative determination of staining products was consistent with the 
histochemical analysis. Conformably, quantitative data revealed a similar collagen 
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content for both control and STZ cultures at days 5, and a tendency for a reducing 
collagen production afterwards, for STZ-derived cell cultures, in comparison with 
control. This reduction attained statistical significance at day 12. The results for collagen 
quantitative determination are presented on figure 3.8 below. 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 - Colorimetric determination of the total collagen stained product 
within the established STZ-derived bone marrow mesenchymal stem cell cultures. 
Results were expressed as the percentage variation from control corresponding to 100% 
at each time point. * - significantly different form control (𝑃 ≤ 0.05). 
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3.4.8 – GENE EXPRESSION IN STANDARD CONDITIONS AND IN OSTEOGENIC-INDUCING 
CONDITIONS 
qPCR analysis showed the expression of significant osteogenic and adipogenic 
markers, from both control and STZ-derived cell cultures. The results are shown in figure 
3.9 and 3.10. The results addressing the osteogenic gene expression (figure 3.9) 
demonstrated that in undifferentiating conditions, STZ-derived cell cultures were able 
to express significantly higher levels of ALP, while the expression of remaining 
osteogenic genes (RUNX2, COL1α1, OPN, OC and OPG) were hindered, both at day 5 and 
12, as compared to control. 
 
 
 
 
 
 
 
 
 
Figure 3.9 - qPCR gene expression analysis of ALP, RUNX2, Col1α1, osteopontin, 
osteocalcin, and osteoprotegerin in MSCs cultures, established for days 5 and 12, from 
control and STZ-induced diabetic animals (𝑛 = 6).  Cultures were grown in 
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undifferentiating (STZ) and osteogenic-differentiating (Osteo STZ) conditions. Results 
were expressed as the percentage variation from control corresponding to 100% at each 
time point. * - significantly different form control (𝑃 ≤ 0.05). 
 
The results concerning adipogenic gene expression are presented in figure 3.10. 
According to the assay, STZ-derived cell cultures, grown in undifferentiating conditions, 
showed significantly increased expression of PPARγ, IRS1, and IRS2, at both days 5 and 
12 of the culture. In the other hand, AP2 expression was not affected.  
 
 
 
 
 
 
 
 
 
Figure 3.10 - qPCR gene expression assessment of adipogenic genes PPARγ, IRS1, 
IRS2, and AP2, in undifferentiated STZ-derived MSCs cultures, established for 5 and 12 
days. Results were expressed as the percentage variation from control corresponding to 
100% at each time point. * - significantly different form control (𝑃 ≤ 0.05). 
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3.4.9 – MINERALIZATION ASSESSMENT IN OSTEOGENIC- AND STZ-INDUCED 
CONDITIONS 
The ability of MSCs to promote mineralization was evaluated by the Alizarin Red 
assay and the attained micrographs are shown at figure 3.11. According to the staining, 
at day 12 of the cultures, a significant mineralization of the extracellular matrix, as 
assessed by Alizarin Red assay, was verified in STZ-derived cultures 
. 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 - Colorimetric determination of the mineralization nodules within the 
established control- and STZ-derived bone marrow mesenchymal stem cell cultures, at 
day 12. 
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3.4.10 – EVALUATION OF SPECIFIC SIGNALING PATHWAYS 
The data concerning the activation of specific signalling pathways are showed in 
figure 3.12. Accordingly, inhibition assays with specific inhibitors demonstrated that, 
comparing to control, STZ-derived cell cultures exhibited diminished metabolic activity 
regarding ERK and WNT activation. In contrast, increased metabolic activity was verified 
within p38 assessment. 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 - Metabolic activity and gene expression analysis (of ALP, RUNX2, and 
PPARγ) of MSCs cultures, grown for 8 days. Cultures were incubated with specific 
inhibitors of the ERK (PD 98059), p38 (SB203580), and WNT (ICG-001) signalling 
pathways for the last 6 hours of culture (n=6). Results were expressed as the percentage 
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variation from control corresponding to 100%. * - significantly different form control 
(𝑃 ≤ 0.05). 
 
 
Concerning ALP expression in STZ group, increased levels were found to be 
associated with ERK and p38 pathways while a significant reduced expression was found 
to be bound with WNT pathway. A reduced expression of RUNX2 and increased 
expression of PPARγ were verified within the experimental conditions conducted to 
evaluate the three assayed pathways. 
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3.5 - DISCUSSION 
 
Diabetic conditions seem to play a negative role on bone tissue metabolism and 
regeneration, even though little is known regarding the determinant molecular and 
cellular mechanisms, affecting the maturation and functional activity of osteoblastic 
precursor populations. This study focused on the characterization of the behaviour of 
unstimulated MSCs developed within a diabetic environment, an issue that was not 
addressed before. MSCs were harvested from the bone marrow of diabetic animals and 
allowed to adhere and expand in vitro, under undifferentiating conditions (i.e., in the 
absence of supplemented lineage-specific growth factors or diabetic-simulated 
conditions). Attained results support the notion that bone marrow-derived MSCs, 
developed under the diabetic microenvironment, display an impaired 
viability/proliferation, increased apoptosis, and diminished osteogenic and increased 
adipogenic priming. Furthermore, osteogenic induction of these cells, further confirmed 
the impaired osteogenic commitment, in comparison to those grown from non-diabetic 
animals. 
Within the used animal model, diabetic induction with STZ allowed the 
development of hyperglycaemia (plasma glucose ≥ 300 𝑚𝑔. 𝑑𝑙−1), with associated 
body weight decrease, and changes in the bone structure. Microtomographic evaluation 
of the proximal tibia showed significant morphological alterations and reduced 
morphometric indexes (i.e., decreased BV/TV and trabecular thickness), supporting the 
development of a hyperglycaemia-mediated osteopenic condition (82). 
105 
 
MSCs cultures from diabetic animals, at late culture time points, revealed an 
increased apoptotic rate, impaired proliferation - reduced total DNA content - and a 
reduced metabolic activity, which may be related with the reduced number of active 
cells in STZ-derived cultures. This behaviour was similar to the one verified within in vitro 
models mimicking the diabetic microenvironment, such as hyperglycaemia and 
hypoinsulinemia (185, 186, 188, 195), reporting an impaired proliferation of osteoblastic 
populations. Also, an increased apoptosis was verified in dexamethasone-induced 
osteoblastic differentiating MSCs, from diabetic animals (191). These alterations may be 
related to a deficient insulin receptor activation by insulin, which induces a mitogenic 
stimulation, coupled with the inhibition of apoptosis, in a process probably mediated by 
the downregulation of p27 (a cyclin-dependent kinase inhibitor that seems to attenuate 
cell proliferation) (93). Other osteotropic factors produced by pancreatic β cells, such as 
islet amyloid polypeptide and preptin (which are absent or significantly reduced in 
diabetic conditions), also seem to favor osteoblastic proliferation and to reduce the 
frequency of apoptotic events (196). 
In terms of cytoskeleton organization, at 3 days, STZ-derived cultures presented a 
reduced number of stress fibers and decreased F-actin labelling at the cell border. This 
is line with previous observations in MSCs grown from diabetic mice, revealing a 
decreased adhesion to substrate, and a disturbed distribution and expression of F-actin, 
leading to abnormal stress fibers formation (189). The cytoskeleton organization is 
critical for cell morphology and homeostasis, notwithstanding its involvement in other 
cellular processes, such as intracellular transport and differentiation (197). Osteoblastic 
function is highly dependent upon cell adhesion and cytoskeletal organization, as 
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extracellular cues seem to direct MSCs functionality and, particularly, the osteogenic 
differentiation (198). 
Grown MSCs from STZ animals revealed an increased ALP activity and an impaired 
collagen production at late culture time points. Increased ALP activity was previously 
described in osteoblastic cells grown in vitro, in chronic hyperglycemic conditions (184, 
185), and in the serum of diabetic patients (80, 199). Nonetheless, it has been suggested 
that ALP within the diabetic environment presents an altered kinetic profile, supposedly 
in a process related to changes in metal-binding properties (200, 201). Regarding 
collagen expression in diabetic conditions, a significant reduction of total collagen was 
verified in the bone of diabetic rats (202). Furthermore, collagen synthesis of human 
osteoblasts was significantly reduced in the presence of human diabetic serum (187). 
The high level of pro-inflammatory cytokines verified within the diabetic environment 
(203) may contribute to the altered ALP/collagen expression, as tumour necrosis factor 
α and interleukin 1β were found to stimulate ALP activity and lessen collagen expression 
in human MSCs (204). 
Regarding MSCs gene expression profile, normally, this population expresses a 
genetic signature of its potential multilineage differentiation capacity, even at early 
differentiating stages (205). In the present work, MSCs harvested from diabetic animals 
presented an altered gene expression profile. In STZ-derived cultures, the osteogenic-
related gene expression revealed an increased ALP expression, and a decreased 
expression of RUNX2 - the master regulator of the osteogenic differentiation - and, as 
well, a decreased expression of several of its downstream targets (i.e., Col1a1, 
osteopontin, osteocalcin, osteoprotegerin). This is an interesting finding supporting that 
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the diabetic microenvironment may hinder RUNX2 activity and downregulate the 
expression of its downstream targets. ALP expression, found to be increased in STZ 
cultures, and thus sustaining its acknowledged increased activity, seems to be 
independently regulated from RUNX2 activation. This comes in line with previous data 
on the inhibition of RUNX2, with either small interfering RNA (206), or overexpression 
of a dominant negative (204), which were found not to alter ALP expression, and 
suggested that it may be unrelated to this transcription factor regulation. Additionally, 
gene expression analyses were also conducted on osteogenic-induced MSCs. Cultures 
from STZ-derived animals revealed an impaired osteogenic induction, both at days 5 and 
12, with significantly reduced expression of both ALP and RUNX2, as well as its assayed 
downstream targets, thus validating the compromised osteogenic priming of 
undifferentiated precursors. In accordance, a reduced mineralization of the extracellular 
matrix - the summit of the osteogenic differentiation process - was further verified in 
STZ-derived cultures through Alizarin Red staining. The impaired osteogenic capability 
of differentiating diabetic MSCs has been previously established in both in vitro (207) 
and in vivo (90, 91) models. 
Additionally, in undifferentiated MSCs from diabetic animals, expression of the 
adipogenic markers PPARγ, IRS1, and IRS2 was significantly upregulated, while the 
expression of AP2 was not affected. PPARγ is a key regulator of adipogenic 
differentiation and shifts the balance of MSCs fate by favoring adipocyte differentiation 
and thus, inhibiting osteoblast differentiation (208). An increased expression of PPARγ 
has been verified in osteoblastic cells grown in hyperglycaemic conditions (183) and in 
growing osteoblasts from diabetic animals (190). Results on the present work suggest 
that the enhanced adipogenic priming might be related to the upregulation of IRS-1 and 
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IRS-2, since the activation of these adapter proteins and associated PI 3-kinase pathway 
were found to be determinant for the activation of PPARγ, resulting in the induction of 
adipogenic differentiation (209). Most interestingly, the expression of AP2, abundantly 
synthesized in the late phase of developing adipocytes (209), was found not to differ 
significantly between growing STZ and control-derived MSCs cultures. This seems to 
support an increased priming of the adipogenic trigger by diabetic-derived MSCs, 
without an effective progression into this differentiation pathway. 
The assessment of significant signalling pathways revealed a reduced metabolic 
activity associated with ERK and WNT signalling, in STZ-derived MSCs cultures. 
Furthermore, a different regulation on the assayed osteogenic markers was verified in 
diabetic-derived cultures, as ALP expression was found to be enhanced by p38 pathway 
and diminished by WNT pathway; while ERK, WNT, and p38 pathways converged to a 
decreased expression of RUNX2. Contrariwise, PPARγ levels were found to be increased 
in STZ-derived cultures, in close association with the three assayed pathways. 
These results are in accordance with previous literature data on the activity of the 
different signalling pathways. ERK pathway activation was shown to be crucial for the 
regulation of cell proliferation, and also to play a determining role in the differentiation 
of MSCs (210). Briefly, the specific inhibition of this pathway was found to block the 
osteogenic differentiation of human MSCs and to induce the adipogenic differentiation 
of these cells (211). ERK activation was thus found to stimulate osteoblastic-specific 
gene expression through RUNX2 activation (212). Of additional relevance, insulin and 
insulin-like growth factor 1, known to be reduced on the diabetic milieu, was found to 
induce osteoblast proliferation and differentiation via ERK activation (213). 
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WNT signalling has also been associated with the osteogenic commitment and 
adipogenic repression of precursor cells, namely by the stimulation of RUNX2 and 
downregulation of PPARγ, respectively (214). In this work, the expression of both 
osteogenic markers, ALP, and RUNX2, was downregulated in association with WNT 
signalling, while the expression of PPARγ was enhanced, in STZ-derived cultures, thus 
sustaining an impaired activation of this signalling pathway. In type 1 diabetes, a 
decreased osteoblastogenesis was found to be associated with the inhibition of WNT 
pathway (215); while hyperglycaemia was found to target distinct components of the 
WNT pathway in osteoblasts, leading to its inhibition (216), in a process mediated, at 
least in part, by the increased activation of p38 pathway (217). 
In the present study, the metabolic activity of the STZ-derived cultures was found 
to be enhanced through p38 activation, which was also associated with an increased ALP 
and PPARγ expression. p38 activation was previously found to specifically increase ALP 
expression in osteoblastic populations, despite its negative association with the 
osteoblastic differentiation process (217, 218). This correlates with the findings of the 
present research in which an increased ALP expression and activity were verified in STZ-
derived MSCs cultures, regardless of the reduced RUNX2 activity and impaired 
osteogenic priming. Furthermore, within the diabetic milieu, an increased activation of 
p38 has been verified, through different signalling approaches and cellular populations 
(219), thus supporting an increased p38 activity within STZ-derived cultures. 
Generally, MSCs developed within a diabetic microenvironment, and cultured in 
undifferentiating conditions, displayed an impaired functionality, with diminished cell 
proliferation and increased apoptosis. Furthermore, an altered cytoskeleton 
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organization, increased ALP activity, and decreased collagen synthesis were verified. In 
terms of gene expression, altered osteogenic gene profile was verified, with decreased 
expression of RUNX2 and several of its downstream targets; while increased adipogenic 
gene expression was attained. Furthermore, the osteogenic-induction of cultured STZ-
derived MSCs confirmed the impaired osteogenic phenotype, through gene expression 
analysis and assessment of the extracellular mineralization process. Overall, this 
behaviour is consistent with an impaired osteogenic priming of bone marrow-derived 
undifferentiated MSCs, that can be associated with the maintenance of a less mature 
phenotype of this population (220). In agreement, a deficiency in the conversion of 
immature mesenchymal cells to mature osteoblasts was verified in a marrow ablation 
model of diabetic mice (91). Assessment of relevant signalling pathways revealed a 
decreased activity of ERK and WNT, and an increased signalling through p38, which may 
determine, at least in part, the verified functional hindrances. 
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3.6 - CONCLUSION 
 
The present study revealed that diabetic environment may affect MSCs signalling 
and functionality in an intrinsic and long-lasting way. These alterations may contribute 
to the diabetic-derived bone alterations, as verified by the impaired behaviour of 
osteogenic-induced cell populations acquired from diabetic animals, within the bone 
tissue of animal models of experimental diabetes and in clinical trials with diabetic 
patients. 
Thereby, is possible that local or systemic strategies, specially targeted to 
modulate the verified hindrances, may improve the functionality of MSCs in diabetic 
conditions and subsequently enhance the metabolism and regeneration of the bone 
tissue in diabetic conditions. 
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CHAPTER 4 – DOXYCYCLINE ENHANCES THE 
OSTEOGENIC FUNCTIONALITY OF DIABETIC-
DERIVED MESENCHYMAL STEM CELLS 
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4.1 – INTRODUCTION 
 
Diabetes mellitus is a common metabolic disorder associated with hyperglycemia 
and hyperlipidemia, due to lack of insulin production or peripheral insulin resistance 
(221). 
DM affects bone metabolism, as a close and complex association between fragility 
fracture risk and DM, of both type 1 and type 2 diabetes, have been established in 
clinical trials (182, 221, 222). Insulinopenia as occurs in T1D, or resistance to the 
metabolic actions of insulin, as occurs in T2D, are both associated with several 
deleterious consequences for skeletal health (223). Despite the emerging clinical 
evidences, the mechanisms underlying the diabetes-induced skeletal alterations are not 
completely understood. In vitro studies with relevant cell populations developed under 
diabetic-stimulated conditions support a decreased activation of osteogenic 
transcription factors and a reduced expression of osteoblastic markers (186, 224). 
In this context, our group has recently demonstrated that bone marrow-derived 
mesenchymal stem cells developed within the diabetic environment have impaired 
osteoblastic priming, with an increased activation of the adipogenic pathway (224). 
Furthermore, data from in vivo studies with experimental diabetic models and clinical 
trials with diabetic patients sustain an impaired bone metabolic activity, as biochemical 
markers of bone formation and histomorphometric indices of both trabecular and 
cortical bone seem to be significantly impaired (80, 82). Accordingly, the development 
of therapies involving anabolic agents for bone have been particular regarded.  
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Tetracyclines, by their non-antibacterial properties, were earlier found to be 
effective in the reduction of distinct diabetes-induced abnormalities in the diabetic rat 
model. For instance, a decreased weight loss was verified, as well as a substantial 
reduction in the activity of several matrix metalloproteinases. MMPs are members of a 
family of zinc-dependent proteases that can cleave native collagens, playing an 
important role in the extracellular regulation of cell growth, migration, and extracellular 
matrix remodeling (225). In the diabetic environment, MMPs levels are found to be 
pathologically elevated, which may account for the increased degradation and altered 
collagen content of the bone’s ECM. Tetracyclines administration was found to suppress 
MMPs-mediated catabolic processes, resulting in the regularization of the collagen 
synthesis and structure, and in the improvement of the compromised bone remodeling. 
In a diabetic animal model, TCs were found to increase the procollagen and collagen 
synthesis, and to enhance osteoblast activity, regarding the production and 
mineralization of bone matrix. Moreover, in bone and cartilage, MMPs play an 
important function during embryonic endochondral ossification, modeling/remodeling 
of bone postnatally, and during physiological bone repair/regeneration (226, 227). 
Furthermore, MMP’s relation with collagen synthesis and structural organization was 
broadly verified as the subsequently effects on bone remodeling (159).  
In animal models of both low-turnover bone loss (osteopenic diabetic rat), as well 
as in high-turnover bone loss (ovariectomized rat), tetracyclines administration was 
found to increase the bone formation. Accordingly, the use of second generation 
tetracyclines, such as the administration of doxycycline in either local or systemic sub-
antimicrobial doses (SDD), have been widely studied with the aim to decrease host 
tissue breakdown (8, 228). Within these doses ranging from 0.5 µg/mL to 1 µg/mL, 
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doxycycline was found to exert beneficial modulatory effects in both physiological and 
pathological conditions in several tissues including bone (7, 158). Apart from the 
inactivation of MMPs, TCs were also found to have a direct anabolic effect in bone 
metabolism. Briefly, in experimental pathological conditions, TCs increased the 
procollagen and collagen synthesis, enhanced osteoblast activity in the formation and 
mineralization of bone matrix formation during disease (diabetes); and increased the 
number of active osteoblasts relatively to inactive (7, 158).  
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4.2 – RESEARCH HYPOTHESIS AND OBJECTIVES 
 
In this module we aim to conduct a detailed characterization of the molecular 
events developing within mesenchymal stem cell cultures, derived from STZ diabetic-
induced and control animals, in presence and absence of a low dosage regimen of 
doxycycline. Grown cultures will be characterized regarding proliferation, functional 
activity and differentiation, and evaluation of the osteogenic priming. In addition, the 
effect of the low dosage regimen of doxycycline within the bone remodelling and 
regeneration, will be further addressed, with the ex vivo model of the neonatal rat 
calvarial bone defect regeneration. 
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4.3 – MATERIALS AND METHODS 
 
4.3.1 – ANIMALS 
This study was conducted in accordance with accepted standards for the humane 
animal care and manipulation. Procedures were approved by Direção Geral de 
Alimentação e Veterinária and encompassed the standards for the protection of 
experimental animals, according to the Portuguese and European legislations. Briefly, 
12 male Wistar rats (7 to 8 weeks old), acquired from a certified vendor, were housed in 
groups of 2, in conventional type II cages, and allowed standard rat pelleted diet (4RF21 
Mucedola, Settimo Milanese, Italy) and water ad libitum, in accordance to home office 
regulations.  
Experimental diabetes was induced in 6 animals, by a single intraperitoneal (IP) 
injection of streptozotocin, Sigma®, (60 𝑚𝑔. 𝑘𝑔−1, in 10 mM citrate buffer, pH 4.5) – STZ 
group (n=6). Control animals were injected with vehicle alone – control group (n=6). 
Glycemic levels were confirmed 3 days after administration with a glucometer (Accu 
Check GO, Roche Diagnostics). Animals with blood glucose levels ≥ 300 𝑚𝑔. 𝑑𝑙−1 were 
considered to be diabetic and enrolled into the STZ group.  
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4.3.2 – CHARACTERIZATION OF THE EXPERIMENTAL GROUPS 
Six weeks following STZ or control administration, glycemic levels were 
determined in the peripheral blood. Following, animals were euthanized by 
exsanguination under general anesthesia (intraperitoneal injection of pentobarbital 
sodium 35 𝑚𝑔. 𝑘𝑔−1). Femurs and left tibias were harvested and processed for cell 
culture establishment. Right tibias were harvested, fixed in ethanol 70% and scanned by 
microcomputed tomography. Analysis were performed in a CT 35 (Scanco Medical), 
with a voxel size of 12 m, X-ray tube voltage of 70 kVp, current intensity of 114 A, and 
integration time of 600 ms. Quantitative histomorphometrical data of the trabecular 
content were conducted with the Scanco Medical software, version 6.0. Measured 
variables included bone volume per total volume (BV/TV), connective density (CD), 
trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabecular separation 
(Tb.Sp). 
 
 
4.3.3 – CELL CULTURES  
Bone marrow-derived MSCs were isolated using a modification of the protocols 
previously described by Dobson (193) and Sekiya (194), for bone marrow harvest and 
MSCs isolation. Briefly, left and right femurs and left tibias were carefully excised, 
cleaned of soft tissues and decontaminated. Following, epiphyses were cut off and 
diaphyses were flushed out with Rat-Mesenchymal Stem Cell Growth Medium (Lonza). 
Nucleated cells were isolated with a density gradient (Ficoll-Paque Premium®), 
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resuspended in culture medium with 10% heat inactivated fetal bovine serum (FBS, 
Gicbo), penicillin-streptomycin (100 UI.mL-1 – 100 mg.mL-1, Gibco) and fungizone® 
amphotericin B (2.5 𝜇𝑔. 𝑚𝑙−1, Gibco), plated and maintained in a humidified 
atmosphere (5% CO2/air, 37 ºC) until around 70% confluence (approximately 15 days). 
Cells were enzymatically released (trypsin 0.04% and 0.25% EDTA solution), and seeded 
at a concentration of 104 cells.cm-2. Where noted, cultures were grown in the presence 
of doxycycline 1 m.ml-1 (Sigma-Aldrich). The culture medium was changed every 2-3 
days and cultures were maintained for 12 days, and characterized as follows. 
 
 
4.3.4 – CELL PROLIFERATION AND METABOLIC ACTIVITY 
Metabolic activity of the cultures was estimated by the MTT assay. Briefly, cultures 
were incubated with MTT (0.5 mg.ml-1, 4 hours). Formazan crystals were following 
dissolved and the absorbance was measured at 550 nm in an ELISA reader (Synergy HT, 
Biotek). 
 
 
4.3.5 – CELL MORPHOLOGY 
Fixed cultures (3.7% paraformaldehyde, 15 minutes) were stained for F-actin 
cytoskeleton and nucleus counterstaining. Cells were permeabilized (0.1% Triton, 5 
minutes), incubated with albumin (10 mg.ml-1), and treated with Alexa Fluor 488®-
conjugated phalloidin (1:20 dilution, 20 minutes) and propidium iodide (1 µg.ml-1, 10 
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minutes). Cultures were observed in a confocal laser scanning microscope (Leica SP2 
AOBS, Leica Microsystems). 
 
 
4.3.6 – ALKALINE PHOSPHATASE ACTIVITY 
Alkaline phosphatase (ALP) activity was determined in cell lysates by the hydrolysis 
of p-nitrophenyl phosphate into p-nitrophenol (30 minutes, 37 °C), assessed at 405 nm 
in an ELISA reader (Synergy HT, Biotek). ALP activity was normalized to total protein 
content (measured according to the Lowry method). 
 
 
4.3.7 – APOPTOTIC BEHAVIOUR 
Apoptosis was quantified by measuring caspase-3 activity with the EnzCheck® 
Caspase-3 Assay Kit #2 (Molecular Probes), according to manufacturer’s instructions. 
 
 
4.3.8 – COLLAGEN SYNTHESIS  
Fixed cultures were stained with 0.1% Sirius red solution (BDH, UK) in saturated 
picric acid (1 hour), followed by rinsing with HCl (0.01N). Collagen matrix was 
photodocumented before stain dissolution in 0.1N NaOH, 30 minutes. The absorbance 
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was measured at 550 nm (Synergy HT, Biotek) and results were presented as % of 
staining compared to control. 
 
 
4.3.9 – GENE EXPRESSION 
Cell cultures were analyzed by qPCR for the expression of housekeeping beta-actin 
(-actin), alkaline phosphatase (ALP), bone morphogenic protein-2 (BMP-2), collagen 
type I (COL I), osteopontin (OPN), osteocalcin (OC), osteoprotegerin (OPG), and 
lipoprotein receptor-related protein 5 (LRP5). Total RNA was extracted using the 
NucleoSpin® RNA II Kit (Macherey-Nagel), according to the manufacturer’s instructions. 
Total RNA concentration and purity were assessed by UV spectrophotometry by 
calculating A260nm/A280nm ratio. qPCR was conducted using the Bio-Rad iQ5 real-time 
PCR system (Bio-Rad, Hercules, CA, USA) using SYBR Premix Ex Taq kit (Takara). 
 The relative gene expression level was normalized to the internal control (β-actin) 
based on the 2−∆∆𝐶𝑇  method. 
Results were expressed as the percentage variation from control, corresponding 
to 100% at each time point. The primers used are listed on table 4.1. 
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Table 4.1 – Forward and reverse sequences of the primers used for the qPCR 
analysis. 
 
GENE FORWARD SEQUENCE REVERSE SEQUENCE 
Β-ACTIN AGTACCCCATTGAACACGGC TTTTCACGGTTAGCCTTAGG 
ALP GGCTCTGCCGTTGTTTC GGGTTGGGTTGAGGGACT 
BMP-2 AGTGACTTTTGGCCACGACG CGCTTCCGCTGTTTGTGTTT 
COLLAGEN 1 TGGCAAGAACGGAGATGA AGCTGTTCCAGGCAATCC 
OSTEOPONTIN AAAAATGCTCACCATCACTGC AATTGCCACACTGACTTCCAC 
OSTEOCALCIN GCCCTGACTGCATTCTGCCTCT TCACCACCTTACTGCCCTCCTG 
OSTEOPROTEGERIN ATTGGCTGAGTGTTCTGGT CTGGTCTCTGTTTTGATGC 
LRP5 TGCCACTGGTGAGATTGAC ACTGCTGCTTGATGAGGAC 
 
 
4.3.10 – NEONATAL CALVARIA DEFECT EX VIVO MODEL 
In this protocol 10 new-born rats were used from 2 different litters. The protocol 
was conducted as previously described by Wu and co-workers (229) with several 
modifications. Briefly, the animals were euthanized at third day after birth by 
decapitation and the heads were disinfected with 70% ethanol. Following, the skin was 
carefully removed to expose the calvaria, and the parietal bones were dissected out and 
cleaned of remnant soft tissues. Full-thickness circular defects of 0.8 mm diameter were 
created through the parietal bones using a surgical instrument. 
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Bones were cultured concave-side down in 48-well cell culture microplates in 
αMEM supplemented according to experimental conditions. Accordingly, four 
experimental groups were established: (1) Control group (CTRL), supplemented with 
10% FBS, penicillin-streptomycin (100 UI.mL-1 – 100 mg.mL-1), fungizone (2.5 𝜇𝑔. 𝑚𝑙−1); 
(2) Diabetic group (GLC), supplemented with 10% FBS, penicillin-streptomycin (100 
UI.mL-1 – 100 mg.mL-1), fungizone (2.5 𝜇𝑔. 𝑚𝑙−1), and glucose (20 mM) in order to mimic 
blood glucose concentrations in diabetic condition; (3) Control with doxycycline group 
(CTRL Doxy), supplemented with 10% FBS, penicillin-streptomycin (100 UI.mL-1 – 100 
mg.mL-1) and fungizone (2.5 𝜇𝑔. 𝑚𝑙−1), and doxycycline (1𝜇𝑔. 𝑚𝐿−1); and (4) Diabetic 
with doxycycline group (GLC Doxy), supplemented with 10% heat inactivated foetal 
bovine serum (FBS, Gicbo), penicillin-streptomycin (100 UI.mL-1 – 100 mg.mL-1, Gibco) 
and fungizone/amphotericin B (2.5 𝜇𝑔. 𝑚𝑙−1, Gibco), glucose (20 mM, Sigma-Aldrich), 
and doxycycline (1𝜇𝑔. 𝑚𝐿−1 , Sigma-Aldrich). Bones were maintained in a humidified 
atmosphere (5% CO2/air, 37 ºC) for 15 days. 
 
 
4.3.10.1 – OPTICAL MICROSCOPY 
Newborn rat bones in culture were monitored regularly by phase contrast optical 
microscopy to assess qualitatively bone regeneration and remodeling over the 15 days 
of organ culture. 
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4.3.10.2 – SCANNING ELECTRON MICROSCOPY 
At day 15, bones were rinsed with PBS and fixed with 1.5% glutaraldehyde (Fluka, 
Germany) in 0.14 M sodium cacodylate buffer (Sigma-Aldrich) for 20 minutes at room 
temperature. The samples were then dehydrated in a sequence of ethanol-water 
solutions, for 10 minutes each, using increasing concentrations of ethanol up from 50% 
to 100%. The samples were then fixed with hexamethyldisilazane (Sigma-Aldrich) at the 
same increasing concentration sequence and left to dry overnight inside the laminar 
flow cabinet. Subsequently, samples were sputter-coated (SPI-Module) with a thin 
gold/palladium film and observed in SEM (FEI Quanta 400FEG). Mineralization nodules 
were evaluated by energy-dispersive X-ray spectroscopy (EDS) analysis of the calcium 
phosphates deposits on cell layer surface. The percentage of regenerated area was 
calculated using the ImageJ software to address the defects area. 
 
 
4.3.11 – STATISTICAL ANALYSIS 
Three independent experiments were performed, with the cell cultures 
established from different animals. In quantitative assays, each point represents the 
mean ± standard error of 6 replicates. Statistical analysis was done by one-way analysis 
of variance (ANOVA). p values ≤ 0.05 were considered significant. 
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4.4 RESULTS 
 
4.4.1 – ESTABLISHMENT OF A DIABETES EXPERIMENTAL MODEL 
All animals, of both control and STZ groups, survived throughout the duration of 
the experimental protocol. Whether no significant differences were found on the initial 
weight (control, 339.5 ± 23.1; STZ, 317.0 ± 33.8), 6 weeks following diabetic induction, 
animals of the control group increased in weight (396.7 ± 37.3), while animals of the STZ 
group loss weight (228.1 ± 26.41). Further, at euthanasia, all diabetic animals had 
glycemic levels over 300 𝑚𝑔. 𝑑𝑙−1, while animals from the control group had a mean 
glycemia of ± 120 𝑚𝑔. 𝑑𝑙−1. 
 
 
4.4.2 – EVALUATION OF DIABETES EFFECTS ON BONE 
The microtomographic analysis of the proximal tibia also revealed significant 
differences between control (figure 4.1, right) and STZ group (figure 4.1, left). 
Comparatively, a decreased BV/TV and CD were verified. Furthermore, in terms of the 
characterization of the trabecular structure, diabetic animals reported a significant 
reduced Tb.N and Tb.Th, as well as in creased Tb.Sp. The resulting morphometric indexes 
are shown in table of figure 4.1. 
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Figure 4.1 – Top: representative 2D microtomographic images of the proximal tibia 
methaphysis, in control (right) and STZ (left) animals (𝑛 = 6). Bottom: table of 
microstructural parameters of the trabecula structure of the proximal tibia. The 
addressed variables included BV/TV (bone volume per total volume), CD (connective 
density), Tb.N (trabecular number), Tb.Th (trabecular thickness), and Tb.Sp (trabecular 
separation). * - significantly different from control (𝑃 ≤ 0.05). 
 
 
 
 
 
129 
 
4.4.3 – CHARACTERIZATION OF MSCS CULTURES GROWN IN THE PRESENCE OF 
DOXYCYCLINE 
MSCs cultures were established from the bone marrow of control and STZ-induced 
diabetic animals. In order to disclose the effect of a low dosage doxycycline regimen on 
the behaviour of diabetic MSCs, STZ-derived cultures were grown in the absence and in 
the presence of doxycycline, at a concentration of 1 g.ml-1. The antibiotic was renewed 
at every medium change that occurred 2 times a week. 
 
 
4.4.3.1 – METABOLIC ACTIVITY AND CELL PROLIFERATION 
The results concerning MTT assessment of cells viability and proliferation are 
shown in figure 4.2. MSCs cultures from control animals presented an increased 
metabolic activity until day 8, diminishing afterwards. STZ-derived cultures followed a 
similar pattern despite that, comparatively to control, a decreased metabolic activity 
was attained at day 8 and 12. The addition of doxycycline increased the metabolic 
activity of the STZ cultures from day 5 onwards. At this time point (day 5), the metabolic 
activity of STZ-derived cultures grown in the presence of doxycycline was significant 
higher than that of the controls. At late culture time points, i.e., days 8 and 12, no 
significant differences were found between doxycycline-treated STZ cultures and 
control. 
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Figure 4.2 – Cell viability/metabolic activity (MTT assay) of rat bone marrow-
derived cells cultured in presence and absence of doxycycline (1 𝜇𝑔. 𝑚𝑙−1) from both 
control and STZ-induced animals, for 12 days. Percentage of variation from control at 
each time point. * - significantly different form control (𝑃 ≤ 0.05). ** - significantly 
different form STZ (𝑃 ≤ 0.05). 
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4.4.3.2 – CELL MORPHOLOGY ANALYSIS 
The morphology of established cultures was detailed with confocal laser scanning 
microscopy (CLSM), following staining of the actin cytoskeleton and nucleus 
counterstaining. Representative images are shown in figure 4.3. Control cultures, at day 
3, presented the characteristic fibroblastic-like morphology, with elongated and 
polygonal cytoplasm. Numerous microfilaments could be identified in a dense network, 
with evidence of stress fibers formation. Strong labelling was often observed along 
cellular edge and within the extended cellular filopodia.  Cells were found to proliferate 
actively and, at day 12, cells organized into a flattened sheet of a continuous cell layer. 
The addition of doxycycline to the culture system was found to increase actin 
cytoskeletal staining, with great evidence of stress fibers formation. At day 12, no 
significant differences were found between conditions.  
The STZ-derived cultures showed a similar behaviour in this time course. However, 
at day 3, fewer stress fibers were visible on proliferating cells and the intense labelling 
at the cellular edge, broadly observed in control, was more rarely identified. The 
addition of doxycycline was found to increase cytoskeletal staining and stress fibers 
formation, particularly at early time points, i.e., day 3 of the culture. 
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Figure 4.3 – Confocal laser scanning microscopy imaging of rat bone marrow-
derived cell cultures, from control and STZ-induced diabetic animals in presence and 
absence of doxycycline, established for 12 days. Cytoskeleton was stained in green and 
nucleus counterstained in red. Scale bar corresponds to 200 µm. 
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4.4.3.3 – ALKALINE PHOSPHATASE ACTIVITY 
ALP activity increased throughout the experimental period for both cultures 
established in the absence and presence of doxycycline (figure 4.4). The addition of 
doxycycline significantly increased the activity of this enzyme at day 8 of the culture and 
forward.  
 
 
 
 
 
 
 
 
 
 
Figure 4.4 – Alkaline phosphatase activity (ALP per total protein content) of rat 
bone marrow-derived cells cultured in presence and absence of doxycycline 
(1 𝜇𝑔. 𝑚𝑙−1) from both control and STZ-induced animals, for 12 days. Percentage of 
variation from control at each time point. * - significantly different form control (𝑃 ≤
0.05). ** - significantly different form STZ (𝑃 ≤ 0.05). 
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Histochemical assessment of ALP confirmed biochemical data, revealing an 
increased staining of the cultures grown in the presence of doxycycline (figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 – Alkaline phosphatase staining of rat bone marrow-derived cell 
cultures, established for 12 days, from control and STZ-induced diabetic animals in 
presence and in absence of doxycycline. Scale bar corresponds to 300 m. 
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4.4.3.4 – APOPTOTIC BEHAVIOUR 
Results regarding the caspase 3 activity assay to apoptosis evaluation are shown 
in figure 4.6 below. STZ-derived cultures presented an increased apoptosis, as 
comparing to control. Significant higher levels of caspase-3 activity were verified at days 
8 and 12 of the STZ cultures. The addition of doxycycline did not significantly increase 
the apoptotic index of the cultures.  
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – Apoptotic analysis (caspase-3 activity assay) of rat bone marrow-
derived cells cultured in presence and in absence of doxycycline (1 𝜇𝑔. 𝑚𝑙−1) from both 
control and STZ-induced animals, for 12 days. Percentage of variation from control at 
each time point. * - significantly different form control (𝑃 ≤ 0.05). 
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4.4.3.5 – COLLAGEN SYNTHESIS 
Total collagen synthesis was addressed by the Sirius red histochemical staining 
technique (figure 4.7 below).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 – Total type 1 collagen staining of rat bone marrow-derived cell 
cultures, established for 12 days, from control and STZ-induced diabetic animals in 
presence and in absence of doxycycline. Scale bar corresponds to 750 m. 
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A qualitative analyze was conducted on stained micrographs of the cultures, while 
a quantitative determination of the stained products was conducted and prone to 
statistical analysis. In control cultures, an increased collagen synthesis was verified by 
the increased staining intensity of the cultures. Comparatively, STZ-derived cultures 
revealed a decreased collagen synthesis, which was found to be significant at day 12 of 
the culture period. The addition of doxycycline to the STZ culture environment 
significantly increased total collagen synthesis. Comparatively, a significantly higher 
staining intensity was found in doxycycline treated-cultures, at day 12. Quantitative 
colorimetric determination of the stained products supported the qualitative 
histochemical evaluation (figure 4.8). 
 
 
 
 
 
 
 
 
 
Figure 4.8 – Colorimetric determination of the total collagen stained product 
within the established MSCs cultures from both control and STZ-induced diabetic 
animals in presence and absence of doxycycline. Results were expressed as the 
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percentage variation from control corresponding to 100% at each time point. * - 
significantly different form control (𝑃 ≤ 0.05). ** - significantly different form STZ (𝑃 ≤
0.05). 
 
 
4.4.3.6 – GENE EXPRESSION 
qPCR analysis showed the expression of significant osteogenic markers, from both 
control and STZ-derived cell cultures in the presence and absence of doxycycline. The 
results are shown in figure 4.9. Broadly, in STZ-derived cultures, a significantly reduced 
expression of the osteogenic genes BMP-2, COL1α1, OPN, LRP5, OC and OPG were 
verified, whether a higher ALP expression was attained, particularly at day 5. The 
addition of doxycycline broadly induced the expression of osteogenic markers, in both 
control and STZ-derived cultures.  
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Figure 4.9 – qPCR gene expression analysis of ALP, BMP-2, Col 1, OPN, LRP5, OC, 
and OPG in MSCs cultures, established for days 5 and 8, from control (𝑛 = 6) and STZ-
induced diabetic animals (𝑛 = 6).  Cultures were grown in undifferentiating (STZ) and 
osteogenic-differentiating (Osteo STZ) conditions. Results were expressed as the 
percentage variation from control corresponding to 100% at each time point. * - 
significantly different form control (𝑃 ≤ 0.05). ** - significantly different form STZ at the 
same time point (𝑃 ≤ 0.05). 
 
 
4.4.4 – CALVARIAL BONE DEFECT REGENERATION – EX VIVO MODEL 
Organ cultures of new-born rat in physiologic and pathological diabetic-like 
conditions were maintained for 15 days. The method aimed to analyze the effects of 
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SDD in bone regeneration and remodeling in an ex vivo model which comprises other 
variables than a type-specific cell culture such as the organ structure and tissue 
properties while keeping the model under the complexity of a systemic interferences as 
in the case of in vivo bone defects regeneration protocols. The percentage of 
regenerated are was estimated by using the software ImageJ.  
 
 
4.4.4.1 – PHASE CONTRAST MICROSCOPY EVALUATION 
Calvaria bone defect regeneration was qualitatively addressed by phase contrast 
microscopy and the evolution throughout the organ culture span are shown in figure 
4.10. Optical microscopy photodocumented images showed progressive and concentric 
bone defect regeneration with cognizable new bone tissue formation on defect borders, 
in the four experimental conditions, from day 0. At day 8, an apparent higher 
regeneration in both GLC and GLC Doxy groups was registered. However, at day 20, total 
bone regeneration was attained and new bone remodeling seemed to take place in all 
experimental groups with exception of GLC group which failed to achieve full 
regeneration of bone defect. 
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Figure 4.10 – Phase contrast optical microscopy images obtained at days 0, 10 and 
20 for the established experimental conditions of new-born rat calvarial organ culture, 
following the establishment of the defect. Scale bar corresponds to 400 m. 
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4.4.4.2 – CALVARIAL BONE DEFECT REGENERATION – SCANNING ELECTRON 
MICROSCOPY EVALUATION 
Samples surface morphology and bone defect regeneration were analyzed by SEM 
and the results are shown ate figure 4.11 below. The images obtained by SEM evaluation 
showed accordance with phase contrast microscopy in that bone regeneration occurred 
from day 0 with visible layers of newly formed bone along the defect borders. 
Accordingly, full bone regeneration was attained for all experimental conditions but the 
GLC condition. 
The circular defects in CTRL, CTRL Doxy and GLC Doxy groups were closed however 
the phase of regeneration was different between conditions. SEM revealed a 
significantly thicker new bone membrane in the CTRL Doxy group and comparison with 
the other conditions. In contrast, in GLC group, newly formed tissue was considerably 
thinner in comparison with CTRL and GLC Doxy groups. 
Through EDS analysis, it was possible to identify the deposition of Ca/P rich 
nodular structures, a process substantiating the development of a mineralized matrix 
within the regenerated area (figure 4.12). The addition of doxycycline seems to increase 
the mineral deposition within the mineralized tissues. 
The percentages of regenerated area were calculated for each experimental 
condition. The results were expressed in a percentage of regenerated area in relation 
with the size of the original defect and are shown in figure 4.13. A reduced defect healing 
was verified for diabetic simulated conditions. However, the addition of doxycycline was 
found to enhance the healing process in diabetic conditions, being achieved results 
similar to control. 
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Figure 4.11 – SEM images of new-born rat parietal bone at days 8 and 15, following 
the establishment of the defect. Scale bar corresponds to 500 m. 
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Figure 4.12 – SEM images of mineralization deposits after 15 days of culture of 
new-born rat parietal bones, following the establishment of the bone defect. Assessed 
area is within the newly formed tissue. Scale bar corresponds to 20 m. 
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Figure 4.13 – Percentage of regenerated area along the 15 days of new-born rat 
parietal bones’ culture, following the establishment of the defect. * - significantly 
different form control (𝑃 ≤ 0.05). 
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4.5 – DISCUSSION 
 
Diabetes has been previously shown to affect bone tissue remodeling and 
formation. Data from animal models and clinical trials sustain that osteopenia and 
osteoporosis may be frequent complications of T1D, both in children and adults, being 
associated with a decreased bone density and increased bone fracture risk (80, 221, 
230). In contrast, whether T2D has not been typically associated with decreased mineral 
mass and, in fact, has been more often associated with increased BMD, new data show 
that bone quality and bone microarchitecture may be compromised in both conditions 
(5, 182), converging to a sustained increase in the risk to fracture, that may be 
contributory from both forms of diabetes. 
Additionally, in vitro cell culture studies support a deficient function from 
osteoblastic and osteoprecursor populations (75, 93). We have previously shown that 
diabetic-derived MSCs grown on undifferentiating conditions, report an impaired cell 
functionality, with diminished cell proliferation, increased apoptosis and altered gene 
expression profile – i.e., decreased expression of Runx2 and several of its downstream 
targets and an increased adipogenic gene priming (224). These alterations may 
withstand a deficiency in the conversion of diabetic immature mesenchymal cells to the 
osteoblastic phenotype; a process that may be mediated by the decreased activity of 
ERK and WNT, and an increased signaling through p38 signaling pathway (217, 219). 
In this work, we have shown that doxycycline, in a low dosage regimen, was found 
to enhance the osteogenic capability of MSCs derived from STZ-induced diabetic rats. 
Briefly, this antibacterial agent was found to enhance cell proliferation and metabolic 
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activity, without interfering with cell apoptosis. In addition, a higher total collagen 
production was verified in doxycycline-treated cultures, which, at later culture time 
points, was found to exceed the production of control. The expression of osteogenic 
genes was also found to be upregulated, particularly, at early culture time points. Within 
the ex vivo model, the addition of doxycycline was further found to improve defect 
healing in diabetic-simulated conditions and enhance mineral deposition.  
Tetracyclines, due to their capability to inhibit collagenases and other host-derived 
matrix metalloproteinases (MMPs), in a process independent of their antibacterial 
activity, have been widely used in the modulation of local and systemic conditions in 
which the excessive activation of these enzymes is the hallmark feature of the disease 
pathogenesis (145, 231). More recently, the use of TCs within the modulation of 
conditions leading to reduced bone mass, either locally (e.g., periodontitis-mediated 
alveolar bone loss) or systemically (e.g., osteopenia/osteoporosis), has brought new 
attention into the clinical use of these drugs (232-234).  
Low dosage regimens of tetracyclines were previously found to induce an anabolic 
action on the differentiation of osteoprecursor populations. Low levels of doxycycline 
(ranging from 0.1 to 1 M) were found to increase cell proliferation and to stimulate the 
osteogenic differentiation of precursor cells (235, 236). Our group has previously shown 
that low concentrations of both doxycycline and minocycline, added to growing human 
osteoblastic populations, were found to increase the metabolic activity and the 
osteogenic potential, with increased levels of alkaline phosphatase activity and culture 
mineralization (236). In accordance, treatment of osteoprogenitor cell cultures with low 
dosage doxycycline was found to report osteoinductive effects over growing cells, in a 
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similar way to the addition of bone morphogenic protein 2 (BMP-2) – a known 
osteogenic inducer (237). Osteoblastic cultures established on biomaterials’ surfaces 
adsorbed with low levels of tetracylines, were also found to reveal low cytotoxicity and 
an improved osteogenic activation (238, 239). Some reports sustained dissimilar results 
of tetracyclines activity over osteoblastic-related populations, supporting a cytotoxic 
effect of these drugs. These studies broadly addressed higher levels of tetracyclines and 
described an impaired osteoblastic proliferation and differentiation (240-242). Attained 
deleterious effects may be essentially dose-dependent, as in a  previous report, 
addressing the effect of doxycycline and minocycline (1 to 50 g.ml-1) in human 
osteoblastic populations, cytotoxic effects were significantly noticed when 
concentrations over 10 g.ml-1 were used (236). 
Anabolic effects of tetracyclines were also demonstrated in clinical studies. In a 2-
year long placebo-controlled clinical trial, the subantimicrobial dosage doxycycline 
(SDD) regimen  was found to significantly reduce the alveolar bone loss in pathologically-
elevated periodontal pocket sites, exhibiting moderate to advanced periodontitis (232). 
Locally, SDD was found to significantly reduce collagenases and MMPs activity, at the 
same time that IL-1β, a pro-inflammatory cytokine and a biomarker associated with 
bone resorption, was decreased (243). These data were highly correlated with the 
attained reduction of the levels of C-telopeptide to helix (ICTP), a pyridinoline-crosslink-
containing degradation fragment of the C-terminal telopeptide region of type I collagen, 
a known biomarker of bone resorption. Most interestingly, SDD was also found to 
significantly reduced the serum ICTP levels, and to slightly reduced C-telopeptide cross-
link of type I collagen (CTX), a deoxypyridinoline-containing degradation fragment of the 
C-terminal telopeptide region of type I collagen (234). SDD regimen was proven to 
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reduce serum biomarkers of systemic inflammation, including C-reactive protein (CRP) 
(233, 244), which has been found to reflect susceptibility to skeletal bone-deficiency 
disease (174). Overall, a reduced bone loss was verified, with clinical improvement, and 
evidence of a reduced collagen catabolism.  
In accordance with the verified clinical improvement in bone’s collagen 
metabolism, in the present experiment, doxycycline administration in STZ-derived 
cultures was found to enhance collagen synthesis to levels higher than those attained in 
control, as an increased expression of collagen type I gene and total collagen production 
were verified. Further, the expression of osteogenic genes and bone healing were 
verified. 
Tetracyclines were previously found to have an anabolic effect on collagen 
synthesis in several tissues of the STZ-induced diabetic rat (245, 246). In addition to the 
ability to inhibit MMP-mediated extracellular collagen degradation (228), tetracyclines 
were found to increase both steady-state levels of type I procollagen mRNA and collagen 
synthesis (247, 248). Autoradiographic studies revealed that in the diabetic bone of STZ-
induced rats, the synthesis of collagen and its precursors was restored to near-normal 
levels, following treatment with tetracyclines (249). Doxycycline was also found improve 
periodontal wound healing in experimental animal model of diabetes (250) and in the 
clinical forms of type I diabetes mellitus (251, 252) and type II diabetes mellitus (253), 
thus sustaining an enhanced collagen deposition within the regenerated tissues. Of 
additional relevance, tetracyclines may further prevent collagen degradation, as 
tetracycline impregnation was found to lessen degradation of collagen constructs in 
both diabetic and normoglycemic conditions (254). 
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While no data on the effect of tetracyclines on diabetes-derived osteoblastic 
populations has been reported, in vivo data supports an anabolic effect of these drugs 
on experimental models of diabetes, as further verified within the developed ex vivo 
assay. Low dose administration of minocycline to STZ-induced diabetic rats was found 
to preserve growth plate thickness, and to increase bone formation rates and cancellous 
bone areas to levels equivalent to those observed in control (255). Further, tetracyclines 
administration was found to prevent the development of the STZ-induced osteopenia in 
the rat, in a process associated with the restoration of the defective osteoblast 
morphology and metabolic activity (246). In fact, following treatment with tetracyclines, 
the osteoblastic synthesis of protein towards the osteoid matrix and alkaline 
phosphatase activity were broadly normalized in the humeri of diabetic rats (256).  
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4.6 CONCLUSION 
 
Apart from the enhancement of the osteoblastic function in diabetic conditions, 
tetracyclines administration, in the particular case regarding a low dosage regimen of 
doxycycline, may further normalize the impaired osteogenic commitment of precursor 
populations, as detailed in the present study. Bone marrow derived mesenchymal stem 
cells, developed within a diabetic microenvironment were found to develop an 
increased commitment within the osteogenic lineage upon treatment with a low dosage 
regimen of doxycycline. Increased osteogenic gene expression was verified and a higher 
expression and synthesis of collagen were attained, and even found to overcome control 
levels. Further, within a bone defect healing model in diabetic-simulated conditions, 
doxycycline further enhanced tissue healing and mineralization.   
This may further sustain that, apart from the modulatory effect over MMPs, with 
a positive effect on the diabetic bone, tetracyclines’ release may further directly 
enhance the commitment of osteoblastic precursor populations, further enhancing the 
metabolic equilibrium within the diabetic bone. 
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CHAPTER 5 – MINOCYCLINE-LOADED PMMA 
BONE CEMENT AS A DELIVERY SYSTEM TO 
ENHANCE BONE HEALING – 
BIOCOMPATIBILITY EVALUATION IN A 
DIABETIC MODEL 
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5.1 – INTRODUCTION 
 
Diabetes mellitus (DM) is becoming increasingly common and a major concern 
worldwide. It ensembles a group of metabolic disorders related with hindered insulin 
production and action, and consequent abnormal glucose metabolism. DM-associated 
long-term hyperglycaemia is known to cause severe damage and ultimately failure of a 
variety of tissues and organs (48, 53). Although the systemic causes are still unclear, it is 
accepted that type 1 diabetes affects the bone tissue more sharply than other diabetes 
forms (230). Accordingly, T1D is associated with numerous tissue alterations such as 
impaired cellular proliferation, differentiation and functionality, abnormal calcium 
metabolism and extracellular matrix organization (11, 224, 257, 258). These alterations 
together, lead to an unbalanced bone remodelling and bone mineral density reduction, 
which are consistent with reported bone weakening and increased occurrence of 
fractures (182). 
With the increasing number of bone fractures, especially in long bones, the need 
for orthopaedic implants among diabetic patients is also increasing (11). Although the 
commonly used implantable medical devices have their cytocompatibility and 
biocompatible demonstrated prior to its clinical application, the biological response to 
foreign objects is still a major cause of implant failure and need for removal (259). 
Furthermore, DM is known to be associated with impaired inflammatory response and 
subsequent altered tissue healing, higher susceptibility to infections and greater rate of 
implant rejection (115, 116). Notwithstanding, the assessment of the biological 
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response to implanted biomaterials in diabetic conditions is rarely conducted and is 
fundamental for the safety biomaterials’ application in compromised conditions. 
Poly(methyl methacrylate) (PMMA) bone cements, represent a well-known and 
broadly used biomaterial group in orthopaedic surgeries, namely as fixatives of 
prosthetic devices and wound fillers. In addition to its biocompatibility, PMMA reveals 
other attractive properties such as toughness, high morphological adaptability and 
excellent resistance to biomechanical loading within the biological milieu (260). PMMA 
cements have been widely used as bone space-fillers, maintaining the targeted area 
cleaned of soft tissues and preventing wound contracture, while delaying bone 
regeneration until suitable conditions for bone healing and remodelling are attained 
(261). Nevertheless, the success of a device implantation may be compromised due to 
several factors including the injury extension, difficult access to the anatomical site, 
patient lifestyle (e.g. smoking, alcohol), medication, infections and chronic systemic 
metabolic diseases, such as diabetes (259). 
Acute and chronic infections represent a major concern regarding bone implant 
surgeries as its development may lead to implant removal and infection management  
through a second surgery and a long lasting antibiotic treatment (259). A bright spot for 
bone cements implantation, aiming to minimize the risk of infection, is the successful 
development of antibiotic-loaded PMMA formulations. This local therapeutic approach 
was first developed with gentamicin-loaded PMMA and it presented advantages when 
compared to a systemic antibiotic therapy for bone infection management, including 
local targeted anatomic delivery of the drug to the wound site, lower overall dosage, 
minimization of potential systemic side effects of drug administration, among others 
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(259). Further, it was established that the desirable antibiotic to include in bone cements 
should presents specific properties beyond a broad-spectrum of activity. Since PMMA 
preparation occurs during the surgical procedure, antibiotics must also be thermally 
stables, water-soluble and must be available in powder phase, to improve mix with 
cement powder (262). Minocycline holds all these properties of a suitable antibiotic for 
PMMA-inclusion and it represents an attractive option due to its pharmacological 
characteristics. In addition to its chemical and thermal stability, minocycline possess a 
long half-life, combined with excellent absorption by the tissues (167). 
Additionally, minocycline was broadly reported to exert beneficial effects in 
systemic conditions such as diabetes mellitus. The compound anti-inflammatory 
properties were previously described in a variety of experimental and clinical settings 
including cerebral (170) and renal ischemia (263), periodontal disease (7), and 
cutaneous inflammation (264), among other. Accordingly, these inflammation 
modulatory properties may contribute to an enhanced implant acceptance and 
integration, while the antibiotic action is ordinarily ensured by minocycline. Additionally, 
in which regards bone tissue, minocycline may represent an optimal compound as it was 
demonstrated to improve collagen matrix quality and organization and prevent tissue 
breakdown, by inhibiting collagenase activity (159). In other hand, minocycline was 
reported to impair significantly the structural disorganization of both osteoid and the 
layer of osteoblasts further enabling new bone formation and reducing trabecular bone 
loss (10). 
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5.2 – RESEARCH HYPOTHESIS AND OBJECTIVES 
 
In this work, it is aimed the biological evaluation of minocycline-loaded PMMA 
bone cement, following the subcutaneous implantation within a relevant experimental 
animal model. Additionally, in order to characterize the biological response in simulated 
diabetic conditions, developed minocycline-releasing constructs will be further 
implanted in STZ-induced diabetic rats, a commonly used experimental animal model 
representative of the human type 1 diabetic condition. 
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5.3 – MATERIALS AND METHODS 
 
5.3.1 – PMMA AND MINOCYCLINE-LOADED PMMA SAMPLES PREPARATION 
The different bone cements were prepared following the previously described 
methods (265, 266). Commercial acrylic BC, CMW1® Radiopaque, and stabilized 
minocycline hydrochloride were provided by DePuy Iberia (Spain & Portugal) and Atral 
Cipan (Castanheira do Ribatejo, Portugal), respectively. Briefly, both CMW1® and 
minocycline powders and the liquid monomer were carefully mixed in a glass mortar till 
total homogenization into a homogeneous yellowish-toned mixture. When the desired 
consistency was obtained, BC mass was manually casted into aluminium molds and 
shaped in the form of square plates (7 𝑚𝑚, 𝑝𝑒𝑟 7 𝑚𝑚, 𝑝𝑒𝑟 2 𝑚𝑚). 
Three different BC specimens were obtained: PMMA (PMMA without 
minocycline), LOW (PMMA loaded with 1 𝜇𝑔. 𝑚𝑙−1 minocycline), and HIGH (PMMA 
loaded with 2.5 𝜇𝑔. 𝑚𝑙−1 minocycline). 
 
 
5.3.2 – PMMA AND MINOCYCLINE-LOADED PMMA SAMPLES CHARACTERIZATION 
Bone cement samples and minocycline powder were characterized regarding their 
infrared spectrum absorption/emission, by the Fourier Transform Infrared (FTIR) 
spectroscopy; surface topography, by scanning electron microscopy (SEM); and in vitro 
drug release. 
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5.3.2.1 – FOURIER TRANSFORM INFRARED (FTIR) SPECTROSCOPY 
FTIR spectra were obtained with IRAffinity-1 spectrophotometer (Shimadzu, 
Kyoto, Japan) at 400-4000 cm-1 scanning range. Powder samples of minocycline, and 
powdered samples of the BC matrices control and loaded with 2.5% of minocycline, 
were incorporated with potassium bromide in an agate mortar. A pellet was obtained 
by compressing the powder mixture into disks in hydraulic press, under 10 ton pressure, 
for 3 minutes. The pellet was placed in the light path and spectra obtained were the 
results of averaging 30 scans. 
 
 
5.3.2.2 – SURFACE CHARACTERIZATION  
The surface of prepared BC materials was visualized by scanning electron 
microscopy (SEM), in quintuplicates (n=5). Material samples were rinsed with deionized 
water, cleaned with alcohol, sputter-coated with gold and observed in a JEOL JSM 6301F 
scanning electron microscope. 
 
 
5.3.2.3 – DRUG RELEASE STUDIES 
An in vitro release study was carried out in triplicate (n=3), with developed 
specimens, immersed at 37 ºC, in saline solution, consisting of NaCl 0.9% (w/V) 
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(AppliChem GmbH) and 0.05% (V/V) of Tween20 (Sigma-Aldrich). At predetermined time 
points (0, 30 min, 1, 2, 4, 6, 24, 48 h, 1 and 2 weeks), aliquots of the supernatant were 
collected and then replaced with equal volume of fresh saline medium, thus ensuring 
the sink conditions during the whole study.  
Minocycline content in the aliquots was determined with a UV-HPLC system 
(Shimadzu system LC-6A, Shimadzu Corporation). Chromatographic analysis was 
performed employing a 5 µm analytical column (LiChrospher® 100 RP-18 LiChroCART® 
125-4 HPLC cartridge, Merck, Darmstadt, Germany), into a thermostatic column 
compartment at 25 ºC. The mobile phase was set at a flow rate of 1.2 𝑚𝑙. 𝑚𝑖𝑛−1 and 
consisted in a mixture of acetonitrile (Sigma-Aldrich) and water, with a volume ratio of 
15:85 (V/V), respectively, and 0.6% (V/V) of triethylamine (Panreac), adjusted to pH 3, 
using orthophosphoric acid (Panreac). The detection wavelength was set at 273 nm. All 
samples were spiked with 1% (V/V) of internal standard (Levofloxacin-water solution at 
75 𝜇𝑔. 𝑚𝑙−1) before analysis. The unknown concentrations of minocycline were 
calculated using the internal standard method. The cumulative release (𝜇𝑔. 𝑚𝑙−1) was 
expressed as the total minocycline released over time.  
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5.3.3 – ANIMALS 
This in vivo study was conducted according to the accepted standards of humane 
animal care, as outline in the Ethical Guidelines. All the procedures were authorized by 
Direção Geral de Alimentação e Veterinária (DGAV) and comprised the standards for the 
protection of experimental in accordance with Portuguese (Decree No. 113/2013) and 
European (Directive 2010/63) legislations. 
In this study, 72 male Wistar rats (Charles River, Wilmington, MA), 7 to 8 weeks 
old, with a body weight of 250 to 300 g, were used. Following the arrival to the animal 
facility, animals were allowed to acclimatize for 1 week before the beginning of the 
study. Animals were then housed in groups, in conventional type II cages, on a controlled 
environment of temperature and humidity, in a 12 hours light/dark cycle. The 
identification was carried out with indelible ink and dry food and water were supplied 
ad libitum. 
Experimental diabetes was chemically induced in healthy Wistar rats by a single 
intraperitoneal injection of STZ (60 𝑚𝑔. 𝑘𝑔−1, Sigma®), freshly prepared in ice cold 10 
mM citrate buffer, 𝑝𝐻 = 4.5 – STZ group (𝑛 = 36). Control rats were injected with 
citrate buffer alone – control group (𝑛 =  36). Diabetic state and subsequent 
hyperglycaemia was confirmed by measuring tail vein blood glucose levels with a 
glucometer (Accu Check, Roche Diagnostics, Portugal), 72 hours after streptozotocin or 
vehicle administration. Animals with blood glucose levels ≥ 300 𝑚𝑔. 𝑑𝑙−1, were 
considered to be diabetic. Fifteen days following diabetes induction, the surgical 
procedures aiming for the subcutaneous implantation of the materials were conducted. 
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5.3.4 – SUBCUTANEOUS IMPLANTATION OF MINOCYCLINE-LOADED PMMA 
The surgical procedure was fully photodocumented and the surgical main steps 
are shown in figure 5.1. Briefly, animals were anesthetized by an intraperitoneal (IP) 
injection of a solution containing  90 𝑚𝑔. 𝑘𝑔−1 ketamine (Imalgéne 1000, Merial®) and 
10 𝑚𝑔. 𝑘𝑔−1 xylazine (Rompun® 2%, Bayer Health Care). Once unconscious, the back 
was trichotomized (figure 5.1a) and the area was cleaned of remnant fur and disinfected 
with a povidone-iodine solution (Betadine®). 
A superficial 2 cm incision was made in the skin (figure 5.1b) and surrounding skin 
tissue was internally debrided in order to get access to the posterior limbs and right 
anterior limb (figure 5.1c). Following, a sample of each biomaterial (figure 5.1d) – 
PMMA, LOW, and HIGH – was randomly implanted in the created subcutaneous pockets, 
around the left posterior limb, right posterior limb and right anterior limb (figure 5.1e). 
The skin was then closed with a 3/0 suture (Silkem®, silk, B Braun) and the wound 
was disinfected with povidone-iodine solution (figure 5.1f) and subcutaneous injection 
(SC) of 10 𝑚𝑔. 𝑘𝑔−1 tramadol was given to the animal, for postoperative analgesia. The 
animal was kept warm until gaining conscience, and was given food and water ad 
libitum. Also, it was monitored daily, in the postoperative period until euthanasia. 
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Figure 5.1 – Subcutaneous mPMMA implantation. Preparation of the surgical area 
by trichotomy and iodo-povidone disinfection (a); skin incision of around 2 cm (b) and 
subcutaneous tissue debridement (c); subcutaneous implantation of PMMA and 
mPMMA samples (d and e); Wound suture and disinfection (f). Scale bar corresponds to 
1 cm.  
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5.3.5 – SAMPLE GATHERING AND FIXATION 
At days 3, 14 and 28 after the implantation surgery, 6 rats of each group (control 
and STZ-induced) were euthanized by exsanguination under general anaesthesia 
(intraperitoneal injection of pentobarbital sodium 35 𝑚𝑔. 𝑘𝑔−1). Following, the 
implanted PMMA and mPMMA samples, including the surrounding tissue, were 
carefully excised and collected. For each animal, three explants (corresponding to 
PMMA, LOW and HIGH experimental groups), were fixed in 10% phosphate-buffered 
formalin. 
 
 
5.3.6 – HISTOLOGICAL ANALYSIS OF INFLAMMATORY RESPONSE 
Samples were processed 24 hours following their fixation. Accordingly, each 
sample embedded in paraffin and were sectioned longitudinally with a microtome 
Leica® 20035 (3 µm thickness). Then, sections were stained with haematoxylin and eosin 
solution (HE) and examined and semi-qualitatively evaluated using light microscopy 
(Nikon Eclipse 50i Microscope). 
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5.4 – RESULTS 
 
5.4.1 – FTIR EVALUATION OF PMMA AND MINOCYCLINE-LOADED PMMA SAMPLES 
The results concerning FT-IR spectroscopy characterization are shown at figure 
5.2. FTIR evaluation indicated that minocycline loading, with either concentrations, 
resulted in none significant change, in the inner or outer structure of the BC. In fact, FT-
IR results showed that no new bands were identified on HIGH samples, during 
evaluation. 
 
 
5.4.2 – SURFACE ANALYSIS OF PMMA AND MINOCYCLINE-LOADED PMMA SAMPLES 
Representative micrographs of SEM analysis of each distinct prepared bone 
cement samples are represented at figure 5.3. No significant differences between 
control and minocycline-loaded BC were attained. In general, a homogenous surface 
with minor topographic irregularities, was verified on all the assayed compositions.  
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Figure 5.2 – FTIR spectra of PMMA, 2.5 𝜇𝑔. 𝑚𝑙−1 minocycline-loaded PMMA and 
free minocycline. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 – SEM micrographs of the 
control BC matrix (PMMA), and BC loaded 
with 1 𝜇𝑔. 𝑚𝑙−1 and 2.5 𝜇𝑔. 𝑚𝑙−1 
minocycline, respectively, LOW and HIGH. 
Scale bar corresponds to 50 m 
PMMA LOW 
HIGH 
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5.4.3 – MINOCYCLINE RELEASE EVALUATION 
Minocycline release studies were performed in a saline media, over a period of 
two weeks. Both profiles of LOW and HIGH are presented in figure 5.4, showing the 
cumulative minocycline release over time. Release profiles evidenced a two-phase 
stage, with an initial burst, followed by a sustained release - a profile more evident 
within the HIGH formulation. Additionally, the variation of minocycline release was 
found to be higher for the HIGH formulation, as comparing to LOW, throughout the 
assayed period. 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 – In vitro release profiles of minocycline, in both LOW and HIGH 
concentrations, for up 2 weeks. 
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5.4.4 – DIABETIC EXPERIMENTAL MODEL 
Diabetes mellitus was chemically induced by a single IP injection of streptozotocin. 
Hyperglycaemia was confirmed 72 hours following STZ administration. After 15 days, 
animals lost weight (37.57% ± 8.65) and this weight variation pattern prevailed during 
the experimental period. At euthanasia, STZ-induced animals had a significantly higher 
glycaemia (> 300 𝑚𝑔. 𝑑𝑙−1) in comparison to basal glycaemic values (≤ 125 𝑚𝑔. 𝑑𝑙−1). 
 
 
5.4.5 – INFLAMMATORY RESPONSE TO PMMA AND MINOCYCLINE-IMPREGNATED 
PMMA 
Images corresponding to the histological analysis of the tissues surrounding to the 
implanted PMMA constructs, in both control and STZ animals, at distinct time points, 
are shown at figures 5.5, 5.6 and 5.7. In figure 5.5, representative samples, of the 
PMMA-alone samples, in both control and diabetic conditions, are shown; In figure 5.6, 
representative samples of the assayed PMMA constructs with and without minocycline 
loading, in control conditions, are shown. In figure 5.7 representative samples of the 
assayed PMMA constructs with and without minocycline loading, in diabetic conditions, 
are shown. The tissue response to the implanted constructs was qualitatively evaluated 
by light microscopy following HE staining and the results were expressed in a scale of 
intensities ranging from “0” (absence of intensity or prevalence) to “+++” (high intensity 
or prevalence) for all the assayed parameters with the exception of macrophages and 
giant cells, which analysis consisted of counting the total amount of these cells and the 
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numbers were then converted in the intensity scale between “0” (no cell found) and 
“+++” (high number of cells). This qualitative evaluation is represented at table 5.1. The 
qualitatively addressed parameters included: inflammatory reaction (IR), fibrotic 
capsule formation (CAP), neutrophils infiltration (PMN), presence of lymphocytes (LYM), 
fibroblasts (FB), macrophages (MAC) and giant cells (GC), and neovascularization (NEO).  
 
 
5.4.5.1 - INFLAMMATORY REACTION 
The overall inflammatory reaction was qualitatively evaluated according to its 
intensity, for each sample, in both control and diabetic conditions. The evaluation was 
conducted by observing tissues appearance, presence of cell infiltrate, new vessels, 
fibrotic formation. The resulting evaluation is represented at table 5.1. The analysis 
revealed a more exuberant inflammatory reaction in samples collected at early time 
points (i.e. day 3) in control animals. The overall inflammatory response seemed to 
diminish with time, particularly in control conditions. In STZ animals it was broadly low, 
throughout the assayed time points. PMMA loaded with high and low doses of 
minocycline seemed to exert a significantly reduced IR as compared with PMMA alone, 
in both control and diabetic animals (figure 5.5 and table 5.1). 
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Figure 5.5 – Histological analysis of the tissues surrounding PMMA constructs, 
after 3, 14 and 28 days of in vivo subcutaneous implantation, in control and diabetic 
animals. HE staining. Scale bar corresponds to 200 µm. 
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5.4.5.2 – POLYMORPHONUCLEAR NEUTROPHLIS 
Neutrophils play a central role in the modulation of early events within the acute 
inflammatory response. Their infiltration within tissues neighbouring the implanted 
PMMA constructs was addressed according to its intensity (table 5.1). PMN infiltration 
was highly intense at day 3 in PMMA samples of control animals. Comparatively, 
minocycline-loaded PMMA seemed to reduce neutrophil recruitment, as their presence 
in LOW and HIGH groups was found to be significantly lower when compared with 
PMMA alone. In diabetic animals the presence of PMNs was meaningfully reduced as 
compared with samples obtained from control animals, however minocycline groups 
seemed to slightly reduce neutrophils recruitment. Subsequently, neutrophils 
infiltration was found to be progressively reduced with implantation time, sustaining the 
prime role of these cells within the early events of the inflammatory response (figures 
5.5, 5.4 and 5.6 and table 5.1). 
 
 
5.4.5.3 – MACROPHAGES AND GIANT CELLS 
Macrophages and Giant cells count was determined in the sections of implanted 
PMMA constructs. Macrophages were firstly noticed at day 14 in mild numbers, and 
their presence intensity remained constant, till day 28. These results were similar 
between both control and diabetic conditions, in the tissues surrounding the implanted 
samples with and without minocycline (table 5.1). The same emerging pattern was 
observed regarding GCs, however their presence was more intense from day 14 with 
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increasing prevalence till day 28. No significant differences were achieved when 
comparing PMMA with low and high doses mPMMA samples (table 5.1). 
 
 
 
Figure 5.6 – Histological analysis of tissues surrounding PMMA and mPMMA 
constructs, after 3, 14 and 28 days of in vivo subcutaneous implantation, in control 
animals. HE staining. Scale bar corresponds to 200 µm. 
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Figure 5.7 – Histological analysis of tissues surrounding PMMA and mPMMA 
constructs, after 3, 14 and 28 days of in vivo subcutaneous implantation, in diabetic 
animals. HE staining. Scale bar corresponds to 200 µm. 
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5.4.5.4 – FIBROBLASTS 
The assessment of fibroblasts migration/proliferation in the wounded area was 
also evaluated (table 5.1). Histological analysis showed a considerable high presence of 
fibroblastic-like cells at the earlier days after subcutaneous implantation in control 
animals with a trend for a diminished intensity in both LOW and HIGH groups, at day 3. 
This difference between samples has not been noticed at later experimental time points; 
moreover, at day 28, fibrolast presence was significantly diminished. Concerning 
diabetic animals, fibroblastic cells presence was significantly lower as compared with 
control animals and no differences were attained comparing PMMA with LOW and HIGH 
groups (figures 5.6 and 5.7). 
 
 
5.4.5.5 – FIBROTIC ENCAPSULATION 
The results regarding the semi-qualitative analysis of PMMA and mPMMA samples 
fibrotic encapsulation are shown at table 5.1. The analysis was performed by taking in 
account the capsule thickness. Encapsulation by fibroblasts was observed from day 14 
in both control and diabetic animals. In PMMA samples, an increasing capsule thickness 
was evident from day 14 to day 28 in both control and STZ experimental groups. High 
concentration of minocycline-loaded PMMA was able to interfere with capsule 
formation as a reduced CAP thickness was observed involving these samples at the later 
experimental time point. Despite the progressive development in both conditions, CAP 
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showed to be thicker in those samples implanted in healthy animals presenting a 
stronger net of fibroblasts and collagen around each of materials. 
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Table 5.1 – Semi-qualitative analysis of overall inflammatory reaction and inflammatory 
response parameters around PMMA and mPMMA samples, after 3, 14 and 28 day of in 
vivo subcutaneous implantation, in both control and diabetic conditions. “0” represents 
the lowest intensity or presence and “+++” represents the highest intensity or presence 
within the tissues around the samples. “PMMA” refers to PMMA-alone samples; “LOW”, 
PMMA loaded with 1 𝜇𝑔. 𝑚𝑙−1 minocycline; and “HIGH”, PMMA loaded with 
2.5 𝜇𝑔. 𝑚𝑙−1 minocycline. “IR” refers to inflammatory reaction; “PMN”, 
polymorphonuclear neutrophils; “MAC”, macrophages; “GC”, giant cells; “FB, 
fibroblasts; “CAP”, fibrotic capsule; “LYM”, lymphocytes; and “NEO” stands for 
neovascularization. 
 
Condition IR 
Inflammatory Response Parameters 
PMN MAC GC FB CAP LYM NEO 
CTRL 
3 days 
PMMA +++ +++ 0 0 ++/+++ 0 ++ ++ 
LOW ++ +/++ 0 0 ++ 0 +/++ +/++ 
HIGH ++ ++ 0 0 ++ 0 + ++ 
STZ 
3 days 
PMMA +/++ +/++ 0 0 + 0 + ++ 
LOW + + 0 0 + 0 0/+ + 
HIGH + + 0 0 + 0 + ++ 
CTRL 
14 days 
PMMA ++ + + + +/++ + + + 
LOW ++ + + ++ ++ + + + 
HIGH +/++ + + ++ ++ + + +/++ 
STZ 
14 days 
PMMA +/++ + + ++ ++ + +/++ + 
LOW + + + ++ + + + + 
HIGH + + + +/++ + + + + 
CTRL 
28 days 
PMMA +/++ 0/+ + ++/+++ + ++/+++ ++ +/++ 
LOW + 0/+ + +/++ + ++/+++ + ++ 
HIGH +/++ 0/+ + +/++ +/++ ++ + +/++ 
STZ 
28 days 
PMMA +/++ + + ++/+++ + +/++ ++ ++ 
LOW ++ + + ++ + ++ + ++ 
HIGH +/++ + + ++/+++ + + +/++ ++ 
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5.4.5.6 – LYMPHOCYTES 
Presence of lymphocytes was addressed as an evidence of immune system 
activation against developed PMMA systems. At day 3, a moderate presence of 
lymphocytes was registered with significantly diminished presence around PMMA 
loaded with high doses of minocycline, in control animals. At day 14, lymphocyte 
presence was less intense and no differences were achieved between PMMA and 
minocycline-loaded samples. 28 days after the implantation, an increased presence, 
similar to that obtained at day 3, was observed in PMMA group. In diabetic animals a 
significantly lower number of lymphocytes was found at day 3 when compared with 
control groups. Also, no differences between samples were found at this time point. 
Over the experimental course, lymphocytes number seemed to slightly increase in 
PMMA samples with significant differences between PMMA and the other two 
conditions, at day 28. 
 
 
5.4.5.7 – NEOVASCULARIZATION 
In which regards the formation of new blood vessels, the addressment of this 
parameter was conducted by counting the blood vessels present in the tissues around 
the implants. No clear difference was found between experimental time points, nor 
between control and diabetic groups. Also, minocycline-loaded samples seemed to have 
no significant effect in neovascularization (table 5.1). 
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5.5 – DISCUSSION 
 
Diabetes mellitus, one of the most established systemic conditions, nowadays, 
representing a major cause of death and disability worldwide (267). Chronic 
hyperglycaemia is known to severely affect bone tissue in a variety of ways leading to a 
substantial increase of fractures occurrence (76, 78) combined with impaired healing 
and abnormal inflammatory response (115), resulting in diabetic patients’ increased 
morbidity or even death (6). In which regards the cellular affection, DM was broadly 
described to cause bone remodelling unbalances, by disrupting osteoblastic precursor 
cells differentiation and further hindering their specialized function to renew bone (83, 
91). This unbalance leads to a cycle of higher bone resorption over new bone formation 
contributing to a continuous decrease of mineral density and increased trabeculae gaps, 
ultimately establishing an osteopenic state and subsequent osteoporosis development 
(6). 
Conformably, diabetic patients are more likely to experience longer periods of 
therapy to regenerate bone wounds, as longer periods for osseointegration are 
required, when biomaterials are implanted (11, 121).  Furthermore, hindered healing 
process in DM is intimately associated with abnormal inflammatory response and higher 
risk of surgical and post-surgical infections (113, 116), both contributing as major causes 
of implant failure and rejection, in diabetes mellitus patients. 
In order to avoid infections due to biocompatible devices implantation, new 
formulations of antibiotic-impregnated bone cements emerged as favourable 
alternative to systemic administration of antibiotics. PMMA represents a suitable 
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biomaterial to support bone regeneration not only as an implant fixative but also a bony 
defect filler preventing structural collapse while keeping the defect clean of invasive soft 
and scar tissues (262). Due to its chemical properties, PMMA bone cements may be 
easily loaded with a proper antibiotic and applied locally during the surgery, being 
widely adaptable to the wound morphology. Antibiotic-loaded PMMA cements have 
been broadly used in the treatment of bone fractures and osteomyelitis (268), aiming to 
attain a local antibiotic therapy with suitable antibiotic concentrations, without the need 
of antibiotic systemic administration, which may not specifically target the 
compromised tissues or organs (260, 262). 
Minocycline, a second generation, semi-synthetic tetracycline has been 
intensively for more than three decades due to its broad spectrum of activity against 
both gram-positive and -negative bacteria. More recently, it was described to exert 
beneficial non-antibacterial properties including anti-inflammatory and anti-apoptotic 
activity (10, 170, 263). Those properties were thought to be useful as combined with 
biocompatible of PMMA systems. 
In this study, we aimed to evaluate the biological response of PMMA impregnated 
with two different concentrations of minocycline, upon subcutaneous implantation in 
both control and diabetic-induced animals. The subcutaneous implantation was widely 
used to assess tissue biocompatibility and potential inflammatory response to 
biomedical materials, as it allows to conduct site specific studies with minimal 
invasiveness and long-term trauma to the animals (269-271). Our intent was to address 
not only the inflammatory response, but also the evidences of enhanced surrounding 
tissue healing, neovascularization and implant acceptance or rejection. 
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The selected model of diabetic pathology was the streptozotocin-diabetic-induced 
rat. STZ, a broad-spectrum antibiotic, is able to damage selectively pancreatic β-cells 
leading to a hyperglycaemic state similar to the one of human pathology (92, 105). A 
single dose of 60 𝑚𝑔. 𝑘𝑔−1, was reported to be enough to  induce diabetes in rodents 
(106) with minimal mortality. Following STZ intraperitoneal administration, 
hyperglycaemia is established in the first 48 hours. At day 15 after induction, diabetic 
animals demonstrated the characteristic symptoms of the diabetic state, including 
weight loss, increased water consumption and consequent increased urine volume 
(109). Also, in comparison with controls, STZ-injected animals presented higher 
glycaemia, ranging from 300 𝑡𝑜 400 𝑚𝑔. 𝑑𝑙−1, thus confirming the hyperglycemic state. 
Tissue response following biomaterial implantation was found to be significantly 
different between control and diabetic conditions. In the present study, specially at 
earlier days after subcutaneous biomaterials implantation, inflammatory reaction 
seemed to be delayed in diabetes as its intensity, around all PMMA and minocycline-
loaded PMMA samples was diminished, as compared with the reaction obtained around 
materials subcutaneously implanted in control animals. This phenomenon was reviewed 
intensively in literature, in which numerous reports support that diabetes alters the host 
response to implants, initially due to the impairment of inflammatory cells recruitment 
and activation (272-274). Accordingly, in diabetic wounds, an impaired expression of 
chemokines was found to cause substantial reduction of growth factors secretion, which 
results in delayed inflammatory cells infiltration (272). Additionally to efficient 
inflammatory cell recruitment, wound healing requires a functional and well-structured 
provisional matrix, in diabetes these conditions do not seem to occur (272). Further, our 
data suggests that minocycline, in both experimental doses, exerted an acute and 
182 
 
substantial reduction of inflammatory reaction triggering, in both control and diabetic 
conditions.   
In physiological conditions, neutrophils predominate in the early inflammatory 
infiltrate and are later replaced by macrophages. Following vasodilation and 
microvasculature permeability, PMN neutrophils begin to accumulate along the vascular 
endothelial surface (margination process) in order to migrate to inflammation focus 
(275). Commonly, these processes take place during the first three days after 
inflammation triggering. This was observed in our histological evaluation, in which PMNs 
presence was intense at day 3 after subcutaneous PMMA samples implantation in 
control animals group. In contrast, in diabetic samples, the presence of recruited PMNs 
was significantly reduced. Conformably, many studies have found severe changes in 
neutrophils’ abilities and abnormal functionality, including impaired adhesion to 
endothelium and recruitment to inflammation site (276), bacterial and phagocytic 
activity (277, 278), and chemotaxis (279-281). Neutrophils play a major importance role 
as they are able to synthesize pro- and anti-inflammatory cytokines and growth factors 
that modulate inflammatory response. Further, factors such as IL-8 (11, 282), tumor 
necrosis factor-α (TNF-α) and IL-1β are pro-inflammatory cytokines with critical role in 
the inflammation processes (283). IL-8 was reported to exert chemotactic stimuli, 
providing the recruitment of greater number of PMN leukocytes and support 
neovascularization processes (284). Its expression was reported to be lowered in 
diabetic conditions (11). TNF-α is known to mediate the systemic effects of inflammation 
(i.e. fever, haematopoiesis) but is also a strong modulator of neutrophils metabolic 
functions. Its expression was described to be greatly higher in diabetic patients which 
combined with hyperglycaemia, lead to abnormal augmentation of intracellular Ca2+ of 
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neutrophils and consequent over production of cytokines (285). The uncontrolled 
release of factors contributes to chronic activation of phagocytes, despite also triggering 
neutrophils apoptosis (286). Concerning IL-1β, its overexpression combined with altered 
expression of IL-8 and TNF-α, was described to lead to tissue injury and wound healing 
impairment (285).  
With respect to PMMA samples with minocycline controlled release, the added 
drug was able to reduce neutrophil recruitment in both concentrations, as their 
presence was notably reduced when compared to PMMA group. This decreased 
neutrophil recruitment was previously reported by Shine and co-workers (287). As 
expected, in control animals PMNs presence diminished continually till day 28, however 
in diabetic animals, neutrophils presence had the same intensity thus suggesting a 
hindered migration of neutrophils, a chronic presence of a reduced number of these 
cells, and subsequent chronic expression of inflammation cytokines. 
Macrophages recruitment represent the dominant feature in chronic 
inflammation. Following monocyte migration to the inflammatory site, macrophages are 
differentiated and activated by a variety of factors including microbes, dead cells or 
cellular debris, cytokines (i.e. interferon-γ, IFN- γ), and other (275). In the present study, 
data shows that macrophages emerged following 14 days of PMMA constructs 
implantation. Their number was constant till day 28 and no relevant differences were 
achieved between control and diabetic animals. The same behaviour was observed for 
the assessment of giant cells, nevertheless these were in higher number than 
macrophages suggesting an advanced stage of macrophage fusion, at least from day 14 
onwards, in both control and diabetic conditions. Despite the lack of verified differences 
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between control and diabetic animals, diabetes is known to affect macrophage function 
(11, 288, 289). At the molecular level, diabetic macrophages were reported to produce 
higher levels of pro-inflammatory cytokines thus increasing the number of PMN cells 
merging to inflammation area (290). Contrariwise, in diabetes, macrophages and giant 
cell phagocytic ability was described to be hindered leading to an inappropriate 
clearance of dead cells and other cellular debris (291, 292). Overall, these effects may 
mutually compensate – i.e., in diabetes, weather activated macrophages were found to 
produce higher levels of inflammatory mediators, the functional activity of macrophages 
and giant cells was found to be hindered. Counterbalanced effects may converge to the 
absence of differences verified between control and diabetic animals in the present 
study. Additionally, macrophage chemotaxis is also associated with IL-8 which was 
previously mentioned to be diminished in diabetic wound healing (11). Moreover IL-8 
was demonstrated to be responsible for the majority of the monocyte-macrophage-
associated angiogenic activity (293). In this way, IL-8 unbalances may also affect 
macrophage function during diabetic wound healing or biomaterial implantation and, in 
the second case, contribute to the altered tissue implant interaction (273). In which 
regards minoclycline-impregnated cements, PMMA-loaded samples did not seem to 
exert any modulator effect on macrophages/giant cells migration or fusion since no 
significant differences were detected between PMMA alone samples and LOW and HIGH 
groups within each condition. 
Fibroblasts are known to play a critical role in healing processes. Posteriorly to 
wound clearance and secretion of determinant growth factors, fibroblasts and other 
epithelial cells migrate to inflammation site to initiate the re-epithelialization and 
healing of damaged tissues (11, 275). Our results showed a decreased presence of 
185 
 
fibroblasts in diabetic animals, in comparison with control animals. In diabetes, the 
distinct stages of wound healing seem to be impaired and a substantial depletion of 
growth factors have been reported (11). Numerous studies demonstrated that diabetes 
disrupt the normal fibroblast proliferation and migration behaviour during healing 
processes. Furthermore, the abnormal inflammatory response in diabetes is 
characterized by decreased expression of IGF-1, transforming growth factor-β1 (TGF-
β1), TNF-α and platelet-derived growth factor (PDGF), which are known to promote 
fibroblasts activation, proliferation and migration (11, 275, 294). Moreover, 
macrophages activation in physiological conditions affects directly fibroblasts 
proliferation, collagen synthesis, and other factors expression (275). Since macrophages 
activity is impaired in diabetes, these cells may also be associated with hindered 
fibroblasts recruitment and function in diabetic conditions. Minocycline appeared to not 
modulate fibroblastic behaviour in either control or diabetic experimental conditions. 
Another important remark of inflammatory reaction upon biomaterial 
implantations regards the formation of a fibrotic capsule, which intends to isolate the 
implant or other intruder, being recognized as a foreign body. It is broadly known that 
the inclusion of foreign bodies, including biomaterials, leads the formation of a dense, 
hypocellular, collagen-rich capsule (295). Our analysis showed that fibrotic 
encapsulation takes place in all experimental conditions, posteriorly to day 3 and 
sometime before day 14. At day 14, a well-formed CAP was present in both control and 
diabetic animals. The evaluation of CAP thickness, showed similarities in both 
experimental groups at day 14, however, significant differences were observed at day 
28 after PMMA implantation. In control groups, a significant thicker CAP was found in 
comparison with the one attained in diabetic animals. Only few studies provided a 
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deeper insight in the relation between insulin-dependent diabetes and foreign-body 
capsule formation. Despite the lack of information, the development of this dense layer 
of fibrotic connective tissue was already considered a major cause of implant failure, 
safety and biocompatibility, in both physiological and diabetic conditions (295-297). 
Recent data reported that attenuated fibrous encapsulation in hyperglycaemic 
environment (270) may be correlated with the high levels of TNF-α expression and 
consequent higher apoptotic index of fibroblastic cells in diabetic conditions (270, 298). 
Accordingly, we found a reduced fibroblastic development in diabetic conditions. These 
findings support our analysis, as CAP were able to grow thicker in control animals at later 
experimental time points. Additionally, the present study revealed that minocycline was 
able to reduce foreign-body encapsulation thickness, slightly in control group and 
significantly in diabetic conditions. 
Lymphocytes are commonly the last type of immuno-inflammatory cells emerging 
to the inflammation area. They are mobilized to the setting of any specific immune 
stimulus, as infections, or other non-immune-mediated processes, as tissue trauma. 
Both T and B lymphocytes are recruited to the inflamed area by the same chemokines 
that mobilizes other inflammatory cells (275). Our findings suggest that lymphocyte 
presence was significantly diminished in diabetic animals, as compared with controls, at 
day 3. Over experimental time points, lymphocytes presence diminished in both 
conditions, nevertheless, at later time points, their presence was still noticed, endorsing 
the existence of a persistent inflammation state, immune activation, and leukocyte 
dysfunction. This comes in line with the delayed migration, verified at earlier 
inflammation time points in diabetic conditions, and found to be associated with several 
dysregulated cellular functions. Accordingly, apart from the previously mentioned 
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defects in leukocyte chemotaxis, phagocytosis and abnormal functional activity of 
fibroblasts and epidermal cells, diabetes is known to yield defective T-cell immunity (47, 
118). A study demonstrated that, in diabetic wounds, CD4/CD8 ratio was reported to be 
significantly lower as compared with normal wounds, due to relatively lowered number 
of CD4+ T cells (299). Moreover, the predominance of CD8+ T cells was previously 
reported to be associated with impairment of certain stages of healing processes (299-
301). 
In which regards the minocycline-impregnated implants results were convergent 
to a reduction in the number of recruited lymphocytes. The first significant difference 
was observed in control group, at day 3, in which both doses of minocycline were able 
to reduce the number of these cell in the inflammation site. At day 28, these differences 
were noticed but, this time, in both control and diabetic groups. This may support that 
minocycline local administration at earlier time points of an inflammation process may 
play a decisive role preventing a sharp chronic invasion of lymphocytes and consequent 
immune-derived healing impairment in diabetic wounds or biomaterial subcutaneous 
implantation. 
Shortly after injury and inflammatory response triggering, hypoxia in induced in 
damaged tissue. As the new extracellular matrix produced and epithelial cells renew the 
damaged area, macrophages and fibroblast tend to compensate the hypoxia secreting 
specific pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF) to promote neovascularization. Despite our analysis does 
not indicate substantial differences between physiological and diabetic conditions, 
diabetes is widely known to hinder new vessel formation and quality, further leading to 
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vascular dysfunctions, such as structural abnormalities, increased permeability and 
vasodilatation (270, 271, 302). In diabetic wounds, the nitric oxide (NO) reduction has 
been reported to exert negative effects in both tissue healing and response to infection 
(303). Moreover, increasing NO levels were demonstrated to play a key role in 
angiogenesis by initiating the recruitment of endothelial progenitor cells from bone 
marrow (121) and by activating VEGF expression by fibroblasts and macrophages (304). 
Thus, diminished levels of NO in diabetic conditions were correlated with insufficient 
chemokine signalling to recruit endothelial cells resulting in decreased 
neovascularization (121). Some approaches have been developed with the aim to 
improve vascularization in diabetic wounds, as well as around implants (273). 
Accordingly, insulin administration and hyperglycaemic control was reported to restore 
the inflammatory response and neovascularization, to a process similar to the one 
verified in physiologic conditions (305). On the other hand, crucial differences may be 
attained in time points different from those assessed, as between day 3 and day 14. 
In our histological analysis minocycline seemed not to influence 
neovascularization, however, it was a semi-quantitative analysis which should 
posteriorly be endorsed with molecular assays in order to address more accurately the 
cellular component of the observed vessels, as well as the dimensional and structural 
organization around the biomaterial. In fact, tetracycline and derivatives such as 
minocycline and doxycycline were broadly associated with anti-angiogenic properties, 
which were widely reported to be useful in pathological conditions associated with 
increased vessel formation and altered vasculature structure such as tumour and 
metastasis (9, 10, 144).  
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5.6 – CONCLUSIONS 
 
In the present study, a successful animal model of chemically-induced 
hyperglycaemia was developed and allowed to mimic the human diabetic condition. 
Subsequently, developed PMMA system for the controlled release of minocycline, 
aiming the application in bone trauma, was characterized for its biocompatibility 
following subcutaneous implantation in both control and diabetic animals. 
Our data endorses an impaired inflammatory response in diabetic conditions, as 
several important inflammation parameters showed to be down-regulated or 
functionally hindered, including neutrophils infiltration at earlier time points of 
inflammatory reaction, chronic presence of macrophages and giant cells, and delayed 
infiltration of lymphocytes corroborating the chronic inflammatory and immune 
activation at later time points. Also, fibrotic encapsulation was find to be reduced in 
diabetic conditions which may represent a positive point regarding biomaterials 
implantation and acceptance. 
Minocycline was observed to modulate inflammatory response by affecting some 
of the studied parameters. Accordingly, the antibiotic in both  1 𝜇𝑔. 𝑚𝑙−1 (low) and  
2.5 𝜇𝑔. 𝑚𝑙−1 (high) concentrations, demonstrated to attenuate the overall 
inflammatory reaction over time, in control animals, as well as in later time points, in 
diabetic animals. Present data seems to suggest that the developed minocycline-
delivery system, based on a PMMA cement, may be of clinical relevance, not only for 
the eventual antibacterial properties ensured by minocycline release, but also regarding 
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the possible anti-inflammatory effect, that may modulate tissue healing in the post-
operative period. 
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CHAPTER 6 – CONCLUSIONS AND FUTURE 
PERSPECTIVES 
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6.1 – GENERAL CONCLUSIONS 
 
Diabetes mellitus is well known to impair bone metabolism and consequently 
increase the risk of fractures and delay healing processes. Despite numerous studies 
focused the understanding of diabetic osteopenia, the mechanisms behind diabetes-
derived bone complications are still unknown, or not fully understood. 
Our work showed that DM is likely to affect MSCs signalling and functionality in a 
deep and long-lasting way, promoting bone weakening. The long-term hyperglycaemia 
was demonstrated to interfere in the behaviour of Wistar rat MSCs, hindering the 
osteogenic differentiation, even in the presence of osteogenic-inducers. These results 
support that local or systemic strategies, such as modulatory-drug delivery systems, 
targeted to specific tissue or hindrances, may enhance the MSCs functionality and 
maturation in diabetes, and subsequently enhance bone metabolism and regeneration 
in this pathological condition. 
Tetracyclines have been described to possess exceptional properties beyond their 
natural antibiotic activity. Our in vivo and ex vivo experiments demonstrated that, in 
addition to the enhancement of osteoblastic function in diabetic conditions, doxycycline 
administration, in low dosage regimens, is able to normalize the impaired osteogenic 
commitment of precursor populations. Upon doxycycline treatment, MSCs cultures 
from diabetic models, showed increased commitment within the osteogenic lineage, as 
well as increased osteogenic priming and collagen synthesis, suggesting that doxycycline 
improves matrix quality for bone formation to occur. In later time points, the compound 
revealed to enhance tissue healing and promote mineralization in the newborn rat 
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calvarial bone defect model. These data converged to the idea that minocycline and 
doxycycline represent optimal candidates to be applied in clinical local therapies for 
bone regeneration enhancement, particularly in compromised conditions induced by 
diabetes. 
In an attempt to create a reliable tetracycline delivery system for bone 
regeneration local therapies, we developed a new formulation of PMMA bone cement, 
loaded with different concentrations of minocycline. Minocycline-impregnated PMMA 
subcutaneously implanted in Wistar rats showed to be biocompatible and able to 
modulate the immune-inflammatory response, enabling a more favourable biomaterial 
acceptance and long-term functionality, in both control and diabetic animals. 
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6.2 – FUTURE PERSPECTIVES 
 
Minocycline and doxycycline have proven to be strong osteogenic-inducers, 
promoting osteogenic priming and enhancing new bone formation. Its association with 
a biocompatible material such as PMMA presents valuable advantages for clinical 
application in situations in which local therapies are required, rather than systemic 
administrations, which reduces significantly the eventual undesirable effects of 
tetracyclines or other antibiotics, over the tissues. 
Despite the positive effects attained in our study, future work is greatly envisaged. 
Accordingly, experimental local application of minocycline or doxycycline-loaded PMMA 
at bone defects or fractures models is essential to address the osteogenic potential of 
these tetracycline-derivatives. Further, the carrier material represents another major 
concern depending on its properties and application. For example, implant 
osseointegration is known to be impaired in diabetes as well, thereby it is important to 
evaluate osseointegration of PMMA bone cements in diabetic conditions, in both 
situations with and without impregnated-tetracyclines. As a bone cement used as filler, 
bone-material interface represents a critical point to be addressed. Moreover, porous 
PMMA is also available, which may constitute a new hypothesis in which minocycline or 
doxycycline are loaded in a bone cement, with beneficial structural properties as it 
mimic the porous component of bone.    
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